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Abstract
The aim of the project was to investigate the use of mercury mediated cyclisation 
reactions resulting in the generation of 2,3 -dihydropyran-4//-one and 3(2//)-furanone 
systems.
Chapter one discusses the general synthesis o f dihydropyranones and furanones. The 
chapter continues and focuses upon the use of a mercury-mediated cyclisation strategy in 
the synthesis of 2,3-dihydropyran-4-ones and 3(2//)-furanones. Finally the chapter 
describes efforts to utilise a mercury-mediated cyclisation strategy to synthesise useful 
synthetic intermediates.
Chapter two is focused upon protein phosphorylation inhibitors, and begins by 
discussing the processes of protein phosphorylation and compounds which inhibit the 
process. The chapter focuses on fostriecin and phospholine compounds, and discusses 
efforts to synthesise key fragments of the compounds using a mercury-mediated 
cyclisation protocol.
Chapter three describes histone deacetylase inhibitors, and their mode of action. The use 
of computational models to predict and rationalise inhibitor activity is discussed. A small 
selection of HD AC inhibitors are used to demonstrate the Autodock system in predicting 
inhibitory activity. A previously unknown compound is synthesized, and inhibitory 
properties compared to those predicted by the Autodock system.
Chapter four discusses efforts to synthesise the spiroketal subunit of (-)-calyculin A. 
Initially a mercury-mediated cyclisation strategy is presented, detailing the preparation 
of two key fragments which are combined to form a key scaffold used in the cyclisation 
strategy. The chapter then describes the use of auxiliary fragments in attempts to 
generate the spiroketal fragment.
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A bbreviations
DCC 1,3-Dicyclohexylcarbodiimide
DEAD Diethyl Azodicarboxylate
DIC V A ’-Diisopropylcarbodiimide
DEPT Diisopropyl Tartrate
DMAP 4-Dimethylaminopyridine
DMF Dimethylformamide
DMSO Dimethylsulfoxide
DNA Deoxyribonucleic acid
HDAC Histone Deacetylase
HDLP Histone Deacetylase Like Protein
HIV Human Immunodeficiency Virus
Ipe z'so-Pinocampheyl
LDA Lithium Diisopropylamine
MMP Matrix Metalloproteinases
NMM V-Methylmorpholine
NMO V-Methylmorpholine V-oxide
NMP V-Methyl-2-Pyrrolidone
NMR Nuclear Magnetic Resonance
j?-TsOH para-Toluenesulfonic acid
PDB Protein Data Bank
PP Protein Phosphatase
PPTS Pyridinium para-T ohime Sulfonate
PTP Protein Tyrosine Phosphatases
SAHA Suberoylanilide Hydroxamic Acid
TBHP tert-Butyl Hydroperoxide
TBS tert-Butyldimethylsilyl
THF Tetrahydrofuran
TLC Thin-layer Chromatography
TMS Trimethylsilyl
TSA Trichostatin A
ZBG Zinc Binding Group
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Chapter 1
The Synthesis of Dihydropyranones and 
3(2H)-Furanones
1.1 Introduction
The pyranoid and furanyl ring systems are present in a broad spectrum of natural 
products which exhibit a variety o f important therapeutic properties. The 
stereocontrolled construction o f such systems is of great synthetic interest and is the 
focus of this chapter, where the synthesis of 2,3-dihydro-4//-pyran-4-ones and 
3(2//)-furanones are demonstrated using a mercury mediated rearrangement of epoxy 
alkynols and alkynone diols to give substituted dihydropyranone and furanone systems.
1.1.1 Dihydropyranones and 3(2H)-Furanones
The presence of dihydropyranones and furanones is to be found in a variety of natural
products. Dihydropyranones, and related systems, can be seen in products such as
1 2 stegobiol (3) the sex pheromone of the drugstore beetle, and other pheromones,
vallartanones3 and HIV protease inhibitors.4,5 Compounds containing a 3-
methyltetrahydropyran moiety include spiroketal compounds,6"9 spongistatins,10-12
milbemycins, avermectins ( l) ,13 and monensin14,15 (2) a polyether antibiotic.
8
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Figure 1.1.1. Examples of tetrahydropyran- and tetrahydrofuran-containing natural products. 1 Avermectin 
A, 2 Monensin, 3 Stegobiol. R1 = Me, R2 = L-oleandrosyl-L-olenandrose, R3 = Et.
The 3(2//)-furanone ring system is similarly prevalent and can be found in a number of 
natural products exhibiting interesting pharmacological properties. These include 
compounds such as butenolide (4), tetronic acid frameworks (5), and the anti-tumour 
agent geiparvarin.16'18
OH
4 5
Figure 1.1.2. Butenolide (4) and tetronic acid frameworks (5).
Their variety in biological activity and potential application in therapeutic treatments has 
prompted the search for new methodology in the synthesis of pyranoid and furanyl 
systems.
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1.1.2 Synthesis of Dihydropyranones and 3(2H)-Furanones
The synthesis of dihydropyranones is an important route through which it is possible to 
obtain a diverse range of substituted tetrahydropyrans and spiroketal systems. One o f the 
best known routes to dihydropyranones, is a method reported and investigated by 
Danishefsky et al.19'21 involving the Lewis acid catalysed Diels-Alder reaction of siloxy 
1,3-dienes with aldehydes; a general illustration of the reaction can be seen in scheme 
1.1.3.
TMSO ^
Scheme 1.1.3. The Danishefsky synthesis of dihydropyranones. i. Lewis acid catalysis. Danishefsky’s 
diene, R1 and R2 = H.
Diastereocontrol of the Danishefsky reaction is dependent upon a number of factors, 
including the substrate, the Lewis acid used, and the solvent.22 Several reports detailing 
enhanced selectivity o f the Danishefsky reaction23'25 have been forthcoming; however, a 
limitation to the Danishefsky reaction exists, in that it does not allow the direct 
generation of C6 substituted pyranoids.
Other methods of pyranoid generation have been reported, and include the work of 
Paterson et al. in aldol condensation reactions (scheme 1.1.4.). Using the chiral boron 
reagent (-)-(Ipc)2BOTf to generate the enolate, Paterson successfully generated material 
with 97% diastereoselectivity, and 80% e.e.
10
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Scheme 1.1.4. An example of dihydropyranone synthesis using the Paterson method, i. ”Bu2BOTf, 
'Pr2NEt; ii. Me3SiOTf, 'Pr2NEt.
27 28Further reports can be found by Clarke et al. ’ who report the synthesis of 
tetrahydropyran-4-ones via aldol condensation of P-ketoesters and aldehydes, and 
Hinterding and co-workers who have described the generation o f P-keto-8-lactone 
through intramolecular Claisen type rearrangements.29
■JA
McDonald et al., using molybdenium and tungsten to mediate cycloisomerisation 
reactions, was able to generate dihydrofurans and dihydropyrans from intermediates 
such as 6.
Scheme 1.1.5. Tungsten mediated cyclisation. i. W(CO)5, THF; ii. Et3N, Et20/THF.
' i  i
Dreessen et al. used base promoted cyclisation of P-hydroxy alkynones to give 
dihydropyranones. This is a one step reaction where the treatment of 7 with sodium 
hydride forms the dihydropyranone 8.
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Scheme 1.1.6. Preparation of dihydropyranones according to the Dreessen procedure, i. NaH, THF.
Dihydrofuran systems have also been prepared using metal catalysis. Saito et al. 
reports the synthesis of compound 10 using palladium catalysis in 91%.
OH
TBSO TBSO
R
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Scheme 1.1.7. Preparation of dihydrofurans using palladium (II) catalysis, i. PdCl2(PhCN)2, MeCN, 60 °C.
The synthesis of 3(2//)-furanone systems has been reported by Raphael et al,33 in the 
synthesis of bullatenone 12, through the heating of the intermediate 11 with potassium 
carbonate in methanol.
1211
Scheme 1.1.8. Preparation of the 3(2//)-furanone 12. i. K2C03, methanol, reflux.
In an analogous system to that used by Raphael et al.,34 Baldwin et al. famously used the 
base induced cyclisation of 13 in methanol as a test system for the 5-endo-dig type ring 
closure,35 and again more recently in the synthesis o f (-)-muscarine.36
13 12
Scheme 1.1.9. The Baldwin test system for 5-endo-dig ring closure, i. NaOMe, MeOH.
One of the more recent methods of dihydrofuran generation has been reported by Evans 
et al?1 and references the use o f palladium (II) in efforts to generate 15.
Scheme 1.1.10. Preparation of dihydrofuran 15. i. Pd(OAc)2, acetic acid, dichloromethane.
1.1.3 Mercury Catalysed Synthesis of 2,3-Dihydropyran-4-ones and 
3(2H)-Furanones
Marson and co-workers have reported the mercury mediated and stereocontrolled 
rearrangement of l-alkynyl-2,3-epoxy alcohols in acidic media. This is a versatile 
reaction that tolerates a wide variety o f functionality, and which can be modified to 
incorporate additional functionality into the pyranoid system.
17
H OH
16
Scheme 1.1.11. General representation for the preparation of pyranoid systems using the mercury 
mediated cyclisation strategy, i. Hg+2/H+, acetone.
13
The configuration of the 2,3-disubstituted dihydropyranone is determined by the 
stereochemistry of the l-alkynyl-2,3-epoxy alcohol (16), which results from asymmetric 
epoxidation of the chosen enynol precursor.
The reaction is believed to proceed though a semi-pinacol rearrangement o f the epoxide, 
swiftly followed by ring closure; however, no intermediates have been found.
Scheme 1.1.12. The rearrangement of epoxy alkynols to give 2,3-dihydro-4//-pyran-4-ones.
The construction of pyranoid systems using the mercury(II) mediated methodology can 
be applied to the synthesis o f naturally occurring compounds. The methodology allows 
the preparation of complex pyranoid systems, which are often found as essential 
components of natural products. The pyranoid system can be synthesised as a small 
fragment, and incorporated into the synthetic procedure as a component within a larger 
convergent synthesis. The mercury(II) mediated methodology also permits the 
generation of the pyranoid system at a later point in the synthesis, this is due to the mild 
reaction conditions and the tolerance o f a wide variety of functional groups, and results 
in greater flexibility in the overall synthesis o f the target compound.
The use o f the mercury(II) mediated cyclisation reaction to generate simple pyranoid 
systems are to be investigated, where R1 to R4 are simple alkyl or phenyl moieties. 
Inclusion o f more complex functional groups in R1 to R4 would allow elaboration of the 
pyranoid system, and could be used to devise syntheses o f natural products such as 
fostriecin,39 phospholine,40 and pironetin,41 illustrated in figure 1.1.13.
H U n + 2 /l_ | +
16 18 17
14
OH
PhospholineOH
H2N
Figure 1.1.13. The natural products fostriecin (top), pironetin (middle), and phospholine (bottom).
Using analogous methodology, Marson et al?% recently reported the use of the mercury 
mediated cyclisation to generate 3(2//)-furanone systems,42 with varied functionality. 
Such systems are of great interest as they constitute versatile precursors in the synthesis 
of natural products.
Scheme 1.1.14. Synthesis of 3(2//)-fiiranone systems using the mercury mediated cyclisation strategy, i. 
Hg+2/H+, acetone.
The generation o f tetronic acid frameworks (5), or butenolide (4) would be possible 
using this methodology, where the use o f a carefully constructed 3(2//)-furanone system 
could be modified into the unsaturated lactones seen in figure 1.1.15.
15
OH
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Figure 1.1.15. Butenolide (4) and tetronic acid frameworks (5).
The synthetic utility of fragment such as 20, and dihydropyranone systems demands 
investigation. The Marson method38 of 3(2//)-furanone and 2,3-dihydropyran-4-one 
generation, could be utilised in synthetic studies to greatly improve upon, and optimise 
the synthesis of natural products across a wide range o f biologically active targets.
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1.2 Results and Discussion
1.2.1 Preparation of 2,3-Disubstituted Dihydropyran-4-ones
Preparation of 2,3-disubstituted dihydropyran-4-ones was attempted using the procedure 
outlined in scheme 1.2.1.
0  QH OH
J ^   JL
22 R=(CH2)2CH3) 92% 24 R=(CH2)2CH3) 63%
23 R=C6H5, 55% 25 R=C6H5, 52%
27
(37%)
26
(45%)
O R
Scheme 1.2.1. Preparation of 2,3-disubstituted dihydropyran-4-ones. R= -(CH2)2CH3, -C6H5. i. «-BuLi,
THF, HC=C-R; ii. VO(acac)2, /-butylhydroperoxide, benzene; iii. Hg+2/H+, acetone
Preparation of the scaffolds 22 and 23 was accomplished by addition of lithium 
acetylides, prepared by the action of w-butyllithium upon pent-l-yne and phenyl 
acetylene respectively, to the enal 21. Conversion into the epoxy alcohol was achieved 
using vanadyl acetylacetanoate, tert-butylhydroperoxide in benzene with yields of 63% 
and 52% for the pentyne (24) and phenylacetylene (25) derivatives respectively.
In order to conduct the cyclisation procedure upon the intermediates 24 and 25, a 
mercury containing solution, comprising mercury (II) oxide yellow, water, and sulfuric 
acid was prepared. A small quantity o f the catalytic solution (typically 0.2 mL) was 
added to a reaction vessel charged with analytical grade acetone, and the scaffold which 
was to undergo the cyclisation procedure. Reaction progress was monitored by TLC, 
using cerium(IV) sulfate solution as a stain to visualise the epoxide starting material. 
Reaction time was rapid, with the epoxide being undetectable by TLG within 10
17
minutes. Quenching the reaction with the addition of sodium hydrogen carbonate, and 
stirring for 1 hour, gave the crude products after filtration and concentration. Flash 
column chromatography was used to obtain the pure samples 26 and 27 in 45% and 37% 
yield respectively. Analysis o f lH and 13C NMR data clearly identified the 
dihydropyranone products, the olefinic hydrogen and carbon being distinctive in both 
NMR spectra.
Use of the Marson method to generate dihydropyranone systems is synthetically 
attractive, stereocontrol and the mild conditions enable the use of complex fragments in 
the cyclisation stages, simplifying the synthetic complexity o f target synthesis.
Use of an acetylene such as ethoxyacetylene in the initial addition to enal 21 would 
result in the generation of a pyranoid system that could be used to derive unsaturated 
lactone species, by reduction of the carbonyl followed by dehydration. The synthetic 
methodology could be enhanced by the use o f asymmetric reactions such as the powerful 
Sharpless asymmetric epoxidation reaction,43 generation o f stereochemically enriched 
intermediates would provide a route to stereochemically pure pyranoid systems, and 
greatly enhance the utility of the methodology. This would allow the generation of 
products and their various isoforms without significant alteration o f the synthetic 
pathway.
1.2.2 Preparation of Furanones
The proposed synthetic route for the generation of furanone species using the 
mercury(II)-mediated cyclisation strategy can be seen in scheme 1.2.2.
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Scheme 1.2.2. The synthetic route to furanone compounds using the mercury(II)-mediated cyclisation 
strategy, i. «-BuLi, THF, HC=C-R; ii. Mn02, dichloromethane; iii. Sharpless asymmetric dihydroxylation; 
iv. Hg+2/H+, acetone.
Alkynylation of enal 28 affords the central scaffold of the furanone fragment 29. 
Oxidation to the enynone 30, followed by dihydroxylation allows the formation of the 
diol 31. Finally, treatment of the diol with the catalytic mercury mediated cyclisation 
conditions yields the furanone species 32.
The route is particularly convenient in that it enables the use of a variety of starting 
materials, acetylenes, and can be modified to take advantage of sterochemically 
controlled dihydroxylation reactions to specifically target desired furanone species.
A small number of substrates were prepared in order to examine the applicability of the 
synthetic route. Scaffold fragments were prepared according to the general reaction 
outlined in scheme 1.2.3.
The general reaction to prepare the enynol scaffold was conducted in dry 
tetrahydrofuran, at -78 °C. Lithium acetylides were prepared by the action of 
tt-butyllithium upon suitable acetylenes. Once prepared, the acetylides were transferred 
by cannula to a vessel containing the appropriate conjugated aldehyde substrate, where 
the coupling reaction took place. After a short period, using thin layer chromatography 
to monitor the reaction, disappearance o f the carbonyl compound would be total and the 
reaction would be considered complete. Work-up, followed by purification using flash 
column chromatography gave the required products, which can be seen as summarised in 
table 1.2.4.
19
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Scheme 1.2.3. Assembly of the carbon framework, i. «-BuLi, THF, HC=C-R.
Compound R1 R2 R3 Yield
32 -H -c h 3 -(CH2)2CH3 68%
33 -(CH2)2CH3 -H -o c h 2c h 3 80%
34 -(CH2)2CH3 -H -OTBS 45%
35 -(CH2)3CH3 -H -(CH2)4CH3 54%
36 -c 6h 5 -H -o c h 2c h 3 55%
Table 1.2.4. Preparation of the Compounds 32 to 36.
Oxidation of the enynol to an enynone was found to be easily accomplished using 
manganese dioxide in dichloromethane, using a method outlined by Jacobi et al.44 in 
their oxidation of enynol substrates.
The enynol was typically added in one portion to a rapidly stirring suspension of 
activated manganese dioxide in dichloromethane under nitrogen. Stirring the mixture 
vigorously at room temperature afforded the enynone after 12-24 hours. Filtration 
allowed isolation o f the enynone product after concentration. The reaction was found to 
be greatly dependent upon a variety of factors, and although simple to conduct, was 
unreliable due to inconsistent oxidative yields; however, the mild reaction conditions 
were considered to be o f greater importance than the overall product yield and it was 
used in preference to other oxidative techniques. The enynones generated are detailed in 
table 1.2.6.
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Scheme 1.2.5. Oxidation of enynols to enynones. i. M n02, dichloromethane, 12-24 h.
Compound R1 R2 R3 Yield
37 -H -c h 3 -(CH2)2CH3 83%
38 -(CH2)2CH3 -H -o c h 2c h 3 18%
39 -(CH2)2CH3 -H -OTB S 84%
40 -(CH2)3CH3 -H -(CH2)4CH3 69%
41 -c 6h 5 -H -o c h 2c h 3 51%
Table 1.2.6. Preparation of the Compounds 37 to 41.
Sharpless asymmetric dihydroxylation according to the general scheme 1.2.7 was 
applied to the enynones.
The intermediates were dihydroxylated using fortified AD-mix-p (1 mol % of 
K2O s02(OH)4 and 1 mol % of ligand) and additional sodium hydrogen carbonate 
according to a procedure reported by Sharpless et al.45 A solution containing 1:1 
tert-butyl alcohol:water, AD-mix-p, 3 equivalents of sodium hydrogen carbonate, and 1 
equivalent o f methanesulfonamide was prepared, and cooled to 0 °C. The substrate was 
added to the vessel, and stirred vigorously until the reaction was complete by TLC. 
Warming the reaction to room temperature, followed by extraction o f products into ethyl 
acetate gave the crude diols. Purification using column chromatography then allowed the 
isolation o f the pure diol. The outcome o f the dihydroxylations can be seen in table
Scheme 1.2.7. Sharpless asymmetric dihydroxylation of enynones. i. Modified AD-mix-P, r-butyl alcohol, 
water, methanesulfonamide, NaHC03, 0 °C.
Compound R1 R2 R3 Yield
42 -H -c h 3 -(CH2)2CH3 0%
43 -(CH2)2CH3 -H -o c h 2c h 3 24%
44 -(CH2)2CH3 -H -OTB S 0%
45 -(CH2)3CH3 -H -(CH2)4CH3 54%
46 -c 6h 5 -H -o c h 2c h 3 0%
Table 1.2.8. Preparation of the compounds 42 to 46 by Sharpless asymmetric dihydroxylation.
Dihydroxylation of the enynone intermediates was found to be lengthy, with reaction 
times far longer then anticipated, even while using fortified AD-mix-p and 
methanesulfonamide. Reactions designed to produce the compounds 42, and 46, resulted 
in the recovery of starting material, with no diol products. The compound 39 did not 
generate the required diol, but produced unwanted side products. It was considered that 
46 would spontaneously cyclise to the furanone species, due to the electron donating 
effect of the ethoxy R3 moiety; however, this was found to be incorrect, and neither the 
diol nor furanone species had been formed.
38 and 40 were successful in generating the diol species 43 and 45 respectively, albeit in 
low yields. The intermediate 43 degraded rapidly upon standing, and prevented accurate 
measurement o f e.e.
The e.e. o f 45 was measured using a chiral column chromatography (Chiracel OD) to be 
6%, an apparent lack of facial specificity in the dihydroxylation reaction.
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Scheme 1.2.9. Preparation of the furanone species, i. Hg+2/H+, acetone.
Material obtained from the dihydroxylation of the enynones was rapidly taken into the 
mercury mediated cyclisation. 43 and 45 were placed into a vessel containing acetone, 
and a small quantity (0.2 mL) of a freshly prepared mercury containing stock solution 
was added. The reaction was monitored by TLC, using anisaldehyde stain to visualise 
starting material and products. Once starting material was consumed, the reaction was 
quenched, and column chromatography used to separate and extract reaction products. 
Isolation and analysis of the reaction mixtures was unable to identify any of the desired 
furanone material.
The failure of the synthetic route to generate any furanone material required further 
investigation; however, the generation of intermediates in sufficient quantities appeared 
to be problematic due to the ineffective dihydroxylation of enynones. A secondary route 
was established to derive the intermediates required for mercury-mediated cyclisation.
1.2.3 Preparation of Furanones Using Weinreb Amides
In previous routes to generate diol intermediates for the mercury-mediated cyclisation, 
the main failure was due to unsuccessful asymmetric dihydroxylation. Poor performance 
of the Sharpless asymmetric dihydroxylation upon electron deficient olefins is known to 
occur.45 It was considered that it may be advantageous to re-sequence the 
dihydroxylation and acetylene coupling reactions to prevent unfavourable electronic 
effects upon the olefin, and to increase the level of catalytic turnover and facial 
specificity in the Sharpless dihydroxylation reaction.
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Scheme 1.2.10. The synthetic route to the dihydroxylated Weinreb amide, i. SOCl2, benzene, reflux; ii. 
HN(OMe)Me.HCl, Et3N, dichloromethane; iii. Modified AD-mix-P, 1:1 /-butyl alchol:water, NaHC03, 
MeS02NH2; iv. Acetone, 2,2-dimethoxypropane,/?-toluenesulfonic acid.
The Weinreb amide 50 was generated from the acid 48 in 72% over two steps. Sharpless 
asymmetric dihydroxylation gave the diol 51, which was then quickly protected to give 
the Weinreb intermediate 52. Coupling of acetylenes to the fragment could proceed 
according to previously established procedures, to give the protected fragment 53. 
Continuation to the furanone fragment could then proceed. The synthetic route can be 
seen in scheme 1.2.11.
24
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54
R
Scheme 1.2.11. Preparation of the furanone using the modified synthetic sequence. R = phenyl acetylene, 
?er/-butyldimethyl(prop-2-ynyloxy)silane. i. HOC-R, «-BuLi, THF; ii. 2 M HC1, methanol; iii. Hg+2/H+, 
acetone.
The Weinreb amide fragment 52 was alkynylated according to procedures previously 
established in the preparation of enynols. Two fragments were constructed, one from 
phenylacetylene, and an additional fragment from
terr-butyldimethyl(prop-2-ynyloxy)silane (56 and 59 respectively, scheme 1.2.12).
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Scheme 1.2.12. Construction of the furanone fragments 58 and 61. i. 2 M HC1, methanol; ii. Hg+2/Hf, 
acetone.
Attempts to use the acidic media of the mercury mediated cyclisation procedure to 
facilitate concomitant deprotection and cyclisation were unsuccessful. The sequential 
deprotection, isolation of the diol, and introduction of the intermediates to the mercury 
containing solution was therefore necessary.
The deprotection of the diols proceeded in good yields o f 81% and 72% (57 and 60 
respectively), in methanol and 2 M hydrochloric acid. The diols were isolated, followed 
by application of the mercury containing solution in acetone. The cyclisation reactions 
were conveniently monitored by TLC, using anisaldehyde stain to visualise products.
Diol 60 failed to generate any furanone material. Analysis of material from the reaction 
after work up, indicated that TBS protecting group cleavage had occurred and complex 
reaction products had been formed. Application of the mercury-containing solution to 
diol 57 was successful, and resulted in the generation of 58 in 77%. Analysis of the e.e 
of the diol, and fuanone systems using chiral column chromatography, determined the 
diol to possess an e.e. o f 82%, and the mercury cyclised material to have an e.e. o f 66%.
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1.2.4 Preparation of Spiro Compounds
The generation of spiro compounds using the mercury mediated cyclisation reaction is of 
great synthetic potential. Application of the mercury mediated cyclisation strategy using 
cyclic diol intermediates was undertaken.
In the first instance, a preliminary investigation into [5.4] spiro systems was initiated. 
Scheme 1.2.13 illustrates attempts to prepare the diol intermediate 65 required for 
mercury mediated cyclisation.
OH
Scheme 1.2.13. Preparation of the diol 65. i. w-BuLi, THF, ethoxyacetylene, -78 °C; ii. Mn02, 
dichloromethane; iii. Modified AD-mix-(3, 1:1 /-BuOH:water, NaHC03, MeS02NH2.
Cyclohexene-l-carboxaldehyde was treated with ethoxyacetylene and «-butyllithium in 
tetrahydrofuran, generating the enynol 63 (42% yield). The choice o f a,p-unsaturated 
aldehyde was based upon the previous reports of Sharpless et a l 45 and their efforts to 
successfully dihydroxylate 1 -acetylcyclohexene using modified AD-mix reactants. It 
was believed that the dihydroxylation o f the enynone 64, generated by MnC>2 oxidation, 
would undergo dihydroxylation similarly; however, enynone 64 using fortified AD-mix- 
p failed to generate any dihydroxylated material or [4.5] spiro material from spontaneous 
cyclisation.
An alternate system was attempted, altering both the a,p-unsaturated aldehyde and the 
acetylene moiety in the intermediates. 1-Cyclopentene-l-carboxaldehyde (6 8 ) was
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prepared from the diol 67 using sodium periodate followed by base.46 Alkynylation 
using «-pentyne and M n02 oxidation yielded the intermediate 71, acetylation using 
phenyl acetylene and oxidation yielded 72.
O 24% CCOH 46%
66 67 68
in
OH OH
IV
R R
73 R=(CH2)2CH3, 0% 71 R=(CH2)2CH3) 81 % 69 R=(CH2)2CH3, 70%
74 R=phenyl, 0% 72 R=phenyl, 84% 70 R=phenyl, 85%
Scheme 1.2.14. Preparation of the diol intermediates for spiro target generation, i. 10% H2S04, 12 h; ii. 
NaI04, water, 20% KOH; iii. HC=C-R (R = phenylacetylene, «-pentyne), n-BuLi, THF; iv. Mn02, 
dichloromethane; v. Modified AD-mix-|3, 1:1 t-BuOH:water, NaHC03.
Dihydroxylation of the enynones 71 and 72 failed to afford products, hydroxylated or 
otherwise.
The inability to perform asymmetric dihydroxylation reactions severely limits the scope 
of the synthetic utility of the method; however, in order to assess the cause of 
intermediate inactivity, the enynone 71 was dihydroxylated according to the Upjohn
47aprocess.
O H o
■ »»
68% 80%
OHOH
71 75
Scheme 1.2.15. Preparation of the [4.4] spiro compound 76. i. Potassium osmate, N-methylmorpholine 
(monohydrate), /-BuOH, acetone, water; ii. Hg+2/H+, acetone.
Using the Upjohn process it was possible to dihydroxylate 71 to 75 in 6 8 %, isolating the 
diol as a pale oil. Treatment o f the diol with the catalytic mercury solution afforded the 
[4.4] spiro compound 76 (80%), identified by and 13C NMR. In particular, the C=0
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carbon at 206.3 ppm corresponded to the strained carbonyl group in the five-membered 
ring, rather than that in the isomeric 4//-pyran-4-one ring. Additionally, the central spiro 
carbon was distinctive at 96.6 ppm, and the alpha-hydrogen of the furanone ring could 
be clearly seen at 5.41 ppm in the ]H spectra.
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1.3 Conclusion
The synthesis of 2,3-dihydropyran-4-ones, 3(2//)-furanones and related spiro compounds 
has been demonstrated. The synthetic utility o f the mercury mediated cyclisation 
procedure is currently limited when attempting to generate furanyl species, due to the 
inability to generate the required diol intermediates stereoselectively. Modification o f the 
Sharpless asymmetric epoxidation, possibly through the use of alternate chiral ligands, 
could provide a means to obtain material o f acceptable stereochemical purity. 
Alternatively, all methodology would have to pass though an intermediate subjected to 
asymmetric dihydroxylation prior to the construction of the central framework, as was 
demonstrated through Weinreb amide intermediates. The generation of furanone 
systems, if possible by this method, remains an interesting possibility and warrants 
further investigation, particularly with respect to stereoselective intermediate generation.
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1.4 Experimental
Thin-layer chromatography (TLC) analyses were performed on Merck 0.2 mm 
aluminium-backed silica gel 60 F25 4  plates and components were visualized by 
illumination with UV light or through the use o f with anisaldehyde stain. Flash column 
chromatography was performed using Merck 0.040 to 0.063 mm, 230 to 400 mesh silica 
gel. !H NMR spectra were recorded on a 300 MHz Bruker AC300 spectrometer. 
Chemical shifts are reported in parts per million (ppm) downfield from internal 
tetramethylsilane (TMS), using residual chloroform (7.27 ppm) as an integral standard. 
The following abbreviations are used to describe NMR signals: 8 , chemical shift; s, 
singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad. Coupling constants J  are 
given in Hertz (Hz). 13C NMR were recorded on a 300 (75 MHz) Bruker AC300 
spectrometer. Chemical shifts are reported in parts per million (ppm) downfield from 
TMS, using the middle resonance o f C D C I 3  (77.0 ppm) as an integral standard. Mass 
spectra were obtained by using a VG7070H mass spectrometer with Finigan Incos II 
operating in electron impact (El) mode, unless otherwise specified in the text. Starting 
materials were purchased from the Aldrich or Lancaster chemical companies. 
Tetrahydrofuran (THF) was distilled from sodium/benzophenone prior to use. Ether 
refers to diethyl ether. All glassware was oven-dried, assembled hot and cooled under a 
stream of nitrogen gas before use. Reactions with air-sensitive materials were carried 
out by standard syringe techniques. Temperatures of -  78 °C were obtained by the 
addition o f dry ice to acetone; -10 °C by the addition of acetone to ice.
te/,*-Butyldimethyl(prop-2-ynyloxy)silane47b
o^TBSTo a stirring solution o f propargyl alcohol (1.86g, 33.2 mmol), imidazole Y
(4.25 g, 66.4 mmol) in DMF (100 mL), TBS-C1 (5 g, 33.2 mmol) was 
added in one portion. The mixture was stirred at room temperature for 12 h. Ethyl 
acetate (50 mL) and water (50 mL) was added. Organic fractions were separated, and 
washed with water (3 x 20 mL). The organic material was dried (MgSO^ and 
concentrated under reduced pressure to give the crude product. Purification by column 
chromatography using an eluant o f 9:1 hexane:ethyl acetate gave the required product as 
an oil, 5.39 g, 95%. 'H NMR (300MHz, CDC13), 5H 4.28 (s, 2H, HC=CH2-), 2.39 (s, 1H,
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HOCHh-O), 0.88 (s, 9H, 0-TBS). 0.11 (s, 6 H, 0 - TBS1. 13C NMR (75 MHz, CDC13), 8 C
82.4,72.8,51.5,25.7,18.3,-3.6.
(£)-Hex-2-enal47c
O
To trans-hexen-1 -ol (4 g, 39.9 mmol) in dichloromethane (200 mL), celite 
(17.2 g), and PCC (2 eq, 17.2 g, 79.8 mmol) was added. The suspension was 
stirred at room temperature for 3 h. The reaction mixture was then filtered 
through a short silica plug, and the filtrate concentrated under reduced pressure to give 
the product which required no further purification, 3.83 g, 98%. !H NMR (300MHz, 
CDC13), 8 h 9.47 (d, .7=8.0 Hz, 1H, CH=CH-CHO), 6.82 (dt, 7=16.0, 7.0 Hz, 1H, CH2- 
CH=CH), 6.08 (dd, 7=16.0, 8.0 Hz, 1H, CH=CH-CHO), 2.28 (m, 2H, CH2-CH2-CH),
1.51 (m, 2H, CH3-CH2-CH2), 0.93 (t, 7=7.3 Hz, 3H, CH3-CH2-CH2). 13C NMR (75 
MHz, CDCI3), 8 c 194.1,158.7,133.1, 34.6,21.1, 13.6.
(£>Hept-2-enal47d
o
To a stirring suspension of PCC (6.5 g, 30 mmol) and celite (6.5 g) in 
dichloromethane (60 mL), (Zs)-hept-2-en-1 -ol (2 g, 20.0 mmol) was added in 
one portion. The mixture was stirred, and monitored by TLC. Upon 
completion, the reaction mixture was filtered through a silica plug. 
Concentration of the filtrate under reduced pressure gave the required material as an oil, 
which required no further purification, 1.32 g, 59%. *H NMR (300MHz, CDCI3), 8 h 9.5 
(d, 7=7.9 Hz, 1H C H C H -CHOL 6 . 8  (dt, 7=15.6, 6 . 8  Hz, 1H, CH2-CH=CH), 6.1 (dd, 
7=15.6, 7.9 Hz, 1H, CH=CH-CHO), 2.27 (dt, 7=7.4, 6 . 8  Hz, 2H, CH-CTL-CHA 1.67- 
1.20 (m, 4H, CH3 -CH2 -CH2, CH2-CH2-CH2), 0.93 (t, 7=7.4 Hz, 3H, CH3-CH2-CH2). 13C 
NMR (75 MHz, CDC13), 5C 194.1, 158.7, 133.1, 34.7, 31.1, 21.0, 13.6. HRMS calcd. for 
C7Hi20  (M+H) 113.0966, found 113.0965
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(E)-4-Methyldec-3-en-6-yn-5-ol (22)
To a stirring solution of pentyne (3.55 g, 52.1 mmol) in 100 mL of ho
THF at 0 °C, ?2-butyllithium was added (2.5 M in hexanes, 22.5 /  =  \ __
mL, 56.3 mmol). The mixture was stirred for 1 h. /  
2-Methylpent-2-enal (4.65 g, 47.4 mmol) in 30 mL of THF was 
added dropwise to the reaction mixture, and maintained at 0 °C. The reaction was stirred 
for 1 h at 0 °C, then allowed to warm to ambient temperature and stirred for 12 h. The 
reaction was quenched with saturated ammonium chloride solution (50 mL), and 
products extracted into dichloromethane (3 x 30 mL). The organic fractions were 
combined, dried (NaSCU), and concentrated under reduced pressure to give the crude 
product as a light yellow oil. Purification by column chromatography gave the desired 
product as a colourless oil, 7.22g, 92%. IR vmax (KBr, cm'1) 3364 ( O H ) ,  2228 (C=C), 
1624 (C=C). NMR (300MHz, C D C 13) ,  6 H 5.55 (t, ,7=7.0 Hz, 1H, C H 2- C H = C ) ,  4.36 
(m, 1H, C H - O H ) ,  2.22-2.17 (m, 4H, C H 3 - C H 2 - C H ,  O C H 2 - C H 2 ) ,  1.72 (s, 3H, C H 3- C ) ,  
1.56-1.49 (m, 2H, C H 2 - C H 2 - C H 3 ) ,  1.24 (t, 7=7.1 Hz, 3H, C H 3 - C H 2 - C H ) ,  0.96 (t, ,7=7.5 
Hz, 3H, C H . - C H 9 - C H 9 ) .  13C NMR (75 MHz, C D C 13) ,  6 C 134.1, 129.6, 8 6 .6 , 79.7, 68.3,
22.1, 21.0, 20.8, 13.8, 13.5, 12.0. HRMS calcd. for C n H 180  (M-H) 165.1279, found 
165.1289.
l-(3-Ethyl-2-methyl-oxiranyl)-hex-2-yn-l-ol (24)
A solution of benzene (200 mL), 4-methyldec-3-en-6-yn-5-ol (3.0 g, HO 
18 mmol), and vanadyl acetylacetanoate (0.06 g, 0 . 2  mmol) was A q  \
prepared and stirred for 5 min. /ert-butylhydoperoxide (70% 7
solution in water, 3.29 g, 25.2 mmol) was added dropwise, and was stirred at ambient 
temperature overnight. The mixture was then poured onto saturated sodium sulfite 
solution, and the organic layer extracted. The organic layer was dried using sodium 
sulfate, and concentrated under reduced pressure to give the crude product as an oil. 
Purification by column chromatography using an eluant of 9:1 hexane:ethyl acetate gave 
the product as a pale yellow oil, 2.08 g, 63%. IR vmax (KBr, cm'1) 3420 ( O H ) ,  2210 
(O C ). NMR (300MHz, C D C 13) ,  8 H 4.37 (m, 1H, C H - O H ) ,  3.08 (t, 7=5.6 Hz, 1H, 
( 0 ) ( C ) C H - C H 2) ,  2.18-2.16 (m, 2H, C = C H ? - C H A  1.65-1.50 (m, 4H, C H 3 - C H 2 - C H ,  
C H 2 - C H 2 - C H 3 ) ,  1.36 (s, 3H, C H 3 - C ) ,  1.01 (t, 7=7.5 Hz, 3H, C H 3 - C H 2 - C H ) ,  0.95 (t,
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J=7.3 Hz, 3H, CH3 -CH2 -CH2 ). 13C NMR (75 MHz, CDC13), 8 C 86.9, 77.5, 6 6 .8 , 65.1,
61.4,21.9,21.5,20.7,13.7, 13.4, 10.4.
(2s)-4-Methyldec-3-en-6-yn-5-one
To a vigorously stirring suspension of M n02 (13.85 g, 320 mmol) 
in dichloromethane (100 mL), 4-methyldec-3-en-6-yn-5-ol (3.03 g,
19.9 mmol) was added in one portion. The reaction was stirred 
vigorously for 12 h, under an inert atmosphere. No reaction was found to occur.
(£)-4-Methyl-l-phenyl-hept-4-en-l-yn-3-ol (23)
To a stirring solution of phenylacetylene (1.35 g, 13.3 mmol) in 
dry THF (30 mL), «-butyllithium (2.5 M in hexanes, 14.3 mmol) 
was added dropwise at 0 °C. The reaction was stirred for 30 min.
2-Methyl-2-pentenal (1 g, 10.2 mmol) was taken into dry THF (20 mL), and added to the 
reaction mixture. The mixture was warmed to room temperature, and stirred for 8  h. The 
reaction was poured on to sat. ammonium sulfate solution (30 mL), and extracted with 
diethyl ether (3 x 20 mL). Combined organic fractions were dried (MgSCU), and 
concentrated under reduced pressure to an oil. Purification by column chromatography 
using an eluant of 2 : 1  hexane:ethyl acetate gave the required product as a light orange 
oil, 1.12 g, 55%. IR vmax (KBr, cm'1) 3373 (OH), 2201 (C=C), 1625 (C=C). lU NMR 
(300MHz, CDCls), 6 H 7.28-7.46 (m, 5H, Ar-H), 5.69-5.52 (m, 1H, CH2-CH=C), 4.98 (s, 
1H, CH-OH), 2.15-2.04 (m, 2H, CH3 -CH2-CH), 1.82 (s, 3H, CH3-C), 1.00 (t, 7=7.5 Hz, 
3H, CH3 -CH2 -CH). 13C NMR (75 MHz, CDC13), 6 C 133.7, 131.7, 130.2, 128.3, 122.7,
88.7, 85.9, 68.5,21.1, 13.8, 12.2.
l-(3-Ethyl-2-methyloxiran-2-yl)-3-phenylprop-2-yn-l-ol (25)
A solution of benzene (100 mL), 4-methyl-1-phenyl-hept-4-en-l- [_|C> /__ \
yn-3-ol (1.12 g, 5.6 mmol), and vanadyl acetylacetanoate (0.02 /  = / /
g, 0.07 mmol) was prepared and stirred for 5 min. J
7er/-butylhydroperoxide (70% solution in water, 1.3 g, 9.96 
mmol) was added dropwise, and was stirred at ambient temperature for 18 h. The 
reaction was then poured onto saturated sodium sulfite solution, and the organic layer
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extracted. The extracted organic layer was dried using sodium sulfate, and concentrated 
under reduced pressure to give the crude product as an oil. Purification by column 
chromatography using an eluant of 6 : 1  hexane:ethyl acetate gave the product as a pale 
yellow oil, 0.634 g, 52%. IR vmax (KBr, c m 1) 3416 (OH), 2231 (C=C). ‘H NMR 
(300MHz, CDCI3), 8 h 7.46-7.26 (m, 5H, Ar-H), 4.54 (m, 1H, CH-OH). 3.18 (t, 7=6.4 
Hz, 1H, (0)(C)CH-CH2), 1.65-1.57 (m, 2H, CH3-CH2-CH), 1.45 (s, 3H, CTfc-C), 1.24 (t, 
7=7.1 Hz, 3H, CH3-CH2 -CH). 13C NMR (75 MHz, CDCI3), 8 C 131.8, 128.3, 122.3, 8 6 .6 ,
85.9, 67.0, 65.6, 62.0, 21.5, 13.8, 10.4. HRMS calcd. for C 14H 16O2 216.1150, found 
216.1149.
Catalytic Mercury Solution
To a rapidly stirred mixture of water (1.2 mL) and concentrated sulfuric acid (0.125 
mL), mercury (II) oxide yellow (0.11 g, 0.5 mmol) was added. Upon dissolution, 3.7 mL 
of water was added, forming the catalytic mercury solution.
2-Ethyl-3-methyl-6-propyl-2,3-dihydro-4//-pyran-4-one (26)
To a stirring solution of l-(3-ethyl-2-methyl-oxiranyl)-hex-2-yn-l-ol o  
(0.1 g, 0.55 mmol) in HPLC grade acetone (10 mL), 0.1 mL of 
freshly prepared mercury stock solution was added to the reaction 
mixture. The mixture was stirred for 20 min and observed by TLC.
Sodium hydrogen carbonate (0.1 g) was added, and the reaction stirred for 1.5 h. Ethyl 
acetate (10 mL) was added, and the reaction mixture filtered. The filtrate was 
concentrated under reduced pressure, to an oil. Purification by column chromatography 
using an eluant o f 10:1 hexane:ethyl acetate, gave the product 26 as an oil, 46 mg, 45%. 
IR vmax (KBr, cm'1) 1680 (C=0), 1615 (C=C). 'H NMR (300MHz, CDCI3), SH 5.23 (s, 
1H, C=CH-CO), 4.21-4.14 (m, 1H, CH2-CH-(0)(CH)), 2.34-2.18 (m, 3H, CH3 -CH, C- 
CH2 -CH2), 1.93-1.72 (m, 2H, CH3-CH2 -CH), 1.63-1.55 (m, 2H, CH2 -CH2 -CH3), 1.04- 
0.97 (m, 6 H, CH3-CH2-CH, CH3-CH), 0.94 (t, 7=7.1 Hz, 3H, CH3-CH2-CH2). 13C NMR 
(75 MHz, CDCI3), 8 C 198.1, 178.0, 102.7, 83.2, 42.5, 36.5, 23.4, 19.8, 13.5, 9.8, 9.5. 
HRMS calcd. forC ,1Hi80 2 182.1307, found 182.1310.
35
2-Ethyl-3-methyl-6-phenyl-2,3-dihydro-4//-pyran-4-one (27)
To a stirring solution of l-(3-ethyl-2-methyl-oxiranyl)-3-phenyl- q
prop-2-yn-l-ol (0.1 g, 0.46 mmol) in HPLC grade acetone (10 mL),
0.1 mL of freshly prepared mercury stock solution was added to the 
reaction mixture. The mixture was stirred for 20 min, and observed 
by TLC. Sodium hydrogen carbonate (0.1 g) was added, and the reaction stirred for 1.5 
h. Ethyl acetate (10 mL) was added, and the reaction mixture filtered. The filtrate was 
concentrated under reduced pressure, to an oil. Purification by column chromatography 
using an eluant o f 10:1 hexaneiethyl acetate, gave 27 as an oil (38 mg, 37%). IR vmax 
(KBr, cm'1) 1662 (C=0), 1605 (C=C). ‘H NMR (300MHz, CDC13), SH 8.03-7.73 (m, 5H, 
Ar-H), 5.94 (s, 1H, CCH-CO). 4.45-4.39 (m, 1H, CH2-CH-(0)(CH)), 2.47-2.42 (m, 1H, 
CH3-CH), 2.10-1.95 (m, 1H, CH3-CHH-CH), 1.75-1.66 (m, 1H, CH3-CHH-CH), 1.44-
1.09 (m, 3H, CH3-CH), 0.87-0.82 (m, 3H, CH3-CH2 -CH). I3C NMR (75 MHz, CDCI3), 
8 C 198.3, 169.5, 132.8, 131.6, 128.7, 126.5, 100.6, 83.6, 43.0, 23.6, 10.1, 9.5. HRMS 
calcd. forCi4Hi6C>2 216.1150, found 216.1151.
2-Methyloct-l-en-4-yn-3-ol (32)
To a stirring solution of pentyne (18.6 mmol, 1.27 g) in 50 mL of OH
tetrahydrofuran, was added «-butyllithium (2.5 M in hexanes, 19.5 
mmol) dropwise at room temperature. The mixture was left to stir 
for 30 min, and then methacrylaldehyde (1 g, 14.3 mmol) was added 
to the reaction in THF (20 mL). The mixture was stirred for 3 h, and then quenched with 
the addition of saturated ammonium carbonate solution. Extraction of organic material 
by washing the reaction mixture with dichloromethane (3 x 30 mL) yielded the crude 
product after combination, drying (magnesium sulfate), and concentration under reduced 
pressure. Isolation through the use o f column chromatography, using an eluant of 4:1
hexane:ethyl acetate, gave the desired product as a colourless oil, 1.34 g, 6 8 %. IR vmax
(KBr, cm'1) 3350 (OH), 2208 (C=C), 1650 (C=C). ‘H NMR (300MHz, CDCI3), SH 5.14 
(m, 1H, HHC=C), 4.89 (m, 1H, HHC=C), 4.77 (s, 1H, CH-OH), 2.28-2.15 (m, 2H, CHr 
CH2-CH3), 2.05-1.92 (br, 1H, OH), 1.84 (s, 3H, CH3-C), 1.53 (qt, 7=7.4, 7.2 Hz, 2H, 
CHtCHtCHtI. 0.97 (t, 7=7.4 Hz, 3H, CH3-CH2 -CH2). 13C NMR (75 MHz, CDC13), 8 C
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144.7, 111.9, 8 6 .6 , 79.4, 66.5, 22.0, 20.7, 18.0, 13.5. HRMS calcd. for C9H14O
138.1045, found 138.1044.
(2j)-l-Ethoxyoct-4-en-l-yn-3-ol (33)
OH
To a stirring solution of ethoxyacetylene (21 mg, 3 mmol) in dry 
THF (20 mL), rc-butyllithium (2.5 M in hexanes, 3.04 mmol) was 
added dropwise at 0 °C. The reaction was stirred for 10 min, 
followed by the dropwise addition o f (£)-hex-2-enal (221 mg, 2.25 
mmol). The reaction was stirred at 0 °C for 30 min, then warmed to room temperature. 
The reaction was followed by TLC, and quenched with the addition of saturated 
ammonium chloride solution (10 mL). Ethyl acetate (20 mL) was added, and organic 
material separated from the reaction mixture. The organic fraction was washed with 
water (1 x 5  mL) and brine ( 1 x 5  mL), and dried (M gS04). Concentration under reduced 
pressure gave the crude product. Purification by column chromatography using an eluant 
of 4:1 hexane:ethyl acetate gave the product as an oil, 320 mg, 80%. IR vmax(KBr, cm'1) 
3426 ( O H ) ,  2264 (G C ), 1625 ( C C ) .^  NMR (300MHz, CDC13), 6 H 5.78 (dt, 7=15.2,
6.7 Hz, 1H, C H 2- C H = C H ) ,  5.56 (dd, 7=15.2, 6.0 Hz, 1H, C H = C H - C H ( O H ) ) ,  4.90-4.81 
(m, 1H, C H - O H ) ,  4.09 (q, 7=6.1 Hz, 2H, O - C H 2 - C H 3 ) ,  2.08-1.90 (m, 2H, C H - O L -  
C H 2) ,  1.50-1.27 (m, 2H, C H 9 - C H 9 - C H A  1.23 (t, 7=6.1 Hz, 3H, O - C H 9 - C H A  0.88 (t, 
7=7.3 Hz, 3H, C H 9 - C H 9 - C H O . 13C NMR (75 MHz, CDC13), 6 C 132.5, 130.5, 94.7, 74.6,
62.9, 38.4, 33.9, 22.1, 14.3, 13.7. HRMS calcd. for C i 0H J6O 2 168.1150, found 168.1154.
(2i)-l-(terf-Butyldimethylsilyloxy)non-5-en-2-yn-4-ol (34)
OH
To a stirring solution of ter/-buty ldimethyl(prop-2 - 
ynyloxy)silane (0.4 g, 2.3 mmol) in 20 mL of tetrahydrofuran, 
was added «-butyllithium (2.2 M in hexanes, 2.32 mmol) 
dropwise at room temperature. The reaction was left to stir for 
30 minutes, and then (£)-hex-2-enal (0.17 g, 1.73 mmol) was added to the reaction in 5 
mL of tetrahydrofuran. The reaction was stirred for 3 h, and then quenched with the 
addition of saturated ammonium carbonate solution. Extraction of organic material into 
dichloromethane (3 x 20 mL) yielded the crude product after combination, drying 
(magnesium sulfate), and concentration under reduced pressure. Isolation through the 
use o f column chromatography, with an eluant o f 9:1 hexane:ethyl acetate, gave the
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desired product as a colourless oil, 0.280 g, 45%. NMR (300MHz, CDCI3), 8 h 5.95- 
5.75 (m, 1H, CH2-CH=CH), 5.57 (dd, 7=6.1, 15.3 Hz, 1H, CH=CH-CH), 4.84 (d, 7=6.1 
Hz, 1H, CH-CH(OH)(C)), 4.36 (s, 2H, C-CH2 -O), 2.05-1.95 (m, 2H, CH2-CH2-CH), 
1.50-1.10 (m, 2H, CH3-CH2-CH2), 0.93-0.87 (m, 12H, O-TBS. CH3-CH2-CH2), 0.11 (s, 
6 H, O-TBS). 13C NMR (75 MHz, CDC13), 6 C 133.8, 129.0, 84.5, 84.3, 63.0, 51.8, 34.0,
25.8, 23.3, 18.3, 14.1. HRMS calcd. for Ci5H2802Si 268.1859, found 268.1863.
(E)-T etradec-5-en-8-yn-7-ol (35)
OH
To a stirring solution of heptyne (1.14 g, 11.87 mmol) in dry 
THF (20 mL), w-butyllithium (13.06 mmol) was added 
dropwise. The reaction mixture was then added to a flask 
containing (£)-hept-2-enal (1 g, 8.9 mmol) in dry THF (10 mL) 
via cannula. The reaction was stirred for 1 h, and quenched with the addition of saturated 
ammonium carbonate solution. Extraction of organic material by washing the reaction 
mixture with dichloromethane (3 x 20 mL) yielded the crude product after combination, 
drying (MgS0 4 ), and concentration under reduced pressure. Column chromatography, 
using an eluant of 9:1 hexane:ethyl acetate, gave the desired product (1.34 g, 54%) as a 
colourless oil. IR vmax (KBr, cm'1) 3330 (OH), 2204 (O C ), 1610 (C=C). !H NMR 
(300MHz, CDCI3), 8 h 5.81 (dt, 7= 8.0, 15.7 Hz, 1H, CH2 -CH=CH), 5.57 (dd, 7= 4.4, 
15.7 Hz, 1H, CH=CH-CH(OH)), 4.80 (d, 7=4.4 Hz, 1H, CH-OH). 2.20 (m, 2H, CH- 
CH2-CH2), 2.00-1.90 (m, 2 H, C-CH2-CH2), 1.47-1.30 (m, 1 0 H, -O L-). 1.24 (t, 7=7.2 
Hz, 3H, CH3-CH2), 0.90 (t, 7=4.8 Hz, 3H, CH3 -CH2). 13C NMR (75 MHz, CDC13), 5C
133.2, 129.8, 8 6 .8 , 79.7, 63.2, 34.0, 31.1, 28.3, 22.2, 22.1, 21.0, 18.7, 13.9, 13.7.
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5-Ethoxy-l-phenyl-pent-l-en-4-yn-3-ol (36)
To a stirring solution of ethoxyacetylene (0.44 g, 6.3 mmol) in qh
100 mL of THF at 0 °C, «-butyllithium (2.5 M in hexanes, 6 . 6  
mmol) was added. The mixture was stirred for 1 h.
Cinnamaldehyde (0.621 g, 4.7 mmol) in THF (5 mL) was added 
dropwise to the reaction mixture, and maintained at 0 °C. The reaction was stirred for 1 
h at 0 °C, then allowed to warm to ambient temperature and stirred for 12 h. The reaction 
was quenched with saturated ammonium chloride solution (20 mL), and products 
extracted into dichloromethane (3 x 30 mL). Organic fractions were combined, dried 
(NaS0 4 ), and concentrated under reduced pressure to give the crude product as a light 
yellow oil. Purification by column chromatography gave the desired product as a 
colourless oil, 0.52, 55%. !H NMR (300MHz, CDC13), 8 h 7.52-7.21 (m, 5H, Ar-H), 6.73 
(d, 7=15.6 Hz, 1H, Ph-CH=CH), 6.30 (dd, 7=15.6, 5.7 Hz, 1H, CH=CH-CH(OH)), 5.15- 
5.02 (m, 1H, CH-CH(OH)(C)), 4.15 (q, 7=7.1 Hz, 2H, O-CH2 -CH3), 2.05 (d, 7=5.7 Hz, 
1H, CH-OH), 1.40 (t, 7=7.1 Hz, 3H, CH3-CH2-O). 13C NMR (75 MHz, CDCI3), 5C
136.4, 130.8, 129.7, 128.6, 126.7, 126.5, 95.2, 74.8, 62.9, 37.9, 14.4. HRMS calcd. for 
C13H 14O2 202.0994, found 202.0997.
2-Methyloct-l -en-4-yn-3-one (37)
To a stirring suspension of Mn0 2  (8.2 g, 116 mmol) in o
dichloromethane (35 mL), 2-methyloct-l-en-4-yn-3-ol (1 g, 7.2 
mmol) was added, and stirred for 1 2  h under an inert atmosphere.
The reaction was filtered through celite, and the filtrate concentrated 
under reduced pressure to give the crude product. Column chromatography using an 
eluant of 19:1 hexane:ethyl acetate gave the product as an oil, 820 mg, 83%. IR vmax 
(KBr, c m 1) 2204 (O C ), 1652 (C=0), 1615 (C=C). ‘H NMR (300MHz, CDC13), 8  6.39 
(m, 1H, HHC=C), 5.95 (m, 1H, HHC=C), 2.35 (t, 7=7.0 Hz, 2H, CH2-CH2-C), 1.86 (s, 
3H, CH3-C), 1.64-1.62 (m, 2H, CH2-CH2 -CH3), 1.01 (t, 7=6.4 Hz, 3H, CH2-CH3). I3C 
NMR (75 MHz, CDCI3), 8  180.3, 145.1, 130.3, 94.6, 78.9, 21.3,20.9, 16.1, 13.5. HRMS 
calcd. forC9H130  (M+H) 137.0966, found 137.0971.
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(2s)-l-Ethoxyoct-4-en-l-yn-3-one (38)
To a stirring suspension o f MnC>2 (2.5 g, 28.8 mmol) in O
dichloromethane (20 mL), (£)-l-ethoxyoct-4-en-l-yn-3-ol (0.32 g,
1 . 8  mmol) was added, and stirred for 1 2  h under an inert 
atmosphere. The reaction was filtered through celite, and the filtrate 
concentrated under reduced pressure to give the crude product. Column chromatography 
using an eluant of 9:1 hexane:ethyl acetate gave the product as an oil, 55 mg, 18%. IR 
vmax (KBr, cm'1) 2245 (D C ), 1685 (C=0), 1559 (C=C). *H NMR (300MHz, CDC13), 6 H
6.97 (dt, 7=15.7, 6.9 Hz, 1H, CH2-CH=CH), 6.07 (d, 7=15.7 Hz, 1H, CH=CH-C), 4.32 
(q, 7=7.1 Hz, 2H, C-CH2-CH3), 2.31-2.15 (m, 2H, CH2-CH2-CH), 1.59-1.38 (m, 2H, 
CH3-CH2-CH2), 1.20 (t, 7=7.1 Hz, 3H, O-CH2 -CH3), 0.82 (t, 7=6.2 Hz, 3H, CH2-CH2- 
CH3). 13C NMR (75 MHz, CDC13), 6 C 178.9, 151.6, 132.5, 102.3, 77.5, 34.1, 29.0, 22.6,
14.2, 14.0. HRMS calcd. for Ci0Hi4 O2 166.0994, found 166.0994.
CE)-l-(tert-Butyldimethylsilyloxy)non-5-en-2-yn-4-one (39)
To a stirring suspension of M n02 (16 eq, 1.45 g, 16.64 mmol) in 
dichloromethane (15 mL), (E)-\-{tert-
butyldimethylsilyloxy)non-5-en-2-yn-4-ol (0.28 g, 1.04 mmol) 
was added, and stirred for 12 h under an inert atmosphere. The 
reaction was filtered through celite, and the filtrate concentrated under reduced pressure 
to give the crude product. Column chromatography using an eluant o f 9:1 hexane:ethyl 
acetate gave the product as an oil, 230 mg, 84%. *H NMR (300MHz, CDCI3), 8 h 7.17 
(dt, 7=15.8, 6.9 Hz, 1H, CH=CH-CH2), 6.14 (dt, 7=15.8, 1.5 Hz, 1H, C-CH=CH), 4.73 
(s, 2H, C-CH2-O), 2.31-2.18 (m, 2H, CH-CH2-CH2 ), 1.61-1.43 (m, 2H, CH2 -CH2-CH3), 
0.92 (s, 9H, O-TBS). 0.83 (t, J=4.8 Hz, 3H, CH3-CH2), 0.13 (s, 6 H, O-TBS). 13C NMR 
(75 MHz, CDCI3), 5C 178.2, 154.6, 132.2, 90.7, 82.1, 51.6, 36.0, 25.7, 22.6, 18.2, 13.7, -
5.7. HRMS calcd. for C15H2 7O2S1 (M+H) 267.1780, found 267.1777.
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CE)-Tetradec-5-en-8-yn-7-one (40)
O
To a stirring suspension of PCC (1.55 g, 7.2 mmol) and celite 
(1.5 g) in dichloromethane (20 mL), (£)-tetradec-5-en-8-yn-7-ol 
(1 g, 4.8 mmol) was added in one portion. The mixture was 
stirred, and monitored by TLC. Upon completion, the reaction 
mixture was filtered through a silica plug. Concentration of the filtrate under reduced 
pressure gave the required material as an oil. Purification using column chromatography 
using an eluant of 4:1 hexane:ethyl acetate gave the required material as a pale oil, 0.69 
g, 69%. IR vmax(KBr, c m 1) 2210 (C=C), 1645 (C=0), 1622 (C=C). *H NMR (300MHz, 
CDC13), SH 7.13 (dt, .7=15.8, 6.9 Hz, 1H, CH=CH-CH2), 6.12 (d, J= 15.8 Hz, 1H, C- 
CH=CH), 2.38 (t, .7=7.1 Hz, 2H, C-CTL-CHA 2.32-2.16 (m, 2H, CH-CH2-CH2), 1.81- 
1.49 (m, 4H, C-CH2 -CH2-CH2 , CH-CH2 -CH2-CH2), 1.48-1.19 (m, 6 H, -CH2-), 0.97-0.87 
(m, 6 H, -CH3). 13C NMR (75 MHz, CDCI3), 6 C 179.0, 153.7, 132.5, 94.6, 79.1, 34.4,
31.1,27.5, 22.2, 22.1,21.2, 19.8, 13.9, 13.7.
HRMS calcd. for Ci4H230  (M+H) 207.1749, found 207.1750.
5-Ethoxy-l-phenylpent-l-en-4-yn-3-one (41)
O
To a stirring suspension o f M n0 2 (3.64 g, 41.9 mmol) in 
dichloromethane (15 mL), 5-ethoxy-l-phenyl-pent-l-en-4-yn-3- 
ol (0.55 g, 2.6 mmol) was added, and stirred for 12 h under an 
inert atmosphere. The mixture was filtered through celite, and the filtrate concentrated 
under reduced pressure to give the crude product. Column chromatography using an 
eluant of 6:1 hexane:ethyl acetate gave the product as an oil, 265 mg, 51%. The material 
was used immediately in subsequent stages.
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(S)-l,2-Dihydroxy-2-methyloct-4-yn-3-one (42)
A solution of AD-mix-P (1.4 g, modified to contain 1 mol% of 
potassium osmate dehydrate, and 1 mol% of ligand) with sodium 
hydrogen carbonate (3 mmol) in water (5 mL) and tert-butanol (5 
mL) was prepared. Cooled to 0 °C, the resulting slurry was stirred 
vigorously for 30 min. Methanesulfonamide (95 mg, 1 mmol), was added and stirred for 
5 min. 2-Methyl-oct-l-en-4-yn-3-one (136 mg, 1 mmol) was added in one portion, and 
the mixture stirred vigorously at 0 °C. The reaction was monitored by TLC. Upon 
completion, the reaction was quenched at 0 °C with the addition of sodium sulfite (1.5 
g), warmed to room temperature, and stirred for 1 hour. The reaction mixture was 
extracted with ethyl acetate ( 3 x 1 0  mL), organic fractions combined and washed with 
2M KOH (5 mL), and dried (MgSCTi). Concentration gave the crude product 145 mg. No 
products were identified which corresponded to 42.
(4i?,5*S)-l-Ethoxy-4,5-dihydroxyoct-l-yn-3-one (43)
HO,
potassium osmate dihydrate, and 1 mol% of ligand) with sodium 
hydrogen carbonate (1 mmol) in water (3 mL) and ter/-butanol (3 
mL) was prepared. Cooled to 0 °C, the resulting slurry was 
stirred vigorously for 30 min. Methanesulfonamide (19 mg, 0.2 mmol), was added and 
stirred for 5 min. (£)-l-ethoxyoct-4-en-l-yn-3-one (55 mg, 0.33 mmol) was added in 
one portion, and the mixture stirred vigorously at 0 °C. The reaction was monitored by 
TLC. Upon completion, the reaction was quenched at 0 °C with the addition of sodium 
sulfite (0.65 g), warmed to room temperature, and stirred for 1 h. The reaction mixture 
was extracted with ethyl acetate (3 x 10 mL), organic fractions combined and washed 
with KOH (2M , 5 mL) and dried (MgS0 4 ). Concentration gave the crude product, 
which was purified by column chromatography using an eluant o f 1:9 hexane:ethyl 
acetate to give the product as an oil, 15 mg, 24%. !H NMR (300MHz, CDCI3), 8 h 4.63-
4.52 (m, 1H, HO-CH(C)(CH)), 4.28 (q, 7=7.1 Hz, 2H, O-CH2 -CH3), 4.20-4.06 (m, 1H, 
HO-CH(CH)CH2)), 1.71-1.48 (m, 4H, CH-CH2-CH2-CH3), 1.46 (t, 7=7.1 Hz, 3H, O- 
CH2 -CH3), 0.95 (t, 7=7.2 Hz, 3H, CH2-CH2 -CH3 ). 13C NMR (75 MHz, CDC13), 8 C 185.5,
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88.2, 81.3, 69.8, 68.1, 43.4, 34.7, 18.8, 14.2, 13.8. HRMS calcd. for Ci0Hi6O4 found 
200.1049, found 200.1045.
(5R,65)-l-(terf-Butyldimethylsilyloxy)-5,6-dihydroxynon-2-yn-4-one (44)
A solution of AD-mix-p (0.52 g, modified to contain 1 mol% of
HOpotassium osmate dihydrate, and 1 mol% of ligand) with sodium ‘ i (R)
l (S )
hydrogen carbonate (1.1 mmol) in water (4 mL) and ter/-butanol HO°
(4 mL) was prepared. Cooled to 0 °C, the resulting slurry was 
stirred vigorously for 30 min. Methanesulfonamide (35 mg, 0.37 mmol), was added and 
stirred for 5 minutes (E)-1 -(tert-butyldimethylsilyloxy)non-5-en-2-yn-4-one (100 mg, 
0.37 mmol) was added in one portion, and the reaction stirred vigorously at 0 °C. The 
reaction was monitored by TLC. Upon completion, the reaction was quenched at 0 °C 
with the addition of sodium sulfite (0.70 g), warmed to room temperature, and stirred for 
1 h. The reaction mixture was extracted with ethyl acetate ( 3 x 1 0  mL), organic fractions 
combined and washed with 2M KOH (5 mL) and dried (MgS04). Concentration gave the 
crude product, which was purified by column chromatography using an eluant of 4:1 
hexaneiethyl acetate to give material as an oil which did not correlate to 44.
(51?,6<S)-5,6-Dihydroxytetradec-8-yn-7-one (45)
A solution of AD-mix-p (1.4 g, modified to contain 1 mol% of 
potassium osmate dihydrate, and 1 mol% o f ligand) with sodium 
hydrogen carbonate (1.1 mmol) in water (5 mL) and tert-butanol 
(5 mL) was prepared and cooled to 0 °C. The resulting slurry 
was stirred vigorously for 30 min. Methanesulfonamide (95 mg) was added and stirred 
for 5 min, (£)-tetradec-5-en-8-yn-7-one (206 mg, 1 mmol) was added in one portion, and 
the reaction stirred vigorously at 0 °C. The reaction was monitored by TLC. Upon 
completion, the reaction was quenched at 0 °C with the addition o f sodium sulfite (1 g), 
warmed to room temperature, and stirred for 1 h. The reaction mixture was extracted 
with ethyl acetate ( 3 x 1 5  mL), organic fractions combined and washed with 2M KOH (5 
mL) and dried (M gS04). Concentration gave the crude material, which was purified by 
column chromatography, using an eluant o f 4:1 hexane:ethyl acetate. Analysis of the 
material indicated that 45 was not formed.
'OH
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(4S,5R)-1 -Ethoxy-4,5-dihydroxy-5-phenylpent-l -yn-3-one (46)
A solution of AD-mix-p (0.70 g, modified to contain 1 mol% of O
potassium osmate dihydrate, and 1 mol% of ligand) with Sodium 
hydrogen carbonate (1.4 mmol) in water (2.5 mL) and tert- 
butanol (2.5 mL) was prepared and cooled to 0 °C. The resulting 
slurry was stirred vigorously for 30 min. Methanesulfonamide (46 mg, 0.48 mmol), was 
added and stirred for 5 min. 5-Ethoxy-1-phenyl-pent-l-en-4-yn-3-one (97 mg, 0.48 
mmol) was added in one portion, and the mixture stirred vigorously at 0 °C. The reaction 
was monitored by TLC. Upon completion, the reaction was quenched at 0 °C with the 
addition of sodium sulfite (0.75 g), warmed to room temperature, and stirred for 1 h. The 
reaction mixture was extracted with ethyl acetate (3 x 10 mL), organic fractions 
combined and washed with 2M KOH (5 mL), and dried (MgS0 4 ).
Concentration gave the crude product, which was purified by 
column chromatography using an eluant of 2 : 1  hexane:ethyl 
acetate to give the product as an oil. Analysis o f the material 
indicated that the diol product had not been isolated, and 
spontaneous rearrangement to the furanone had not occurred.
(ii)-Hex-2-enoyl chloride (49)
O
To a vessel containing thionyl chloride (10.4 g, 87.6 mmol) and 2 drops of 
A,A-dimethylformamide in benzene (50 mL), (£)-hex-2-enoic acid (5 g, p
43.8 mmol) was added. The vessel was then heated to reflux for 2 h. The '  
reaction was allowed to cool to room temperature, and benzene removed under reduced 
pressure. The crude material was used without further purification in later stages.
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(Zs)-A-Methoxy-A-methylhex-2-enamide (50)
To a flask containing triethylamine (13.3 g, 109.5 mmol), O
dichloromethane (45 mL), and NH(OMe)Me.HCl (5.13 g, 52.6 mmol), 
crude (£)-hex-2-enoyl chloride (43.8 mmol) in 50 mL of p
dichloromethane was added slowly. The mixture was stirred at room ^  
temperature for 1 h, then extracted with 1 M potassium hydroxide (20 mL), 1 M 
hydrochloric acid (20 mL), water (20 mL), and brine. Combined organic extracts were 
dried with MgSC>4 , and concentrated under reduced pressure. Column chromatography 
using an eluant of 4:1 hexane:ethyl acetate gave the desired product as a yellow oil, 4.97 
g, 72% over two steps from the corresponding acid. IR vmax(KBr, cm'1) 1740 (C=0), 
1608 (C=C). lH NMR (300MHz, CDC13), 6H 6.96 (dt, 7=15.4, 5.2 Hz, 1H, CH=CH- 
CH2), 6.34 (d, 7=15.4 Hz, 1H, C-CH=CH), 3.64 (s, 3H, O - C H 3 ) ,  3.18 (s, 3H, N-CH3),
2.23-2.11 (m, 2H, CH-OL-CHA 1.54-1.38 (m, 2H, CH9-CH9-CHA 0.89 (t, 7=7.4 Hz, 
3H, CH2 -CH2 -CH3 ). 13C NMR (75 MHz, CDC13), 6 C 167.0, 147.6, 118.8, 61.6, 34.5,
32.3,21.5, 13.6. HRMS calcd. for C8Hi5N 0 2 157.1103, found 157.1101.
(2/?,35}-2,3-Dihydroxv-,Y-methoxy-7V-methylhexanamide (51)
A solution of AD-mix-p (1.4 g, modified to contain 1 mol% of q
potassium osmate dehydrate, and 1 mol% of ligand) with sodium 
hydrogen carbonate (120 mg) in water (5 mL) and ter/-butanol (5 hox' 1 ^
mL) was prepared and cooled to 0 °C. The resulting slurry was ^
stirred vigorously for 30 min. Methanesulfonamide (40 mg), was added and stirred for 5 
min. (7T)-A-methoxy-A-methylpent-2-enamide (157 mg, 1 mmol) was added in one 
portion, and the mixture stirred vigorously at 0 °C. The reaction was monitored by TLC. 
Upon completion, the reaction was quenched at 0 °C with the addition of sodium sulfite 
(1.5 g), warmed to room temperature, and stirred for 1 h. The reaction mixture was 
extracted with ethyl acetate (3 x 10 mL), organic fractions combined and washed with 
2M KOH (5 mL), and dried (Na2 S0 4 ). Concentration gave the product 51, 112 mg, 59%. 
JH NMR (300MHz, CDC13), 6 H 4.32 (m, 1H, C-CH(OH)-CH), 3.84 (m, 1H, CH- 
CH(OH)-CH2), 3.70 (s, 3H, 0-CH.). 3.24 (s, 3H, N-CHA 1.71-1.24 (m, 4H, -O L A  
0.92 (t, 7=7.2 Hz, 3H, C H 2 - C H 3 ) .  13C NMR (75 MHz, CDC13), 6 C 173.2, 71.5, 70.6,
61.2, 36.1, 32.5, 18.9, 13.9. HRMS calcd. forC 8Hi7N 0 4 191.1158, found 191.1159.
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(4i?,5,S)-Ar-Methoxy-AL2,2-trimethyl-5-propyl-l,3-clioxolane-4-carboxamide (52)
O
To a vessel containing (2R,3S)-2,3 -dihydroxy-7V-methoxy-7V- 
methylhexanamide (3.69 g, 19.3 mmol), (+/-)-camphorsulfonic acid ^
(0.18 g, 0.8 mmol), and acetone (60 mL), 2,2-dimethoxy propane 
(19.3 mL, 157 mmol) was added. The mixture was stirred and monitored by TLC. Upon 
completion, the reaction mixture was concentrated under reduced pressure, and purified 
using column chromatography with an eluant o f 19:1 hexaneiethyl actate to give the 
desired product as a yellow oil, 3.04 g, 6 8 %. !H NMR (300MHz, CDCI3), 8 h 4.50-4.21 
(m, 2H, C-CH(OH)-CH, CH-CH(OH)-CH2), 3.71 (s, 3H, O-CH3), 3.20 (s, 3H, N-CHA 
1.72-1.52 (m, 2H, CH-CH?-CHA 1.49-1.24 (m, 8 H, CH2-CH2 -CH3 , C-(CHA). 0.91 (t, 
.7=7.2 Hz, 3H, CH2 -CH3). 13C NMR (75 MHz, CDC13), 8 C 170.5, 110.3, 78,4, 76.8, 61.6,
35.1, 27.4, 26.1, 19.0, 14.0. HRMS calcd. for CnH2 iN 0 4 231.1471, found 213.1468.
l-((47?,55}-2,2-Dimethyl-5-propyl-l,3-dioxolan-4-yl)-3-phenylprop-2-yn-l-one (56)
O
To a stirring solution of phenylacetylene ( 8 8  mg, 0.9 mmol) in 
3 mL of dry THF at -78 °C, «-butyllithium (1.6 M in hexanes,
0.9 mmol) was added. The reaction was stirred for 1 h. (4R,5S)- J
77-methoxy-TV-,2,2-trimethyl-5-propyl-l,3-dioxolane-4-carboxamide (0.2 g, 0.9 mmol) in 
2 mL of THF was added dropwise to the reaction mixture, and maintained at -78 °C. The 
reaction was warmed to 0 °C, stirred for 1 h, then allowed to warm to ambient 
temperature. The reaction was quenched with saturated ammonium chloride solution (20 
mL), and products extracted into dichloromethane (3 x 30 mL). Organic fractions were 
combined, dried (Na2 S0 4 ), and concentrated under reduced pressure to give the crude 
product as a light yellow oil. Purification by column chromatography gave the desired 
product as a colourless oil, 188 mg, 80%. *H NMR (300MHz, CDCI3), 8 h 7.70-7.30 (m, 
5H, Ar-H), 4.28-4.08 (m, 2H, C-CH(OH)-CH, CH-CH(OH)-CH2), 1.89-1.65 (m, 2H, 
CH-CH2-CH2), 1.61-1.34 (m, 8 H, CH2 -CH2-CH3 , C-(CHAL 0.96 (t, 7=7.3 Hz, 3H, 
CH2-CH3 ). 13C NMR (75 MHz, CDCI3), 8 C 186.6, 133.3, 131.2, 128.7, 119.7, 111.2,
95.3, 86.0, 78.5, 35.5, 27.4, 26.3, 19.0, 14.0. HRMS calcd. for C17H2o0 3 302.3760, 
found 302.3758.
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(4K,5£)-4,5-Dihydroxy-l-phenyloct-l-yn-3-one (57)
O
To a stirring solution of l-((4i?,5S)-2,2-dimethyl-5-propyl-l,3-
IfSJ
dioxolan-4-yl)-3-phenylprop-2-yn-l-one (100 mg, 0.37 mmol) in ho'' i |l I
methanol (5 mL), hydrochloric acid (2 M, 3 mL) was added. The /
reaction was stirred at room temperature, and monitored by TLC. Upon completion, 
material was extracted into dichloromethane ( 3 x 5  mL) and dried (MgS0 4 ). 
Concentration under reduced pressure, followed by purification by column 
chromatography gave the required product as a yellow oil, 69 mg, 81%. Chiral HPLC 
analysis using a Chiralcel OD column and an eluant of 1:9 zso-propanol:hexane with a 
flow rate of 0.7 mL.min'1, determined the e.e. to be 82%. NMR (300MHz, CDCI3), 8 h 
7.70-7.31 (m, 5H, Ar-H), 4.47-4.20 (m, 2H, C-CH(OH)-CH, CH-CH(OH)-CH2), 3.60 
(br, OH), 2.00 (br, OH), 1.86-1.33 (m, 4H, -CH2 -), 1.00 (t, 7=7.3 Hz, 3H, CH2-CH3). I3C 
NMR (75 MHz, CDC13), 8 C 187.7, 133.2, 131.4, 128.8, 119.3, 98.0, 85.0, 80.6, 71.8,
36.5, 19.0, 13.9. HRMS calcd. for Ci4Hi60 3 232.1099, found 232.1104.
(/?)-2-((S)-l-Hydroxybutyl)-5-phenylfuran-3(2H)-one (58)
To a stirring solution of (4R,5S)-4,5-dihydroxy- 1-phenyloct- 
l-yn-3-one (69 mg, 0.30 mmol) in acetone (5 mL), was 
added 0.2 mL of a mercury containing solution. The reaction 
was then allowed to stir, until complete by TLC (approximately 10 min). Sodium 
hydrogen carbonate (50 mg) was added and allowed to stir for 20 min. Filtration of solid 
material from the reaction mixture, followed by extraction into ethyl acetate (15 mL), 
drying with sodium sulfate, and concentration yielded the crude furanone. Purification 
by column chromatography (with an eluant of 2 : 1  hexane:ethyl acetate) yielded the 
desired furanone as a colourless oil, 53 mg, 77%. Chiral HPLC analysis using a 
Chiralcel OD column and an eluant of 1:9 /so-propanol:hexane with a flow rate of 0.7 
mL.min'1, determined the e.e. to be 6 6 %. IR vmax(KBr, cm'1) 3410 ( O H ) ,  2262 ( C = 0 ) ,  
1676 (C=C). NMR (400MHz, CDC13), 8  7.96-7.57 (m, 5H, Ar-H), 6.36 (s, 1H, C- 
C H = C ) ,  4.90 (d, 7= 6 . 8  Hz, 1H, C - C H ( 0 ) ( C H ) ) ,  4.69 (m, 1H, C H - O H ) ,  3.89 (m, 1H, C -  
C H ( O H ) - C H 2) ,  1.67 (dt, 7= 7.6, 6 . 8  Hz, 2H, C H ^ C H r C H ) ,  1.56-1.29 (m, 2H, C H 3-  
CH2 -CH2), 0.92 (t, 7= 7.4 Hz, 3H, CH2 -CH3). 13C NMR (100 MHz, CDC13), 8  202.5,
OH
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185.1, 132.6, 128.9, 128.8, 127.0, 101.8, 88.4, 69.4, 35.6, 18.4, 13.8. HRMS calcd. for 
Ci4Hi60 3 232.1099, found 232.1102.
4-(te7tf-Butyldimethylsilyloxy)-l-((4/?,55')-2,2-dimethyl-5-propyl-l,3-(iioxolan-4-
yl)but-2-yn-l-one (59)
To a stirring solution o f ter/-butyldimethyl(prop-2- 
ynyloxy)silane (93.7 mg, 0.55 mmol) in dry THF (5 mL) at - 
78 °C, «-butyllithium (1.6 M in hexanes, 0.6 mmol) was 
added. The mixture was stirred for 1 h. (4i?,55)-iV-methoxy-7Vr-2,2-trimethyl-5-propyl- 
l,3-dioxolane-4-carboxamide (0.112 g, 0.5 mmol) in THF (5 mL) was added dropwise to 
the reaction mixture, and maintained at -78 °C. The mixture was warmed to 0 °C, stirred 
for 1 h, and allowed to warm to ambient temperature. The reaction was quenched with 
saturated ammonium chloride solution (20 mL), and products extracted into 
dichloromethane (3 x 30 mL). Organic fractions were combined, dried (Na2 S0 4 ), and 
concentrated under reduced pressure to give the crude product as a light yellow oil. 
Purification by column chromatography using an eluant of 19:1 hexane:ethyl acetate 
gave the desired product as a colourless oil, 129 mg, 76%. *H NMR (300MHz, CDCI3), 
8 h 4.91-4.73 (m, 1H, C-CH(OH)-CH), 4.74 (s, 2H, C-CH2-O), 4.20-4.00 (m, 1H, CH2- 
CH(OH)-CH), 1.80-1.60 (m, 2H, CH-OL-CHA 1.59 -1.36 (m, 8 H, CH2-CH2-CH3 , 
(CH3 )2-C), 1.06-0.74 (m, 12H, O-TBS. CH,-CHO. 0.12 (s, 6 H, O-TBSl. 13C NMR (75 
MHz, CDCI3), 8 C 185.3, 111.2, 85.8, 82.0, 78.2, 60.3, 51.5, 35.6, 26.1, 25.7, 18.9, 18.1,
13.9. HRMS calcd. forC is^ C ^ S i (M+H) 341.2148, found 341.2147.
(51?,6S)-l-(te#tf-butyldimethylsilyloxy)-5,6-dihydroxynon-2-yn-4-one (60)
O
HOTo a stirring solution of 14-(ter/-butyldimethylsilyloxy)-l- y R)
I (S)
((4/?,55)-2,2-dimethyl-5 -propyl-1,3 -dioxolan-4-yl)but-2-yn-1 - HO'' 
one (100 mg, 0.29 mmol) in methanol (5 mL), hydrochloric acid 
(2 M, 3 mL) was added. The mixture was stirred at room temperature, and monitored by 
TLC. Upon completion, material was extracted into dichloromethane ( 3 x 5  mL) and 
dried (MgS0 4 ). Concentration under reduced pressure, followed by purification by 
column chromatography gave the required product as a colourless oil, 63 mg, 72%. *H 
NMR (300MHz, CDC13), 5H 4.46 (s, 2H, C-CH2-O), 4.33-4.11 (m, 2H, CH2-CH(OH)- 
CH, C-CH(OH)-CH), 1.77-1.30 (m, 4H, -CH2 -), 0.97 (t, J= 7.2 Hz, 3H, CH2 -CH3), 0.92
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(s, 9H, 0-TBS1. 0.13 (s, 6 H, O-TBS). 13C NMR (75 MHz, CDC13), 8 C 187.9, 96.3, 81.6,
80.5, 71.8, 50.7, 36.0, 25.7, 19.0, 18.2, 13.9. HRMS calcd. for CisHigCUSi 300.1757, 
found 300.1756.
(/?)-5-((^r/-Butyldimethylsilyloxy)methyl)-2-((1S}-l-hydroxybutyl)furan-3(2//)-one 
(61)
To a stirring solution o f ((5R,6S)-\-{tert-
butyldimethylsilyloxy)-5,6-dihydroxynon-2-yn-4-one (50 
mg, 0.17 mmol) in acetone (5 mL), was added 0.2 mL of a 
mercury containing solution. The mixture was then allowed to stir, until complete by 
TLC (approximately 10 min). Sodium hydrogen carbonate (50 mg) was added and 
allowed to stir for 20 min. Filtration of solid material from the reaction mixture, 
followed by extraction into ethyl acetate (15 mL), drying with sodium sulfate, and 
concentration yielded the crude furanone. Purification by column chromatography (with 
an eluant of 2 : 1  hexane:ethyl acetate) yielded complex material that did not correlate to 
61.
l-Cyclohex-l-enyl-3-ethoxyprop-2-yn-l-ol (63)
To a stirring solution o f ethoxyacetylene (5.7 mmol, 0.4 g) in 50 OH
mL of tetrahydrofuran, was added «-butyllithium (2.5 M in 
hexanes, 6.0 mmol, 2.4 mL) dropwise at room temperature. The 
mixture was left to stir for 30 min, and then cyclohex-l-enecarboxaldehyde (4.3 mmol, 
0.474 g, 0.49 mL) was added to the reaction in 20 mL of tetrahydrofuran. The reaction 
was stirred for 3 h, and then quenched with the addition of saturated ammonium 
carbonate solution. Extraction of organic material by washing the reaction mixture with 
dichloromethane (3 x 30 mL) yielded the crude product after combination, drying 
(magnesium sulfate), and concentration under reduced pressure. Isolation through the 
use of column chromatography, using an eluant of 4:1 hexane:ethyl acetate, gave the 
desired product as a colourless oil, 0.484 g, 42%. *H NMR (300MHz, C D C I 3 ) ,  8 h 4.75 
(m, 1H, CH2-CH=C), 4.54 (s, 1H, C-CH(OH)-C), 4.11 (q, .7=7.0 Hz, 2H, O-CH9-CHA
2.23-2.03 (m, 4H, -OL-L 1.67-1.55 (m, 4H, -CH2-), 1.36 (t, .7=7.0 Hz, 3H, CH2-CH3). 
13C NMR (75 MHz, CDC13), 5C 138.1, 123.9, 94.6, 74.6, 6 6 .8 , 38.0, 25.0, 24.0, 22.6,
22.3, 14.4. HRMS calcd. forCnH^O 180.1150, found 180.1152.
OH
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l-Cyclohex-l-enyl-3-ethoxypropynone (64)
To a stirring suspension o f MnC>2 (3.76 g, 43.2 mmol) in o
dichloromethane (35 mL), l-cyclohex-l-enyl-3-ethoxyprop-2-yn- 
l-ol (0.48 g, 2.7 mmol) was added, and stirred for 12 h under an 
inert atmosphere. The mixture was filtered through celite, and the filtrate concentrated 
under reduced pressure to give the crude product. Column chromatography using an 
eluant of 19:1 hexane:ethyl acetate gave the product as an oil, 167 mg, 35%. ‘H NMR 
(300MHz, CDCI3), 8h 6.79 (m, 1H, CH2-CH=C), 4.15 (q, 7=7.1 Hz, 2H, O-CH2-CH3), 
2.38-2.16 (m, 4H, -CH2 -), 1.75-1.50 (m, 4H, -CH2 -), 1.25 (t, 7=7.1 Hz, 3H, CH2-CH3). 
13C NMR (75 MHz, CDCI3), 8 C 168.1, 151.4, 144.8, 101.9, 76.8, 41.8, 26.7, 25.7, 22.0,
21.7, 14.1.
(i?)-5-Ethoxy-2-((iS)-l-hydroxybutyl)furan-3(2//)-one
To a stirring solution of ((4R,5S)~ 1 -ethoxy-4,5-dihydroxyoct- 
l-yn-3-one (50 mg, 0.25 mmol) in acetone (5 mL), was added
0.2 mL of a mercury containing solution. The mixture was 
then allowed to stir, until complete by TLC (approximately 10 min). Sodium hydrogen 
carbonate (50 mg) was added and allowed to stir for 20 min. Filtration of solid material 
from the reaction mixture, followed by extraction into ethyl acetate (15 mL), drying with 
sodium sulfate, and concentration yielded the crude material. No products were found in 
the reaction products, rapid decomposition into intractable mixtures was observed.
OH
(l!?,27?)-Cyclohexane-l ,2-diol (67)
To a flask containing 10% sulfuric acid (150 mL), cyclohexene oxide (15 g,
153 mmol) was added. The reaction was stirred overnight, followed by 
extraction of the products into dichloromethane (3 x 30 mL). Concentration, 
followed by recrystallisation from petroleum ether(40-60 °C):ethyl acetate (approx. 
19:1) gave the product as colourless crystals, 4.25 g, 24%. Material correlated with an 
authentic sample provided by the Aldrich chemical company.
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Cyclopent-l-enecarboxaldehyde (68)
o
To a stirring solution of sodium metaperiodate (6.78 g, 31.7 mmol) in water (80 r  \  {/
mL), toms-cyclohexane-1,2-diol (3 g, 25.8 mmol) was added. The reaction was 
stirred for 30 min, followed by the addition of 20% potassium hydroxide (10 mL) and 
diethyl ether (15 mL). The reaction was stirred vigorously for 10 min. Extraction of 
products into diethyl ether ( 3 x 30 mL), followed by drying (MgSOzO, and concentration 
under reduced pressure to give the crude material. Column chromatography afforded the 
required material as a colourless oil, 1.14 g, 46%. Material correlated with an authentic 
sample from the Aldrich chemical company. !H NMR (300MHz, C D C I 3 ) ,  8 h 9.75 (s, 1H, 
C-CHO), 6.84 (m, 1H, CH2-CH=C), 2.65-2.50 (m, 4H, -CEL-). 2.05-1.85 (m, 2H, CH2- 
CEL-CH?). 13C NMR (75 MHz, CDC13), 8 C 189.8, 153.1, 147.9, 33.6, 28.3, 22.9.
1 -Cyclopentenylhex-2-y n-1 -ol (69)
To a flask containing dry THF (20 mL) and «-pentyne (2.46 mL, 25.0 
mmol) at -78 °C, «-butyllithium (1.6 M in hexanes, 27.5 mmol) was 
added dropwise. The reaction mixture was stirred for 10 min, then 
transferred via cannula to a vessel charged with THF (10 mL), and 
cyclopent-l-enecarbaldehyde (2 g, 20.8 mmol) at -78 °C. The mixture was stirred for 30 
min, and allowed to warm to 0 °C. The reaction was quenched with the addition of 
saturated ammonium carbonate solution. Extraction of organic material by washing the 
reaction mixture with dichloromethane (3 x 20 mL) yielded the crude product after 
combination, drying (MgSOz*), and concentration under reduced pressure. Isolation 
through the use o f column chromatography, using an eluant of 19:1 hexaneiethyl acetate, 
gave the desired product as a pale oil, 2.04 g, 70%. IR vmax(KBr, cm'1) 3335 (OH), 2215 
(C=C), 1612 (O C ). *H NMR (300MHz, CDC13), 5H 5.75 (m, 1H, CH2-CH=C), 4.93 (s, 
1H, C-CH(OH)-C), 2.40-2.20 (m, 4H, -CHr), 2.19-2.16 (m, 2H, -CH2-), 1.92 (t, 7=7.2 
Hz, 2H, C-CHrCTL-), 1.52 (qt, 7=7.2, 7.3 Hz, 2H, CH2-CH2-CH3), 0.97 (t, 7=7.3 Hz, 
3H, CH2-CH3). 13C NMR (75 MHz, CDC13), 8 C 144.0, 127.2, 85.9, 79.6, 61.7, 32.3,
31.4, 23.4, 22.1, 20.7, 13.5. HRMS calcd. for CnHi60  164.1201, found 164.1204.
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l-Cyclopentenyl-3-phenylprop-2-yn-l-ol (70)
To a flask containing dry THF (15 mL) and phenylacetylene (0.57 
mL, 5.2 mmol) at -78 °C, «-butyllithium (1.6 M in hexanes, 5.2 
mmol) was added dropwise. The reaction mixture was stirred for 10 
min, then transferred via cannula to a vessel charged with THF (10 
mL), and cyclopent-l-enecarbaldehyde (0.5 g, 5.2 mmol) at -78 °C. The reaction was 
stirred for 30 min, then allowed to warm to 0 °C. The reaction was quenched with the 
addition of saturated ammonium carbonate solution. Extraction of organic material by 
washing the reaction mixture with dichloromethane (3 x 20 mL) yielded the crude 
product after combination, drying (MgSOzi), and concentration under reduced pressure. 
Isolation through the use o f column chromatography, using an eluant of 4:1 hexane:ethyl 
acetate, gave the desired product as a pale oil, 0.87 g, 85%. IR vmax (KBr, cm'1) 3375 
(OH), 2204 (O C ), 1615 (C=C). lU NMR (300MHz, CDC13), 6 H 7.46-7.26 (m, 5H, Ar­
if), 5.88 (m, 1H, CH2 -CH=C), 5.19 (s, 1H, C-CH(OH)-C), 2.59-2.20 (m, 4H, -CH2-), 
2.11-1.95 (m, 2H, CH9-CH9-CHA 13C NMR (75 MHz, CDCI3), 6 C 143.3, 131.7, 128.4,
128.3, 127.9, 122.6, 88.4, 85.3, 62.1, 32.3, 31.5, 23.4. HRMS calcd. for C14H14O
198.1045, found 198.1040.
1 -Cyclopentenylhex-2-yn-1 -one (71)
To a stirring solution of l-cyclopentenylhex-2-yn-l-ol (2 g, 12.2 mmol) in 
dichloromethane (100 mL), Mn0 2  (9.86 g, 113.5 mmol) was added. The 
mixture was stirred for 12 h at room temperature. Upon completion, the 
mixture was filtered through Celite, and concentrated under reduced pressure 
to a pale yellow oil that required no further purification, 1.7 g, 8 8 %. IR vmax(KBr, cm'1) 
2213 (C=C), 1645 (O O ), 1625 (O C ). 1H NMR (300MHz, CDC13), 6 H 7.02 (m, 1H, 
CH2-CH=C), 2.63-2.28 (m, 6 H, -CH2 -), 1.95 (t, <7=7.5 Hz, 2H, C-OL-CHA 1.70-1.53 
(m, 2H, CH2-CH2-CH3), 1.00 (t, .7=7.5 Hz, 3H, CH2 -CH3). 13C NMR (75 MHz, CDCI3), 
6 C 176.1, 149.8, 147.3, 92.9, 79.8, 33.8, 29.7, 23.2, 21.4, 20.9, 13.5. HRMS calcd. for 
C,iH,40  162.1045, found 162.1043.
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l-Cyclopentenyl-3-phenylprop-2-yn-l-one (72)
To a stirring solution o f l-cyclopentenyl-3-phenylprop-2-yn-l-ol (0.5 g,
2.5 mmol) in dichloromethane (25 mL), MnC>2 (1.86 g, 21.4 mmol) was 
added. The reaction was stirred for 12 h at room temperature. Upon 
completion, the reaction was filtered through celite, and concentrated 
under reduced pressure to a pale yellow oil that required no further purification, 0.42 g, 
84%. IR vmax (KBr, c m 1) 2202 (C=C), 1655 (C=0), 1624 (C=C). NMR (300MHz, 
CDC13), SH 7.60-7.18 (m, 5H, Ar-H), 6.77 (s, 1H, CH2-CH=C), 2.67-2.61 (m, 4H, -CH2- 
), 2.07-1.97 (m, 2H, CH9-CH9-CHA 13C NMR (75 MHz, CDC13), 8 C 189.0, 149.0,
146.3, 132.8, 130.4, 128.6, 120.5, 93.2, 80.5, 34.0, 29.9, 23.2. HRMS calcd. for C14H12O 
(M+H) 197.0966, found 197.0960.
l-((lS,2/?)-l,2-Dihydroxycyclopentyl)hex-2-yn-l-one (73)
A solution of AD-mix-p (1.68 g, modified to contain 1 mol% of potassium 
osmate dihydrate, and 1 mol% of ligand) with sodium hydrogen carbonate 
(258 mg) in water (5 mL) and tert-butanol (5 mL) was prepared. Cooled to 
0 °C, the resulting slurry was stirred vigorously for 30 min. 
Methanesulfonamide (114 mg, 1.2 mmol), was added and stirred for 5 min 1-
cyclopentenylhex-2 -yn-l-one ( 2 0 0  mg, 1 . 2  mmol) was added in one portion, and the
reaction stirred vigorously at 0 °C. The reaction was monitored by TLC. Upon 
completion, the reaction was quenched at 0 °C with the addition of sodium sulfite (1.8 
g), warmed to room temperature, and stirred for 1 hour. The reaction mixture was 
extracted with ethyl acetate ( 3 x 1 0  mL), organic fractions combined and washed with 
2M KOH (5 mL) and dried (MgSC>4). Analysis indicated that 73 was not formed in the 
reaction.
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!-((!£,2/?)-l,2-Dihydroxycyclopentyl)-3-phenylprop-2-yn-l-one (74)
A solution of AD-mix-p (0.71 g, modified to contain 1 mol% of 
potassium osmate dihydrate, and 1 mol% of ligand) with sodium 
hydrogen carbonate (1.5 mmol) in water (2.5 mL) and ter/-butanol 
(2.5 mL) was prepared. Cooled to 0 °C, the resulting slurry was 
stirred vigorously for 30 min. Methanesulfonamide (49 mg, 0.51 
mmol), was added and stirred for 5 min l-cyclopentenyl-3-phenylprop-2-yn-l-one (100 
mg, 0.51 mmol) was added in one portion, and the mixture stirred vigorously at 0 °C. 
The reaction was monitored by TLC. Upon completion, the reaction was quenched at 0 
°C with the addition o f sodium sulfite (0.70 g), warmed to room temperature, and stirred 
for 1 h. The reaction mixture was extracted with ethyl acetate (3 x 10 mL), organic 
fractions combined and washed with 2M KOH (5 mL) and dried (MgS0 4 ). Analysis 
indicated that 74 was not formed in the reaction.
l-(l,2-Dihydroxycyclopentyl)hex-2-yn-l-one (75)
To a flask containing potassium osmate (2.9 mg, 7.8 x 10' 6 moles), 
acetone (2.7 mL), water (0.6 mL), tert-butyl alcohol, and 
A-methylmorpholine (monohydrate, 89 mg, 0.66 mmol), 
l-cyclopentenylhex-2-yn-l-one (100 mg, 0.6 mmol) was added. The 
reaction was monitored by TLC, and extracted using ethyl acetate ( 3 x 5  mL) upon 
completion. Combination o f the organic fraction, followed by drying (Na2 S0 4 ), and 
concentration under reduced pressure gave the crude product. Column chromatography 
using an eluant o f 11:1 petroleum ether (40-60 °C):ethyl acetate gave the product as a 
viscous pale oil, 81 mg, 6 8 %. *H NMR (300MHz, CDC13), SH 3.76-3.50 (m, 1 H, CH2- 
CH(OH)-C), 2.58-2.15 (m, 4H, -CIL-). 2.00-1.43 (m, 6 H, -CfL-h 1.04 (t, 7=7.3 Hz, 3H, 
CH2-CH3). 13C NMR (75 MHz, CDC13), 6 C 186, 97.5, 96.8, 89.5, 75.4, 36.5, 27.8, 21.3, 
21.0, 16.9, 13.6. HRMS calcd. for CnHi60 3 196.1099, found 196.1102.
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6-Hydroxy-2-propyl-l-oxa-spiro[4.4]non-2-en-4-one (76)
O
To a flask containing analytical grade acetone (10 mL), and 1-(1,2- 
dihydroxycyclopentyl)hex-2-yn-l-one (50 mg, 0.25 mmol), 0.2 mL of a 
mercury containing solution was added. The reaction was monitored by OH 
TLC, and upon completion (approximately 5 min), sodium hydrogen carbonate (50 mg) 
was added and allowed to stir for 40 min. Filtration of solid material from the reaction 
mixture, followed by an extraction into ethyl acetate (15 mL), drying with sodium 
sulfate, and concentration yielded the crude product. Purification by column 
chromatography (with an eluant o f 2 : 1  hexane:ethyl acetate) yielded the desired product 
as an oil, 39 mg, 80%. IR vmax (KBr, cm'1) 3408 (OH), 2254 (C=0), 1680 (C=C). lU 
NMR (300MHz, CDC13), 8 H 5.49 (s, 1H, C-CH=C), 4.01 (m, 1H, CH2 -CH(OH)-C), 3.57 
(s, 1H), 2.48 (t, J = l . l  Hz, 2H, C-CH2-CH2), 2.28-2.23 (m, 1H, CH2-CHH-CH2), 2.10-
1.98 (m, 2H, CH-CH9-CHA 1.98-1.87 (m, 2H, C-OL-CHA 1.86-1.76 (m, 1H, CH2- 
CHH-CH2), 1.67 (tq, 7=7.3, 7.7 Hz, 2H, CH2 -CH2-CH3), 0.99 (t, 7=7.3 Hz, 3H, CH2- 
CH3). 13C NMR (75 MHz, CDC13), 5C 206.3, 193.6, 103.6, 96.6, 78.6, 33.9, 33.3, 32.8,
21.7, 19.6, 13.6. HRMS calcd. for CnHi60 3 196.1099, found 196.1095.
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Chapter 2 
Enantioselective Synthesis of the Phosphoiine Lactone 
Ring
2.7 Introduction
Protein phosphorylation is a complex cellular process, and employs two categories of 
enzymes, the phosphatases and the protein kinases. Phosphatases remove phosphates 
from proteins, and the kinases are concerned with the addition of phosphates. The action 
of protein phosphorylation has important roles in many aspects of cell regulation, and is 
a crucial component in cell signal transduction pathways. If one considers that most 
diseases have some form of signalling malfunction associated with them, modification of 
the phosphorylation process has become an important strategy for obtaining therapeutic 
effects.
Protein kinases have been considered for some time as viable targets for therapeutic 
agents, and much work has been reported detailing novel compounds which interact in 
this way. In contrast, there is substantially less known about protein phosphatases with 
regard to the cellular processes and control, but that presents an equally exciting and 
varied area with many opportunities for therapeutic advances and remains largely 
unexploited.
2.1.1 Protein Phosphatases
There are many types o f protein phosphatases that have been identified; enzymes which 
act upon serine, tyrosine, and threonine residues are considered to be within their own
i 48 49respective classes. ’
Of the serine/threonine class of phosphatases, these can be classified into two sub­
classes according to catalytic subunit homology. These are the PhosphoProtein 
Phosphatase (PPP) enzymes, and Metallo-PhosPhatases (PPM). Enzymes which act
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upon tyrosine residues are known as Protein Tyrosine Phosphatases (PTPs). There exists 
within the PTP class a subset of enzymes, the dual-specificity enzymes, which can act 
upon all residues.
Within each class the catalytic portion is a highly conserved region; functional diversity 
between the members o f the class is governed by regulatory domains, targeting domains 
or subunits.
Focusing upon the serine and threonine phosphatases, the major contributors to these 
families are PP1, PP2A, and PP2B for the PPP class, and PP2C for the PPM class. It is 
important to note that while these are the major components of the PPP and PPM 
families in vivo, there are many other members of the class that exist at low 
concentrations and contribute to the dephosphorylation process.
PP1, PP2A and PP2B are homologous within a catalytic domain of 280 residues, and are 
distinguished by their associated regulatory subunits, forming a large number of diverse 
holoenzymes.
PP1 has functions which include the regulation of glycogen metabolism, cell cycle 
progression, neuronal activities, and RNA. Differentiation between the processes is 
controlled by PP1 holoenzymes which bind to different regulatory and targeting 
subunits.
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Fig. 2.1.1. Representation of the inhibitor okadaic acid bound to the PP1 enzyme, derived from the PDB 
database model 1JK7.
PP2A functions are very diverse and not yet fully characterized, but regulate processes 
such as metabolism, cell signaling, cell cycles, and telomerase activity. As with PP1, the 
PP2A class is defined by PP2A holoenzymes.
PP2B is identified by its dependence on Ca2+ ions, and plays an important part in the 
Ca2+ signaling cascade of T-cells.
The PPM family share no main sequence homology with the PPP class. The main 
component, PP2C, is present in all mammalian cells and its activity is dependent upon 
the concentration of Mg2+ ions. It is monomeric, and no regulatory proteins or 
mechanisms have been reported. Specific roles for PP2C are unclear due to significant 
overlapping with the PPP class, however, it has been observed that they play a particular 
role in connection with cellular stress.
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2.1.2 Protein Phosphatase Inhibitors
PPl and PP2A are potently and specifically inhibited by a variety of natural products,50 
and are commonly found to have been utilized as a predatory defence mechanism and 
appear to mainly target PPl and PP2A, but not PP2B. These inhibitors are known as the 
okadaic acid class o f compounds, and their selectivity, potency, and origin is of great 
diversity. Some of the inhibitors can be seen in Fig. 2.1.2.
Okadaic acid51 (77) was the first of the natural product inhibitors to be reported. It was 
first isolated from the marine sponge Halicondria okadai and is found to be produced by 
dinoflagellate. It is a potent inhibitor, but is also a strong tumour promoter and is one of 
the main agents of diarrhetic seafood poisoning.
Tautomycin52,53 (78) is an inhibitor that was the first to display 5-fold selectivity of PPl 
over PP2A.
Calyculin54 (79) was isolated from the sponge Discodermia calyx and is a potent 
inhibitor of both PPl and PP2A.
Fostriecin55 (80)is a small, novel antibiotic isolated from Streptomyces pulveraceus. It is 
one of the most selective small molecule inhibitor known, and exhibits a 30000 fold 
selectivity of PP2A over PPl.
Cantharidin56 (81) was isolated from over 1500 species of blister beetle found 
throughout the world. It is a moderate inhibitor of PPl, PP2A, and a weak inhibitor of 
PP2C.
57  58  5 0Nodularin (82), Motuporin, and Microcystins are a variety identified by their cyclic 
peptide structures. First isolated from blue-green algae, they are varied in their potency 
and inhibition.
In this chapter we shall focus on just one type inhibitor, fostriecin and its analogues.
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Fig. 2.1.2. PPP Phosphatase inhibitors. 77. Okadaic acid; 78. Tautomycin; 79. Calyculin; 80. Fostriecin; 
81. Cantharidin; 82. Nodularin.
2.1.3 Fostriecin
Fostriecin, phospholine, and phoslactomycins are structurally related compounds 
exhibiting potent, highly selective inhibition of protein phosphatases (Fig. 2.1.3).
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Fig. 2.1.3. Fostriecin (top) and Phospholine (below, R=H).
Fostriecin, isolated from Strepomyces pulveraceus, was first reported by Tunac.60 
Investigations found that in general, there was anti-tumour activity rather than tumour 
promoting activity as is seen with okadaic acid type compounds. This has spurred a great 
deal of interest, and its chemistry, and biology have been the subject of numerous 
studies.
Fostriecin has been shown to inhibit selectively protein phosphatases PPl, PP2A, and 
PP4 with an IC50 o f 45 pM, 1.5 nM, and 3.0 nM respectively. It is known to be active in 
vitro against leukaemia (LI210), lung, breast, and ovarian cancers, is also known to be 
active in vivo against LI210, P338 leukaemia,61 and has also been seen to radio-sensitise 
tumour cells.62
Little regarding the mechanism of inhibition is known, however it was believed that it 
was a topoisomerase II catalytic inhibitor,63 this is now known to be false. It is now 
considered that fostriecin interferes with the mitosis entry checkpoint. Mitosis is a 
heavily controlled process and requires complete and undamaged DNA to succeed. 
Fostriecin forces cycling cells to enter mitosis prematurely64,65 and prevents progression 
through the latter stages.
The ability o f fostriecin to inhibit mitosis, and the inhibition of protein phosphatases are 
novel and desirable properties for anti-tumour compounds. Hence, fostriecin was 
advanced to phase I clinical trials by the NCI with initial success, and was found to 
possess significant tumour growth inhibition in vitro short of the maximum tolerated 
dose. Studies, however, were unfortunately halted due to concerns with the purity and 
the storage o f the naturally occurring material. It was found that fostriecin, placed in
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incubated culture medium loses activity within 30 minutes. Similar half-lives were also 
observed in patient plasma shortly after administration.63 While being a setback, this has 
not stifled interest into fostriecin as an anti-tumour therapeutic.
Fostriecin has found a useful role as a biological tool even after the failure of the 
therapeutic trials. Fostriecin is highly selective to PP2A enzymes compared to PPl, and 
has been found to be particularly useful in aiding the elucidation of cell 
dephosphorylation pathways.
Fostriecin remains an interesting and promising natural product, and there has been 
much reported regarding its synthesis and biological action. Studies investigating the 
features of fostriecin in comparison to a pharmacophore derived from a PP2A homology 
model and a non-specific PPl inhibitor have shown interesting relationships between the 
two. It was postulated that fostriecin can be considered to have three main sections. The 
first was the presence o f a phosphate that binds to metal ions; secondly, a methyl group 
proximal to the phosphate; and finally, a hydrophobic section which mimics 
hydrophobic residues found in substrates normally bound to the enzyme.
It was surprising that the unsaturated lactone of fostriecin, one of the most significant 
features of the compound, was not represented in the pharmacophore. It was proposed 
that the lactone was the reason for PP2A selectivity. SAR studies conducted by the 
Boger group,66 in which fostriecin analogues were synthesized and tested for PP2A and 
PPl activity, indicated that the unsaturated lactone increased the potency of PP2A 
inhibition by a factor of 200. However, removal o f the lactone portion did not negate the 
inhibition of protein phosphatases completely, such compounds still exhibited strong and 
selective PP2A inhibition. It was believed that the critical electrophile interacts with 
C269 o f PP2A, which is not present in PP1 and accounts for the selectivity. This was 
later reported to be the case in PP2A inhibition studies of phoslactomycin.67 
Other functional groups found to be important for protein phosphatase activity were the 
phosphate group, which was found to be essential, and the Cl 1 alcohol, which was also 
seen to contribute significantly to the efficacy o f the compound.
A representation o f fostriecin and the moieties contributing to overall activity can be 
seen in scheme 2.1.4.
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Fig. 2.1.4. The major components of fostriecin that contribute to protein phosphatase inhibition.
2.1.4 Synthesis of Fostriecin
The structure of fostriecin was first eluded to by French,68 who conducted very limited 
research into the compound. However, further more conclusive research was finally 
reported several years later by Boger,69 who elucidated the structure by means of 
degradation and other synthetic methodology. Once the structure was conclusively 
defined, fostriecin was rapidly made the subject of several synthetic attempts. The first 
total synthesis was reported by Boger,55 shortly after their publication of structural 
information.
Boger’s approach to the synthesis o f fostriecin, was to prepare 3 main synthetic 
fragments. The lactone fragment 83 (Cl to C6), a central fragment containing 2 chiral 
centres 84 (C8 to C l2), and a final fragment 85 providing synthetic access to the triene 
within the target molecule (C l6 to C l8). A retrosynthetic analysis, described by Boger, 
can be seen in scheme 2.1.5.
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Scheme 2.1.5. Boger’s retrosynthetic analysis of fostriecin.
Synthesis of the Cl to C6 fragment began with the formation of a/?-methoxybenzyl ester 
derived directly from the corresponding acid, followed by Sharpless asymmetric 
dihydroxylation to introduce the C5 chiral configuration of fostriecin. Enrichment to 
>98% e.e. was possible by recrystallising from diethyl ether.69 Protection of the primary 
alcohol was conducted with tert-butyl diphenylsilyl chloride, and followed by acid 
catalysed lactonisation to give 88. The a-phenylselenyl lactone was generated, followed 
by oxidation to the selenoxide with hydrogen peroxide and in situ elimination to give the 
unsaturated lactone 90. Reduction to the lactol, and protection gave 91. Deprotection of 
the primary alcohol and oxidation to the aldehyde generated the first key portion of 
Boger’s synthesis, the Cl to C6 fragment 92.
PMBOPMBO.
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Scheme 2.1.6. The construction of the Cl to C6 fragment, i. K3Fe(CN)6, K2C03, NaHC03, (DHQD)2- 
AQN, f-BuOH, H20; ii. TBDPSC1, imidazole; iii. TFA, anisole; iv. LDA, PhSeBr; v. H20 2; vi. DIBAL-H, 
PPTS, /-PrOH; vii. BU4NF, AcOH, THF; viii. TPAP-NMO.
Synthesis of the C7 to Cl 8 segment was conducted in two sections. The first was the C8 
to C12 fragment, incorporating important stereocentres at C9 and Cl 1. An outline of its 
synthesis can be seen in scheme 2.1.7. The starting material 93 was obtained from 
D-glutamic acid in 2 steps, and provided the C9 stereocentre. Protection of the free 
alcohol, followed by reduction to the lactol and elimination gave 94 in 69% from 93. 
Introduction of the C ll  centre was accomplished through Sharpless asymmetric 
dihydroxylation giving the diol 95 in 100% with a >10:1 ratio of diastereoisomers. 
Selective protection of the C ll  alcohol using TBSOTf at a low temperature concluded 
the synthesis of the fragment in 56% yield from 93.
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Scheme 2.1.7. Preparation of the C8 to C12 fragment incorporating the C9 and C ll stereocentres. i. PMB 
protection, followed by DIBAL-H, MsCl, Et3N; ii. Sharpless Asymmetric Dihydroxylation using 
(DHDQ)2AQN; iii. TBSOTf, Et3N.
The final segment o f the compound was prepared by building the fragile triene portion 
onto the already existing C8-C12 fragment. Condensation o f 96 with the Still-Gennari 
phosphonate70 gave the first cis olefin of the (Z,Z^£)-triene in 88%. Protection of the 
secondary alcohol with a silyl protecting group, reduction of the unsaturated ester to the 
alcohol, followed by oxidation to the conjugated aldehyde gave 99. A Corey-Fuchs71 
reaction gave the vinyl dibromide 100, followed by selective reduction to the vinyl 
bromide in 84%. Stille coupling72 then furnished the triene fragment in 82% from 101.
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Scheme 2.1.8. Synthesis of the Cl 3 to Cl 8 fragment, i. Et3SiOTf; ii. Dibal-H; iii. Dess-Martin; iv. CBr4, 
PPh3; v.DDQ; vi. Ac20 , DMAP, i-Pr2NEt; vii, Bu3SnH-(Ph3P)4Pd; viii. (CH2CN)2PdCl2, NMP, /-Pr2NEt; 
ix. DIBAL-H; x. Dess-Martin; xi. (EtO)2POCH2Li.
The C8 to C18 fragment 103 was converted into the aldehyde, and then to the 
ketophosphonate 105 completing the C7 to C l8 fragment. Wadsworth-Homer-Emmons 
methodology was then used to couple the two portions together, completing the 
synthesis of the fostriecin carbon scaffold. Methylation at C8 using MeLi/CeCE and 
introduction of the phosphate yielded the completed fostriecin molecule (80) after the 
removal of protecting groups.
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Scheme 2.1.9. Final Synthetic stages in the preparation of fostriecin. i. ?-BuOK, toluene; ii. MeLi-CeCl3, 
toluene-THF; iii. PPTS, EtOH; iv. TBSOTf; v. aq. HC1; vi. Ag2C03.
Boger’s synthetic strategy of constructing the molecule in three distinct sections was so 
effective, that it was easily possible to synthesise fostriecin analogues. Boger then went 
on to produce several variations, modifying and exploring the function the lactone 
moiety in particular.66
Shortly after Boger’s announcement, several other syntheses of fostriecin were reported 
utilising a similar retrosynthetic approach to the construction of the central carbon
73scaffold. Synthetic publications include a total synthesis by Imanishi and co-workers 
via a highly convergent route using a three-segment coupling procedure, in which they 
report the use o f a vinyl iodide intermediate which was instrumental in the synthesis of 
the (Z,Z,£)-triene. The vinyl iodide intermediate has since been the focus of many
71
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reported formal syntheses. ' The use of alkene metathesis by Kobayashi and Cossy 
to generate the lactone fragment in the latter stages of the synthesis. Shibasaki,79 who 
reported a catalytic asymmetric synthesis using catalysis to construct all four chiral
OA
centres. Ramachandran and co-workers, who reported the synthesis of the Cl to C ll 
fragment of 8-epz-fostriecin.
2.1.5 Fostriecin and Structurally Related Compounds
Several compounds, related structurally to fostriecin, are potent inhibitors of protein 
phosphatases and occur naturally. Some of the members can be seen in scheme 2.1.10. 
These include the phoslactomycins, cytostatin, sultreicin, and the leustroducsins. The 
compounds while clearly similar to fostriecin, possess varied therapeutic effects. The 
phoslactomycins and leustroducins are only weakly cytotoxic, but possess strong broad- 
spectrum antifungal activity, whereas compounds such as cytostatin exhibit potent 
cytotoxic activity towards leukaemia and melanoma cancer cell lines.81,82
80 
108
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Fig. 2.1.10. Fostriecin (80), Cytostatin (108), Sultreicin (109). R = H, Phospholine (110). R = OH, 
Leustroducsin (111). R = OCOR, Phoslactomycins.
Synthesis of the compounds has been reported frequently, and due to their structural 
similarity to fostriecin, they have been constructed using similar methodology. A total 
synthesis constructing leustroducsin B, a compound closely related to phospholine,
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was reported by Fukuyama83in 2003. A synthesis of phospholine,84,85 also known as 
phoslactomycin B, by Kobayashi86 in 2006 as was a total synthesis of cytostatin and
OTf Q A  Q 1  Q 9
several analogues by Waldmann, ' and more recently by Marshall and Boger.
The Boger SAR study66 prior to the onset of clinical fostriecin trials, highlighted a major 
flaw in the use o f fostriecin therapeutically. During the study, two metabolites, 
dephosphofostriecin, and the lactone hydrolysed analogue were shown to be rapidly 
generated in culture medium, and both compounds were shown to have a significant 
decrease in activity. There considerable interest in the generation of fostriecin analogues 
which do not degrade or metabolise as rapidly as fostriecin.
Learning from data obtained from the previous clinical study, there are two obvious 
areas for development o f fostriecin: modification o f the metal chelating phosphate group, 
and modification o f the lactone moiety.
The reported synthesises o f fostriecin and the analogous compounds, being somewhat 
modular, can therefore be used to obtain new compounds of greater therapeutic potential 
building on the established synthetic methodology. Synthesis of alternative lactone 
fragments, or the inclusion o f alternative acidic or metal chelating groups in the position 
of the phosphate can be easily accommodated.
2.1.6 Modification of the Lactone Fragment
Modification of the fostriecin lactone fragment provides an enticing synthetic 
opportunity in the development o f new, potent, and novel anti-tumour compounds. 
Lactone fragment modification has been explored,66 but the use of a fostriecin analogue 
with a lactone fragment mimicking those found within the phoslactomycins or cytostatin 
are of particular interest.
Fig. 2.1.11. The lactone fragments of fostriecin, cytostatin, and phospholine respectively.
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Phospholine, is less active than fostriecin, but is also a selective inhibitor of protein 
phosphatases and substantially more stable. It has been used as a biological tool to aid in 
the analysis of PP2A inhibition and the dephosphorylation pathways, due to its 
specificity in PP2A inhibition.
The lactone fragment o f phospholine differs only in the inclusion of an ethyl group at the 
C4 position. Elaboration o f the lactone moiety in fostriecin to mimic that found in 
phospholine, gives the potential for the resulting hybrid to be not only as potent as 
fostriecin, but far longer lived in culture medium. This would present a truly exciting 
development in the search for potent anti-tumour compounds.
As most of the reported synthesises o f fostriecin use a modular approach to incorporate 
the lactone fragment, it is possible to modify the procedure to include a modified lactone 
moiety. Continuation o f the synthesis will then lead to the completed fostriecin analogue. 
It is believed that a mercury-mediated cyclisation methodology reported by Marson et
Q 'y
al. could provide a route to the generation o f the lactone species, and could be easily 
extended to generate a variety o f analogues enantioselectively.
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oScheme 2.1.12. The proposed Hg mediated cyclisation. i. Hg+2, H2S04; ii. NaBH4, CeCl3; iii.p-TsOH.
The dihydropyranone derived from the mercury-mediated cyclisation of a specifically 
prepared precursor, could then be selectively reduced and dehydrated to give the desired 
lactone. The advantages o f this particular method, are that the lactone can be constructed 
with a high degree o f enantiospecificity, combined with high yield and purity. The 
generated lactone fragment could then be introduced into an already existing successful 
synthetic route to generate the fostriecin analogue. The route, due to the 
enantioselectivity o f the procedure, would also provide access to a variety of 
stereoisomers, and would allow exploration o f other non-natural lactone fragments upon 
the fostriecin scaffold.
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2.2 Results and Discussion
Synthesis of the phospholine lactone ring using a mercury-mediated cyclisation strategy 
was envisioned to proceed as indicated within scheme 2.2.1.
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Scheme 2.2.1. The proposed synthesis of the phospholine lactone ring. i. «-BuLi, ethoxy acetylene; ii. 
(7?)-Alpine-Borane; iii. TBHP, Ti(0'Pr)4, (+)-DET; iv. 1 mM Hg2+ in 0.5 mM H2S04; v. NaBH4, CeCl3; vi. 
p-TsOH.
Weinreb amide 112 is alkynylated using standard procedures and yields 113, the central 
carbon scaffold. Reduction o f enynone 113 using (R)-Alpine borane would yield the 
enynol 114 in high e.e.94 and would provide access to the key intermediate 115 through 
Sharpless asymmetric epoxidation.95 At this point it would be possible for the fragment 
to spontaneously cyclise to 116, however, the fragment would give 116 through the 
mercury (II) rearrangement as indicated in scheme 2.2.1. Luche reduction would then
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give the alcohol 117, and subsequent dehydration would produce 118, the lactone 
terminal fragment.
2.2.1 Synthesis of the Weinreb amide
Synthesis initially focused upon the preparation of the Weinreb amide 112. In order to 
ensure the stereochemistry o f the resulting lactone is correct, and to mimic the 
corresponding (£)-alkene moiety found in phospholine, 112 would have to be of the 
(E, ^ -configuration.
A simple retro-synthetic analysis o f 112 can be seen in scheme 2.2.2.
O O
 ^
112 119 120
Scheme 2.2.2. Retro-synthetic analysis of the Weinreb amide 112.
It was postulated that the Werinreb amide 112 could be derived rapidly from ester 119 
using standard coupling procedures, which are extensively reported in the literature 
using a variety of reagents.96'102 In turn, 119 could be easily derived through the use of 
Wittig methodology with the easily obtainable, isomerically pure starting material, 
crotonaldehyde (120). The use o f Wittig methodology was thought to be sufficient to 
give the required (E,^-configuration in high yield or exclusively,103 aiding the 
precipitation of favourable outcomes from asymmetric procedures later in the synthesis. 
Formulation into a synthetically viable method gave the following synthesis shown in 
scheme 2.2.3.
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Scheme 2.2.3. i. triethyl orthophosphate, reflux; ii. NaH, THF, /ra>w-crotonaldehyde; iii. AlMe3, 
HCl.NH(OMe)Me, toluene, 0 °C.
Synthesis of the phosphonate ester 122 was achieved by introducing 
ethyl-2-bromobutanoate (121) to a gently refluxing flask of triethylphosphite, and 
heating at reflux for 6 hours. During the reaction, bromoethane was evolved, and 
allowed to escape from the vessel. Once all the ester had been consumed, the reaction 
was cooled, and gave crude material containing the required product and unreacted 
triethylphosphite. Distillation then gave the pure phosphonate ester 122 using conditions 
reported by Isbell.104
Coupling of the phosphonate ester to crotonaldehyde using Wittig methodology gave the 
fragment 123 with a yield o f 59%. After purification, the material was then used to 
explore the generation o f 112, the key fragment required to begin the phospholine 
lactone synthesis.
Weinreb generation was initially attempted using an analogous method reported by 
Evans105 and Franklin,106 involving the use o f trimethylaluminium directly from the ester 
123. It was found after several attempts that this method would not be successful. An 
alternative method was sought in the use of the Merck protocol as used by Williams107 
and Enders.108 It was found that this method was also unsuccessful.
Alternative routes to the Weinreb intermediate were considered. Reports in the literature 
describe many procedures that use an acid intermediate combined with the coupling 
agents or through the corresponding acid chloride. Conversion into the already available 
ester 123 to the acid provided a convenient and rapid means of exploring this route.
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Scheme 2.2.4. i. LiOH, MeOH; ii. sulfonyl chloride, toluene, 80 °C; iii. HCl.HN(OMe)Me, Et3N, CH2C12.
Saponification o f 123 using LiOH in methanol109 gave the acid 124 in high yield (91%). 
Conversion to the acid was found to increase substantially the purity after purification, 
and had the added advantage of generating isomerically pure material in the required 
(is,.^-configuration. The acid was then converted into the acid chloride by combining 2 
equivalents of sulfonyl chloride with 123 in toluene and heating to 80 °C, which gave 
the desired product in high yield after concentration of the reaction mixture.
Attempts were then made to generate the Weinreb intermediate 112 from 125. This was 
accomplished by stirring the acid chloride 125 in dichloromethane with triethylamine, 
followed by the addition o f the TV, O-dimethyl hydroxylamine at 0 °C. It was found that 
the generation of the Weinreb amide 112 was unsuccessful, or so low yielding that it 
would be synthetically unviable. Exploration of other routes found that for a variety of 
coupling methods, methods that were successful in converting sorbic acid to its 
corresponding Weinreb amide, were unsuccessful in generating 112. It is believed that in 
this case, there is sufficient steric hindrance from the ethyl group a to the carbonyl which 
is sufficient to prevent the reaction from occurring.110
In failing to generate 112, it was concluded that the Weinreb amide was inhibiting 
progression of the synthesis, and examination of alternative routes to the carbon scaffold 
of the precursors 113, 114 and 115 was initiated. Routes which did not pass though a 
Weinreb intermediate such as 112, were given particular consideration.
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It was considered that in order to generate the precursors correctly, it would be necessary 
for the alkynylation of a suitable aldehyde fragment. The fragment would, depending on 
nature of the fragment, it could generate either precursor 114 or 115, and the synthesis 
could continue along the earlier proposed synthetic route.
From the starting ester 113, the conjugated aldehyde 128 and the epoxy aldehyde 129 
could be derived. It would then be possible for them to undergo alkynylation to derive 
the central scaffolds 114 and 115 respectively.
127
X  iii IV
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Scheme 2.2.5. i. LiAlH4, Et20 , 0 °C; ii. TBHP, Ti(07PR)4, (+)-DET; iii. DMSO, Py.S03; iv. Swem 
oxidation.
Conversion o f 113 to the corresponding alcohol 126 was achieved with the use of 
LiAlFL* in diethyl ether at 0 °C and proceeded in 78% yield, following the methods 
reported by Davidson.111 Oxidation of 126 to the conjugated dienal 128 failed to 
generate any synthetically useful quantities o f material using either PCC112’115 or PySOs 
complex.116'118 Sharpless epoxidation119 of 126 to 127 revealed such significant levels of 
scrambling o f the diene, that the oxidized aldehyde 129 was no longer suitable for use in 
the synthesis. This route was then abandoned, and further alternative routes that deviated 
from the use o f the Hg+2 methodology were explored.
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2.2.2 Hinterding Methodology
Literature was explored for an alternative to the Hg+2 strategy. It was found that 
Hinterding reported the use o f an intramolecular Claisen-like condensation/reduction 
procedure to generate chiral polyketide units.120 Cleavage of an Evans-oxazolidinone 
using an acetate enolate yielded p-keto-8-lactones (cf 134 from 133), reduction then 
furnished p-hydroxy-8-lactones (cf 135) which were ring opened to yield the polyketide 
material.
Rather than furnish polyketide material, it was believed that it would be possible to 
dehydrate the P-keto-8-lactone to the required pyranone system, in one step. The 
proposed synthetic route using the Hinterding methodology can be seen in scheme 2.2.6.
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Scheme 2.2.6. i. butyroyl chloride, Et3N, CH2C12, 0 °C -  r.t.; ii. CH2C12, TiCh, (-)-sparteine, NMP 139; iii. 
DMAP, CH2C12,Ac20, Et3N, 0 °C; iv. LiHMDS, THF, -78 °C; v. f-BuNH2-BH3, citric acid, MeOH, -5 °C; 
vi./?-TsOH.
Preparation o f the Evans auxiliary was accomplished by the reduction of phenylalanine 
to phenylalinol using sodium borohydride and iodine in methanol.121 The material was 
converted into the Evans auxiliary by carefully heating phenylalaninol with diethyl 
carbonate and potassium carbonate at 130-140 °C, and allowing ethanol to distil from 
the reaction mixture. The auxiliary could then be recovered from the residue, and after 
crystallization yielded the pure auxiliary 130 in good yield.122
The auxiliary was coupled to butyroyl chloride using procedures reported by 
Crimmins123 by combining in dichloromethane and triethylamine at 0 °C to give 131 in 
59% yield.
Scheme 2.2.7. i. TBS-C1, imidazole, CH2C12, 0 °C-r.t, 12 h; ii. 0 3, CH2C12, PPh3, -78 °C.
The preparation o f the TBS aldehyde 139 began with the protection of 
frw?s-2-butene-l,4-diol (137) with tert-butyldimethylsilyl groups. Ozonolysis of the 
alkene 138, using methods and procedures described by Lafontaine,124 gave the aldehyde 
139 in 83% yield.
Coupling aldehyde 139 and 131 together in an aldol reaction, using procedures reported 
by Evans122 gave 132 in good yield, and in high e.e. Acetylation of 132 using acetic 
anhydride with DMAP proceeded in high yields, and gave 133. This material was then 
treated with LiHMDS in accordance with the Hinterding procedure. Our findings 
revealed that the reaction was unsuccessful, and attempts using NaHMDS also failed. 
Treatment of 133 with KHMDS did, however, provide the required p-keto-8-lactone 134 
in 72% yield. Treatment o f 134 with sodium borohydride in methanol, sodium 
borohydride in ethanol, and using a reduction method reported to be successful by 
Hinterding using citric acid, all failed to reduce 134 to 135.
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Analysis of the material generated from the attempts to generate 134 revealed that the 
major product was an 11 membered cyclic system. This was consistent with the findings 
of Brandanges,125 who with norephedrine derived oxazolidinones observed predominant 
attack at the endo-carbonyl moiety forming 11 membered systems. Deviation from the 
Hinterding pathway which should have formed the (3-keto-5-lactone, appears to be due to 
the effects of the substituents upon the auxiliary. Unfortunately, this is not restricted to 
the functional groups contained upon the auxiliary itself, but to all fragments attached to 
the auxiliary including the desired chiral portion. As Hinterding himself describes, 
“subtle effects of substituents upon the oxazolidinone auxiliary govern the outcome of 
the reaction”.120 Samples of the material were recrystallized using hexane:ethyl acetate 
and submitted for X-ray analysis to confirm the interpreted NMR data, an illustration of 
the X-ray results can be seen in fig. 2.2.8.
CI O,
C 1 2
cirC14 cia
C15,
C18
C16 C17
HO NH xv
N.
Fig. 2.2.8. Illustration o f the 11 membered system derived from X-ray diffraction data.
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2.2.3 The Keck Approach to the Lactone Fragment
An alternative synthetic route to the lactone terminus was believed to be found in a
recently reported synthesis o f (-)-pironetin by Keck. 126
OH OH
140
Fig. 2.2.9. (-)-pironetin
Within the report he details the use o f P-acetoxy aldehydes and the lithium enolate of 
methyl acetate to facilitate the synthesis o f a,p-unsaturated ketones,127 an integral 
portion of (-)-pironetin. After some consideration it was believed that the generation of  
a,p-unsaturated lactones using the Keck methodology, could be modified to generate the 
desired fragment 118. An outline o f the synthetic route can be seen in scheme 2.2.10.
Scheme 2.2.10. i. butyroyl chloride, Et3N, CH2C12, 0 °C -  r.t.; ii. CH2C12, TiCk (-)-sparteine, NMP 139; 
iii. Red-Al, THF, -60 °C; iv. DMAP, CH2C12,Ac20, Et3N, 0 °C; v. LiHMDS, THF, -78 °C.
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The synthesis using the Keck methodology began with the previously prepared 
Hinterding fragment 132. Reductive cleavage of the auxiliary from the required fragment 
was achieved with the use o f Red-Al, using methodology reported by Cane128 in 89% 
yield to give 141. The material was quickly purified by flash column chromatography, 
and used directly in the next stage o f the synthesis. It was found that once cleaved from 
the chiral auxiliary, the material began to degrade substantially.
The fragment 141 was quickly acetylated to 142, isolated, and rapidly treated with the 
lithium enolate o f methyl acetate, generated from the action of freshly prepared lithium 
diisopropylamide on methyl acetate in tetrahydrofuran, as reported by Keck. 127 After 
work up and purification, 143 was isolated in 23% yield.
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2.3 Conclusion
The construction o f the phospholine lactone fragment was successful using the Keck 
methodology, but not by the original proposed Hg+2 mediated strategy. It was not 
possible to explore the creation o f a fostriecin analogue owing to time constraints.
In the first instance, the use o f the mercury-mediated cyclisation could not be assessed 
for the construction o f the lactone, owing to the inability to generate the required 
Weinreb amide precursor necessary for the cyclisation to occur. It is believed that the 
presence of an ethyl group a to the carbonyl, inhibits or greatly reduces the generation of 
the Weinreb precursor through unfavourable steric interactions.
Attempts to generate an advanced precursor as an alternative to the use of a Weinreb 
amide also failed. In this case the inability to generate synthetically viable quantities of 
conjugated aldehydes and epoxy aldehydes capable of undergoing alkynylation 
prevented continuation to the cyclisation stage.
Deviation from the use o f the mercury-mediated cyclisation strategy to the Hinterding 
procedure resulted in failure. Steric effects, are in this case, responsible in part for the 
inability to generate the required target.
Future work may benefit from a paper published by Dake et al.110 who reports the 
generation of Weinreb amides using acyl mesylate intermediates, and enables the 
synthesis of sterically hindered Werinreb amides. Using the Dake method of Weinreb 
generation would allow the continuation o f the initially proposed methodology, and 
overcome unanticipated steric difficulties that could occur with further modification of 
the lactone fragment.
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2.4 Experimental
The general experimental section can be found in chapter 1.4.
(2is,4ii)-2-Ethy WV-methoxy-7V-methylhexa-2,4-dienamide (112)
Method l : 107
To a slurry of 2-ethyl-hexa-2,4-dienoic acid ethyl ester (0.5 g, 3 
mmol), and N,O-dimethylhydroxylamine (0.44 g, 4.5 mmol) in
O
THF (4 mL) at -10 °C, 'PrMgCl (9 mmol) was added dropwise over 15 minutes. During 
addition, it was ensured that the temperature did not exceed -5 °C. The mixture was 
stirred for 20 minutes at -10 °C. The reaction was then quenched with the addition of 
25% w/w N H 4 C I  solution. The mixture was taken into ethyl acetate (5 mL), followed by 
drying (MgSC>4) to yield the crude product. After column chromatography and analysis, 
it was found that 1 1 2  had not been formed.
To a a stirring suspension o f N,O-dimethylhydroxylamine (0.23 g, 2.36 mmol) in dry 
tetrahydrofuran (5 mL) at 0 °C, MesAl (2.1 mmol) was added slowly. The reaction 
mixture was allowed to warm to room temperature and stirred for 30 min. The mixture 
was re-cooled to 0 °C, and 2-ethylhexa-2,4-dienoic acid ethyl ester (0.1 g, 0.6 mmol) 
was added dropwise. The mixture was allowed to return to room temperature, and stirred 
for a further 30 min. The reaction was carefully quenched with the addition of 1 M HC1, 
followed by the addition o f dichloromethane (10 mL). Extraction of the organic fraction, 
followed by drying (MgS0 4 ), yielded the crude material. Purification and analysis 
indicated that that 1 1 2  had not been formed.
To (2£,4is)-2-ethylhexa-2,4-dienoyl chloride (0.57 g, 3.6 mmol) in toluene (3 mL), N,0- 
dimethylhydroxylamine (0.39 g, 3.96 mmol) was added, and the reaction cooled to 0 °C. 
Triethylamine (0.80 g, 7.92 mmol) was added, and the mixture allowed to stir for 1 h. 
TLC analysis indicated consumption o f starting material. Dichloromethane (10 mL) was 
added, the reaction mixture extracted with water, and brine (10 mL, and 3 mL
Method 2:105106
Method 3:
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respectively). Organic fractions were dried (MgS0 4 ) and concentrated under reduced
pressure. Analysis indicated that that 112 had not been formed.
Hexa-2,4-dienoic acid methoxy-methyl-amide129
Sorbic acid (1.0 g, 8.9 mmol) was added to a mixing solution of 
dry dichloromethane ( 8  mL) and vV-methyl morpholine (2.45 mL,
22.25 mmol). The reaction mixture was cooled to -78 °C using dry ice and acetone. 
Isobutyl chloroformate (1.40 mL, 10.9 mmol) was added dropwise to the reaction 
mixture, and stirred for 30 min. A solution of A^O-dimethylhydroxyamine (1.02 mL, 
10.9 mmol) and 77-methyl morpholine (1.17 mL, 10.9 mmol), in dry dichloromethane (2 
mL) was added to the reaction mixture, and stirred for 30 min. The mixture was then 
allowed to warm to room temperature. Upon completion, 10% sulfuric acid (10 mL) was 
added to the reaction mixture, followed by ethyl acetate (10 mL) and was extracted. The 
organic layer was washed with 10% sulfuric acid (10 mL), water (10 mL), and brine (10 
mL) respectively. The organic layers were dried (Na2 SC>4) and concentrated under 
reduced pressure to a pale yellow oil. Purification by column chromatography using an 
eluant of 4:1 hexane:ethyl acetate, product containing fractions were concentrated under 
reduced pressure to give the desired product as a colourless oil (0.79 g, 57%). NMR 
(300MHz, CDC13), 8 h 7.43 - 7.35 (m, 1 H, CH-CH=CH), 6.42-6.38 (m, 1H, CH3- 
CH=CH), 6.29 - 6.12 (m, 2H, CH3-CH, CH=CH-C), 3.79 (s, 3H, 0-CH3), 3.33 (s, 3H, 
N-CH3), 1.93 (d, J= 6.1 Hz, 3H, CHj-CH). I3C NMR (75 MHz, CDCI3), 8 C 167.9, 144.0,
138.7,130.7, 117.2, 62.0, 32.8, 18.9.
(2ii,4ii)-7V-Methoxy-v/V,2-dimethylhexa-2,4-dienamide
To a flask containing 2-methylhexa-2,4-dienoic acid (0.20 g, 1.6 ^
mmol) and A-methyl morpholine (0.44 mL, 4 mmol) in dry 
dichloromethane (5 mL) at -78  °C under argon, isobutylchlor- ' ^
oformate (1.92 mmol, 0.26 g) was added dropwise. The mixture was then stirred for 10 
min, after which a solution of N,O-dimethylhydroxylamine hydrochloride (3.2 mmol, 
0.31 g) and N-methyl morpholine (0.35 mL, 3.2 mmol) in 5 mL of dry dichloromethane 
was added dropwise. The mixture was then stirred for 30 min at -78 °C, and allowed to 
warm to room temperature. The reaction was quenched with the addition of 10% H2 SO4  
(1 mL) dropwise. The reaction mixture was then washed with 10% H 2 S O 4  (5 mL),
distilled water (5 mL), and brine (2 mL) respectively. Concentration of the organic 
fractions after drying (MgS0 4 ), yielded the crude product. Purification by column 
chromatography using an eluant o f 4:1 hexane:ethyl acetate gave the product as a pale 
yellow oil (0.22 g, 81%). 'H NMR (300MHz, CDC13), 8 H 7.37-7.29 (m, 1H, CH-CH=C), 
6.53-6.44 (m, 1H, CHCH-CH). 6.36-6.22 (m, 1H, CH3-CH=CH), 3.79 (s, 3H, O-CHs), 
3.23 (s, 3H, N -C tt), 2.04 (s, 3H, CHb-C), 1.99 (d, 7=6.7 Hz, 3H, CH3-CH=CH). 13C 
NMR (75 MHz, CDC13), Sc 173.8, 140.6, 138.8, 127.4, 123.9, 61.5,35.6, 18.9,12.0.
(21?,3‘S)“4-(terf-Butyldimethylsilyloxy)-2-ethylbutane-l,3-diol
To a flask containing 4-benzyl-3-[4-(ter/-butyldimethylsilanyloxy)-2- 
ethyl-3-hydroxy-butyroyl]-oxazolidin-2-one (0.1 g, 0.24 mmol) in 
dry diethyl ether (5 mL), LiAlH4 ( 8  mg, 0.2 mmol) was carefully
HOadded. The mixture was stirred at room temperature for 1 h, and 
assessed by TLC. 1 M HC1 (3 mL) was added to quench the reaction, and product 
extracted into dichloromethane (5 mL). Drying (M gS04), and concentration under 
reduced pressure yielded complex reaction materials that gave no products after 
purification.
Ethyl 2-(diethoxyphosphoryl)butanoate104,130 (122)
A flask containing triethyl phosphite (10.19 g, 61.3 mmol), was O
heated to reflux. Ethyl 2-bromobutyrate (10.0 g, 51.1 mmol) was 
added portion wise to the vessel, over a period o f 2 h. The mixture 
was heated to reflux for 5 h, and was then allowed to cool.
Distillation o f excess triethyl phosphite, and ethyl 2-bromobutyrate from the reaction 
mixture afforded the crude product, which was contained within the residue. Further 
distillation at 136-138 °C, 1mm Hg (lit. 117-118, 0.6 mm Hg) 104 122 as an oil (8 . 8  g, 
6 8 %). *H NMR (300MHz, C D C 13) ,  6 H 4.14-4.00 (m, 6 H, C H 3 - C H 2 - O ) ,  2.79 (ddd, 7=4.3, 
8.4 Hz, 7HP=23.4 Hz, 1H, C H 2- C H ( P ) - C ) ,  1.93-1.84 (m, 2H, C H 3 - C H 2 - C H ) ,  1.26-1.20 
(m, 9H, O - C H 2 - C H 3 ) ,  0.89 (t, 7=7.0 Hz, 3H, C H - C H 2 - C H 3 ) .
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2-Ethylhexa-2,4-dienoic acid ethyl ester (123)
Sodium hydride (0.34 g, 14 mmol) in dry THF (20 mL) was O
stirred at 0 °C. 2-(diethoxy-phosphoryl)-butyric acid ethyl ester 
(3.53 g, 14 mmol) was added dropwise over 5 minutes. The 
mixture was allowed to warm to room temperature, and was stirred for 10 min. The 
reaction vessel was re-cooled to 0 °C, followed by the dropwise addition of 
crotonaldehyde (1.0 g, 14 mmol). The mixture was warmed to room temperature and 
stirred for 24 h. The reaction was reduced to a minimum volume under light vacuum, 
ethyl acetate was added, and the reaction mixture washed with water and brine 
respectively. Organic fractions were dried (MgSO^, and concentrated under reduced 
pressure to an oil. The crude product was washed through a small silica plug to remove 
any trace baseline impurities, giving 123 as a colourless oil (1.38 g, 59%). *H NMR 
(300MHz, CDC13), 5h 7.06 (d, 7=11.3 Hz, 1H, CH-CH=C), 6.40-6.30 (m, 1H, CH=CH- 
CH), 6.11-6.01 (m, 1H, CH3-CH=CH), 4.18 (q, 7=6.9 Hz, 2H, O-CH2-CH3), 2.39 (q, 
7=7.3 Hz, 2H, CH3-CH2 -C), 1.85 (d, 7=6.9 Hz, 3H, CH3 -CH2-O), 1.28 (t, 7=7.3 Hz, 3H, 
CH3 -CH2-C), 1.02 (m, 3H, CH3 -CH). 13C NMR (75 MHz, CDC13), 6 C 168.2, 138.0,
137.7, 131.7, 127.1, 60.3, 20.2, 18.1, 14.3, 14.2. HRMS calcd. for Ci0Hi6O2 168.1150, 
found 168.1157.
(22s,4E)-2-Ethylhexa-2,4-dienoic acid (124)
A flask was charged with tetrahydrofuran:MeOH:water (3:1:1, 30 o
mL), and stirred. 2-Ethyl-hexa-2,4-dienoic acid ethyl ester (3.73 g,
22.2 mmol) followed by LiOH (1.06 g, 44.4 mmol) were added to \
the vessel, and the mixture stirred. The reaction was monitored by TLC. Upon 
completion, the reaction mixture was extracted with HC1 (1 M, 30 mL), brine (10 mL), 
and dried (MgSO^. Concentration yielded the crude product as a yellow oil. Column 
chromatography using an eluant o f 4:1 hexane:ethyl acetate gave 124 as an oil (2.82 g, 
91%). *H NMR (300MHz, CDC13), 6 H 7.23 (d, 7=10.0 Hz, 1H, CH-CH=C), 6.42-6.30 
(m, 1H, CH=CH-CH), 6.21-6.09 (m, 1H, CH3-CH=CH), 2.39 (q, 7=7.5 Hz, 2H, CH3- 
CH2-C), 3.76 (d, .7=6.7 Hz, 3H, CHj-CHCH), 1.04 (t, 7=7.5 Hz, 3H, CH3 -CH2-C). 13C 
NMR (75 MHz, CDCI3), 8 C 174.0, 140.6, 139.5, 130.3, 127.1, 19.9, 19.0, 14.2.
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(2ii,42i)-2-Ethylhexa-2,4-dienoyl chloride131 (125)
O
(2iT,4is)-2-Ethylhexa-2,4-dienoic acid (0.5 g, 3.6 mmol) was placed 
into a flask containing toluene (3 mL). Thionyl chloride (0.86 g, 0.52 
mL) was added, and the reaction stirred at 80 °C. The reaction was monitored by TLC. 
Upon completion, the reaction mixture was concentrated under reduced pressure to give
125 as an oil (0.57 g, 100%). The material was used without further purification.
2-Ethylhexa-2,4-dien-l-ol (126)
To a suspension o f lithium aluminum hydride (0.23 g, 6.15 mmol) in 
dry diethyl ether ( 6  mL) cooled to 0 °C, was added 2-ethylhexa-2,4- \
dienoic acid ethyl ester (1.38 g, 8.2 mmol). After 2 h, the mixture was filtered through 
celite, and the filtrate concentrated under reduced pressure to a minimum. Ethyl acetate 
was added, and the solution washed with 1 0 % sulfuric acid and brine respectively. 
Concentration o f product containing fractions gave the crude product as a colourless oil. 
Purification by column chromatography using an eluant o f 4:1 hexane:ethyl acetate gave
126 as a colourless oil (0.42 g, 41%). NMR (300MHz, CDC13), SH 6.31-6.26 (m, 1 H, 
CH=CH-CH), 5.96 (d, .7=10.9 Hz, 1H, CH-CH=C), 5.75-5.54 (m, 1H, CH3-CH=CH),
4.07 (s, 2H, HO-CH2-C), 2.20 (q, 7= 7.6 Hz, 2H, C-OL-CH,). 1.56 (d, 7=6.1 Hz, 3H, 
CH3-CH=CH), 1.02 (t, 7=7.6 Hz, 3H, CH3-CH2 -C). 13C NMR (75 MHz, CDC13), 6 C 
140.5, 129.6, 126.9, 124.9, 6 6 .6 , 21.5, 18.3, 13.5.
((2R,3i?)-2-Ethyl-3-((£)-prop-l-enyl)oxiran-2-yl)methanol119 (127)
To a flask containing dichloromethane (3 mL) at -10 °C, Ti(OzPr)4  
(23 mg, 0.08 mmol) and (-)-DIPT (22 mg, 0.1 mmol) was added.
The mixture was stirred for 5 min, then 2-ethylhexa-2,4-dien-l-ol 
(0.2 g, 1.6 mmol) was added. The mixture was allowed to age at -10 °C for 10 minutes, 
and /-butyl hydroperoxide (4.5 M, 3.2 mmol) was added dropwise. The mixture was 
stirred for 8  h at -10 °C, and quenched upon completion by TLC. Water (1 mL) was 
added and vigorously stirred for 60 min. 30% NaOH/saturated ammonium chloride 
solution (1 mL) was added and the reaction stirred for 60 min. The reaction mixture was 
then filtered, and the filtrate extracted with dichloromethane ( 2 x 5  mL). Drying
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(anhydrous Na2 SC>4 ) and concentration gave the crude product as an oil. No material was 
found to corrispond to 127.
(2/i,4/i)-2-Ethyl hexa-2,4-dienal (128)
To a flask containing dimethyl sulfoxide (15 mL), triethylamine
(1.88g, 18.6 mmol), and Py.SC>3 complex (2.17 g, 13.6 mmol) at -10
°C, the alcohol 2-ethylhexa-2,4-dien-l-ol (1.57g, 12.4 mmol) was added in one portion.
The mixture was then stirred at 0 °C and monitored by TLC. As the reaction progressed,
complex products were seen to be formed.
(l?)-2-Amino-3-phenyl-propan-l-ol, (i?)-phenylalaninol132a
To a stirring solution o f sodium borohydride (125.8 mmol, 4.67 g) in 100 nh9
HO
mL of dry tetrahydrofuran, ^-phenylalanine was added in one portion.
The reaction vessel was purged with argon, and cooled to 0 °C. Iodine [I J
(52.4 mmol, 13.4g) in tetrahydrofuran (25 mL) was added dropwise over 30 min. The 
reaction was allowed to warm to room temperature, and finally heated to reflux 
overnight. Cooling o f the mixture, followed by careful quenching with methanol until a 
clear solution was obtained. Solvents were then removed under reduced pressure, 
yielding a white paste. 100 mL o f 20% potassium hydroxide solution was added and 
stirred for 4 hours. Extraction with 3 x 100 mL o f dichloromethane, followed by drying 
(NaS(>4), and concentration under reduced pressure yielded the crude material. 
Recrystallisation from toluene gave the product as a white crystalline solid, 3.63g, 46%. 
1H, and 13C NMR identical to previously reported data. 132
(4i?)-4-(Phenylmethyl)-2-oxazolidinone122 (130)
A dry flask was prepared containing R-phenylalaninol (3.63 g, 24 O
(0.34 g, 2.4 mmol). The mixture was heated carefully to 135-140 °C, 
and ethanol was distilled as it was formed. When no more ethanol could be distilled, the 
mixture was cooled, and diluted with dichloromethane (10 mL), and filtered. The filtrate 
was washed with 1 M sodium bicarbonate solution, and organic fractions were
mmol), diethyl carbonate (5.67 g, 48 mmol), and potassium carbonate
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concentrated under reduced pressure to give 130 as an off-white solid (3.01 g, 71%). lK, 
and 13C NMR identical to previously reported data. 122
(R)-4-Benzyl-3-butyryl-oxazolidin-2-one (131)
To a flask containing (4R)-4-(phenylmethyl)-2-oxazolidinone (3 g, 17 
mmol) in 70 mL of dry tetrahydrofuran at -78 °C, w-butyllithium (17
mmol) was added dropwise and stirred for 20 min. Butyroyl chloride was 0 __ N^'
added to the reaction mixture dropwise via syringe, stirred for 15 min, and 
warmed to room temperature followed by stirring for 30 min. The reaction 
was quenched with 10% potassium carbonate solution. Extraction with 
dichloromethane (3 x 50 mL), followed by drying (MgSCL), and concentration under 
reduced pressure yielded the product as a colourless oil. Purification by column 
chromatography using an eluant o f 5:1 petroleum spirit (40-60 °C):ethyl acetate, gave 
the product as a colourless oil, 2.54 g, 59%. IR vmax (KBr, cm'1) 1781 (C=0), 1700 
(NC=0). *H NMR (300MHz, CDC13), 5H 7.33-7.19 (m, 5H, Ar-H), 4.69-4.65 (m, 1H, 
Ph-CH2-CH), 4.16-4.12 (m, 2H, O-CH2 -CH), 2.92-2.88 (m, 2H, Ph-CH^CH), 2.80-2.76 
(m, 2H, CH2 -CH2 -C), 2.02-1.68 (m, 2H, CH3 -CH2-CH2), 1.03-0.97 (m, 3H, CH3-CH2). 
13C NMR (75 MHz, CDC13), 6 C 173.2, 153.5, 135.3, 129.4, 129.0, 127.3, 66.2, 55.1,
37.9,37.4, 17.7, 13.7.
(i?)-4-Benzyl-3-((25,3‘S)-4-(tert-butyldimethylsilyloxy)-2-ethyl-3- 
hydroxybutanoyl)oxazolidin-2-one (132)
To a stirring solution o f 4-benzyl-3-butyroyl-oxazolidin-2-one 
(0.22 g, 0.89 mmol) in dry dichloromethane ( 6  mL) at 0 °C,
TiCL (1 M in dichloromethane, 0.84 mmol) was added slowly 
and stirred for 5 min, generating a yellow solution. (-)-Sparteine 
(0.80 mmol, 0.188 g) was added dropwise and stirred for 2 0  min, 
generating a deep red solution. Cooling to -78 °C, followed by 
the addition o f A-methyl-2 -pyrrolidinone (0.80 mmol, 0.080 g).
After stirring for 10 min, (tert-butyldimethylsilyloxy)-acetaldehyde (0.88 mmol, 0.154 
g) was added dropwise, and stirred for 1 h, followed by warming to 0 °C and stirring for 
a further 30 min. The reaction was quenched with half saturated ammonium chloride 
solution (3 mL), and extracted using dichloromethane ( 3 x 5  mL). Combination of
TBS
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organic fractions, drying (Na2 SC>4), followed by concentration under reduced pressure 
gave the crude product as an oil. Purification using column chromatography with an 
eluant o f 10% ethyl acetate/petroleum ether (40-60 °C) gave the product as a colourless 
oil, 0.35 g, 92%. IR vmax(KBr, cm'1) 3468 (OH), 1780 (C=0), 1692 (NC=0). *H NMR 
(300MHz, CDCls), 6 H 7.36-7.21 (m, 5H Ar-H), 4.72-4.68 (m, 1H, Ph-CH2-CH), 4.15-
4.07 (m, 3H, O-CH^CH, C-CH(OH)-CH2), 3.96-3.95 (m, 1H, TBS-O-CHH), 3.70 (m, 
1H, TBS-O-CHH), 3.60-3.32 (m, 2H, Ph-CH^CH), 2.69 (m, 1H, CH3-CH2-CH), 2.0-1.7 
(m, 2H, CH3 -CH2-CH), 0.98 (t, J= 7.4 Hz, 3H, CHb-CH^CH), 0.90 (s, 9H, O-TBS), 0.04 
(s, 6 H, O-TBS)- 13C NMR (75 MHz, CDC13), 6 C 174.9, 153.1, 135.3, 129.4, 129.0,
127.4, 71.8, 65.9, 64.9, 55.5, 46.0, 38.1, 25.8, 21.2, 11.2. HRMS calcd. for C22H35N 0 5Si 
421.2248, found 421.2251.
(2S,3iS)-3-((R)-4-Benzyl-2-oxooxazolidine-3-carbonyl)-l-(te7tf- 
butyldimethylsilyloxy)pentan-2-yl acetate (133)
To a stirred solution o f 4-benzyl-3-[4-(ter7-butyldimethyl- 
silyloxy)-2-ethyl-3-hydroxy-butyryl]-oxazolidin-2-one (1 g, 2.4 
mmol) in dry dichloromethane (10 mL), triethylamine (0.61 mL,
3.84 mmol), dimethylaminopyridine (0.098 g, 0.8 mmol), and 
acetic anhydride (0.34 mL, 3.6 mmol) was added. The mixture 
was stirred and monitored by thin layer chromatography to \ / /  
determine reaction progress. Upon completion, the reaction was quenched with the 
addition of saturated aqueous sodium hydrogen carbonate solution. Extraction of the 
reaction mixture with dichloromethane, followed by combination of product containing 
fractions, drying (MgSC>4), and concentration under reduced pressure, gave the crude 
product as a white solid. Recrystallisation from hexane/ethyl acetate gave the desired 
product as a colourless oil, 0.97 g, 83% yield. *H NMR (300MHz, CDC13), 8 h 7.34-7.19 
(m, 5H, Ar-H), 4.62-4.61 (m, 1H, Ph-CH2 -CH), 4.23-4.10 (m, 3H, O-CH9-CH. CH- 
CH(OH)-CH2), 4.00-3.97 (m, 1H, TBS-O-CHH), 3.62-3.58 (m, 2H, Ph-OL-CHL 3.29 
(m, 1H, TBS-O-CHH), 2.74 (m, 1H, CH3-CH2-CH), 2.00 (s, 3H, f f l 5-C(0 )-0 ), 1.88-
1.81 (m, 2H, C H 3- C H 2 - C H ) ,  0.94 (t, J=12  Hz, 3H, C H r C H 2- C H ) ,  0.86 (s, 9H, O-TBS), 
0.01 (s, 6 H, O-TBS). 13C NMR (75 MHz, CDC13), 5C 173.3, 170.5, 153.2, 135.4, 129.4, 
128.9, 127.3, 74.0, 66.0, 63.2, 55.7, 44.8, 38.1, 25.2, 21.0, 20.6, 18.2, 14.2, 11.3. HRMS 
calcd. for C2 4H37N 0 6Si 463.2390, found 463.2396.
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(5/?,6/?)-6-((terf-butyldimethylsilyloxy)methyl)-5-ethyl-dihydro-3f7-pyran-2,4-
dione120 (134)
Method 1:
OTo a stirring solution o f acetic acid 2-(4-benzyl-2-oxo-oxazolidine-3- 
carbonyl)-1 -(tert-butyldimethylsilyloxymethyl)-butyl ester (0.1 g, 0.22..................................................................................................................  Y i
mmol) in dry tetrahydrofuran (15 mL), at -78 °C, LiHMDS (1 M in 0  0
tetrahydrofuran, 0.66 mmol) was added dropwise. The mixture was stirred for 2 h. 
Analysis of the reaction mixture by TLC indicated that the reaction had progressed, and 
was quenched with the addition o f saturated ammonium chloride:water:MeOH 1:1:1 (50 
mL) at -78 °C. Ethyl acetate (50 mL) and water (15 mL) was added and the organic 
material extracted. The aqueous washings were taken, and acidified to pH 2-3 using 0.5 
M HC1. The acidic aqueous material was then extracted with dichloromethane (3 x 20 
mL). Drying (MgSC>4), and concentration under reduced pressure yielded the crude 
material. Column chromatography afforded a lactone as a white solid, Mp 216 - 217 °C,
34 mg. NMR analysis indicated that the required product had not been formed. Further 
analysis indicated that the product was an 11 membered cyclic structure, generated from 
an intramolecular cyclisation and the loss o f the silyl 
protecting group. C2 4H37NC>6 Si, 34mg, 0.07 mmol, 31% /  O
yield. Elemental; calculated (loss o f TBS group) [C: /  9 V^^NH
61.88, H: 6.64, N: 4.01], found [C: 61.49, H: 6.66, N: ^
3.92]. X-ray data can be found in appendix A. HRMS __
calcd. for Ci8H23N06 (loss o f TBS) 349.1525, found 0
349.1546.
Method 2:
To a stirring solution o f acetic acid 2 -(4-benzyl-2-oxo-oxazolidine-3-carbonyl)- \-{tert- 
butyl-dimethylsilyloxymethyl)-butyl ester (0.1 g, 0.22 mmol) in dry tetrahydrofuran (15 
mL), at -78 °C, NaHMDS (1 M in tetrahydrofuran, 0.66 mmol) was added dropwise. The 
reaction was stirred for 2 h. Analysis o f the reaction mixture by TLC indicated that the 
reaction had progressed, and was quenched with the addition of saturated ammonium 
chloride:water:MeOH 1:1:1 (50 mL) at -78 °C. Ethyl acetate (50 mL) and water (15 mL) 
was added and the organic material extracted. The aqueous washings were taken, and 
acidified to pH 2-3 using 0.5 M HC1. The acidic aqueous material was then extracted 
with dichloromethane (3 x 20 mL). Drying (MgSQ4), and concentration under reduced
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pressure yielded the crude material. NMR analysis indicated that the required product 
had not been formed.
Method 3:
To a stirring solution o f acetic acid 2 -(4-benzyl-2-oxo-oxazolidine-3-carbonyl)-\-(tert- 
butyldimethylsilanyloxymethyl)-butyl ester (0.1 g, 0.22 mmol) in dry tetrahydrofuran (5 
mL), at -78 °C, KHMDS (0.5 M in toluene, 0.66 mmol) was added dropwise. The 
mixture was stirred for 2 h. Analysis o f the reaction mixture by TLC indicated that the 
reaction had progressed, and was quenched with the addition of saturated ammonium 
chloride:water:MeOH 1:1:1 (20 mL) at -78 °C. Ethyl acetate (20 mL) and water (5 mL) 
was added and the organic material extracted. The aqueous washings were taken, and 
acidified to pH 2-3 using 0.5 M HC1. The acidic aqueous material was then extracted 
with dichloromethane ( 3 x 5  mL). Drying (M gS04), and concentration under reduced 
pressure yielded the crude material. Purification by column chromatography gave 134 
(45 mg, 72%). ‘H NMR (300MHz, CDCI3), 5H 4.66-4.63 (m, 1H, CH2-CH(0)(CH)), 
3.93 (dd, .7=11.4, 2.2 Hz, 1H, TBS-O-CHH), 3.74 (dd, J=11.4, 1.53 Hz, 1H, TBS-O- 
CHH), 3.48 (d, 7=20.7 Hz, 1H, C(0)-CHH-C(0)), 3.29 (dd, 7=20.7, 1.1 Hz, 1H, C(O)- 
CHH-C(0)), 2.57 (m, 1 H, CH3-CH2-CH), 2.04 (m, 1 H, CH3-CHH-CH), 1.28 (m, 1 H, 
CH3 -CHH-CH), 1.04 (t, 7=7.5 Hz, 3H, CH3 -CH2), 0.84 (s, 9H, O-TBS). 0.02 (s, 6 H, O- 
TBS). 13C NMR (75 MHz, CDCb), 8 C 200.0, 168.5, 79.1, 62.2, 49.8, 45.6, 25.7, 18.4, 
17.9,12.1. HRMS calcd. for Ci4 H2 6 S i0 4  286.1600, found 286.1613.
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(5S',6/?)-6-((terr-butyldimethylsilyloxy)methyI)-5-ethyl-4-hydroxy-tetrahydropyran-
2-one120 (135)
Method 1:
To a stirring solution o f (5 R,6R)-6-((tert-
butyldimethylsilyloxy)methyl)-5-ethyl-dihydro-3//-pyran-2,4- JBS(
OH
O
dione (45 mg, 0.16 mmol) and dry MeOH (1 mL) at 0 °C, NaBBU
(1 mg, 0.26 mmol) was added. The mixture was stirred at 0 °C and monitored my TLC.
No recoverable product was formed in the reaction.
To a stirring solution of (5i?,6i?)-6-((fert-butyldimethylsilyloxy)methyl)-5-ethyl-dihydro- 
3//-pyran-2,4-dione (50 mg, 0.18 mmol) and dry ethanol (1.5 mL) at 0 °C, NaBTL ( 1 
mg, 0.26 mmol) was added. The mixture was stirred at 0 °C and monitored my TLC. No 
recoverable product was formed in the reaction.
To a stirring solution o f (5i?,6i?)-6-((te/y-butyldimethylsilyloxy)methyl)-5-ethyl-dihydro- 
3//-pyran-2,4-dione (50 mg, 0.18 mmol) and dry ethanol (1.5 mL) at -  5 °C, a solution 
of f-BuNH2 -BH3 (51 mg, 0.55 mmol) in MeOH (2 mL) was added, followed 
immediately by a 1 M solution o f citric acid in water (1.5 mL).The reaction was stirred 
for 4 h at -5 °C. dichloromethane (15 mL) was and water (5 mL) were added. Organic 
layers were extracted, and the aqueous layer extracted with dichloromethane (3 x 10 
mL). Drying (MgS0 4 ) and concentration under reduced pressure yielded crude material. 
Analysis indicated that no required material had been formed in the reaction.
Method 2:
Method 3:
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l,4-Bis-(te/T-butyldimethylsilyloxy)-but-2-ene132b (138)
To but-2-ene-l,4-diol (2.5 g, 56.8 mmol) in 100 mL of dimethyl 
formamide at 0 °C, imidazole (114 mmol, 7.73 g) and tert- 
butyldimethylsilyl chloride (56.8 mmol, 8.55 g) was added. The mixture 
was stirred at ambient temperature for 12 h. The reaction mixture was then extracted 
using diethyl ether (3 x 50 mL) and water (200 mL). Combination, drying (Na2S0 4 ), and 
concentration under reduced pressure gave the product as a colourless oil. The crude 
material was purified by column chromatography using an eluant of 1 0 % ethyl 
acetate/petroleum ether (40-60 °C) giving the product as a colourless oil 14.4 g, 80%. !H 
NMR (300MHz, CDC13), SH 5.56-5.50 (m, 2H, CH=CH-CH2), 4.23-4.22 (m, 4H, CH- 
CH2-O), 0.89 (s, 18H, O-XBS), 0.06 (s, 12H, O-TBSL 13C NMR (75 MHz, CDCI3), 8 C 
130.2, 59.6, 25.9, 18.3.
(ferf-Butyldimethylsilyloxy)-acetaldehyde132c (139)
To a flask containing dichloromethane (60 mL) and 1,4-bis-{tert- 0  
butyldimethylsilyloxy)-but-2-ene (3 g, 9.47 mmol) at -78 °C, O 3 was added ^ ^ 0xtb s  
to the reaction mixture until the mixture appeared blue in colour. Excess O 3 was then 
purged from the reaction mixture, and triphenylphosphine (7.45 g, 28.4 mmol) was 
added. The mixture was then allowed to warm to room temperature slowly, and was 
stirred for 12 h. The reaction mixture was then concentrated under reduced pressure, and 
dichloromethane was added. The solution was passed through a short silica plug, and 
concentrated under reduced pressure. The crude material was then purified using column 
chromatography using an eluant o f 5% ethyl acetate/petroleum ether (40-60 °C), product 
containing fractions were concentrated under reduced pressure to a colourless oil to give 
139 (2.75 g, 83%). lH NMR (300MHz, CDC13), 8 H 9.74 (s, 1H, CHO-CHA 4.22 (s, 2H, 
CHO-CjHb-O), 0.93 (s, 9H, O-TBS), 0.11 (s, 6 H, O-TBS). 13C NMR (75 MHz, CDC13), 
8 C 202.4, 69.6, 25.8, 11.4.
.TBS
TBS
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(2S',3S)-4-(te/tf-Butyldimethylsilyloxy)-2-ethyl-3-hydroxybutanal (141)
To a stirring solution o f Red-Al (0.35 mmol) in tetrahydrofuran (5 mL) tbs
at -78 °C, 4-benzyl-3-[4-(ter/-butyldimethylsilyloxy)-2-ethyl-3-hydroxy- / r" 
butyryl]-oxazolidin-2-one (0.133 g, 0.32 mmol) in 3 mL of 
tetrahydrofuran was added dropwise and stirred for 15 min. The mixture O 
was then warmed to -60 °C, and stirred for 1 h. The reaction was cooled to -78 °C and 
quenched using a 4:1 ethyl acetate:methanol solution (1 mL), and stirred for 15 min. 
Warming the mixture to -20 °C, 1:2 ethyl acetate:5% HC1 mixture was added ( 6  mL), 
and stirred for 15 min. Organic material was decanted from the solid aqueous fractions, 
which were washed quickly with diethyl ether. Combination of the organic extracts, 
drying (Na2 S0 4 ), and concentration under reduced pressure gave the crude product as an 
oil. Purification by column chromatography using an eluant of 5% ethyl 
acetate/petroleum spirit (40-60 °C) gave the product as a colourless oil, 0.072 g, 89%. 
The material was used immediately in further stages.
(2S,3£)-l-(fe/tf-Butyldimethylsilyloxy)-3-formylpentan-2-yl acetate (142)
To a stirring solution o f 4-(tert-butyldimethylsilyloxy)-2-ethyl-3 - 
hydroxy-butyraldehyde (0.32 mmol) in dichloromethane (5 mL) at 0 °C, 
acetic anhydride (27 mg, 0.44 mmol), DMAP (0.012 g, 0.1 mmol), and 
triethylamine (0.46 mmol) was added sequentially. The mixture was 
stirred until completion by TLC analysis. Water was then added (5 mL), and the reaction 
mixture extracted with dichloromethane ( 3 x 5  mL). Combined organic fractions were 
dried (Na2 S0 4 ), and concentrated under reduced pressure to an oil. The product was used 
rapidly as crude material in further stages.
TBS
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(5£,6/?)-6-((te7tf-butyldimethylsilyloxy)methyl)-5-ethyl-5,6-dihydro-2H-pyran-2-
one127 (143)
To tetrahydrofuran (10 mL) and diisopropylamine (267 mg, 2.64
mmol) at -78 °C was added rc-butyllithium (2.5 M in hexanes, 2.4
mmol). The mixture was warmed to 0 °C, stirred for 30 min and re-
TBS
cooled to -78 °C. Methyl acetate (196 mg, 2.64 mmol) was added 
and stirred for 30 min. Acetic acid l-(ter/-butyldimethylsilyloxymethyl)-2-formyl-butyl 
ester (649 mg, 2.4 mmol) was added and stirred for 1 h. The mixture was warmed to -20 
°C, and the reaction left for a further 1 h .The reaction was quenched with the addition of 
saturated ammonium chloride solution. Product containing material was extracted with 
dichloromethane ( 3 x 5  mL), dried (MgSC>4), and concentrated under reduced pressure to 
an oil. Purification by column chromatography using an eluant of 4:1 hexane:ethyl 
acetate gave the desired product as a colourless oil, 0.145g, 23%. IR vmax (KBr, cm'1) 
1728 (C=0). !H NMR (300MHz, CDC13), 5H 7.02 (dd, .7=6.0, 9.7 Hz, 1H, CH-CH=CH),
6.02 (d, 7=9.7 Hz, 1H, C(0)-CH=CH), 4.52-4.46 (m, 1H, CH-CH(0)-CH2), 3.89-3.77 
(m, 2H, TBS-O-CHA 2.49-2.45 (m, 1H, CH-CH(CH3)-CH), 1.71-1.27 (m, 2H, CH3- 
CH2-CH), 0.96 (t, 7=7.4 Hz, 3H, CH3 -CH2), 0.98 (s, 9H, O-TBS), 0.05 (s, 6 H, O-TBSV 
13C NMR (75 MHz, CDC13), 6 C 164.0, 150.5, 120.8, 79.7, 61.4, 34.0, 25.8, 20.4, 18.2,
11.0. HRMS calc, for Ci4 H2 6 S i0 3 270.1651, found 270.1660.
1 0 0
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Chapter 3
Studies Towards Histone Deacetylase Inhibition
3.1 Introduction
The origin, and appropriate forms o f treatment for cancer, is an often discussed topic 
throughout the scientific literature. The range and breadth of the area is staggering, and 
generates a multitude o f publications spanning from the discovery of natural products 
with favourable therapeutic effects, to the study of cellular processes underlying the 
disease.
Recently, there have been many reports indicating the importance of epigenetic 
processes within cancer development. These are processes which affect the transcription 
of DNA, silencing some genes and activating others, without altering the nucleotide 
sequence itself. Two main processes are thought to be regulating gene transcription 
epigenetically, histone acetylation, and DNA methylation.
This chapter will focus upon histone interactions, and in particular upon the role o f 
histone deacetylase in the activation and silencing o f genes through histone acetylation 
and deacetylation.
3.1.1 Chromatin
Deoxyribonucleic acid, or DNA, is a long polymer consisting o f nucleic acids. The 
length of DNA varies from organism to organism, but can be short as tens of kilobases, 
to hundreds o f megabases. Within the sequence o f nucleotides, DNA contains genetic 
instructions known as genes, relating to all aspects o f development and function in living 
organisms. Transcription o f these genes into ribonucleic acid, or RNA, allows the cell to 
orchestrate various cellular processes such as mitosis and cellular death.
In eukaryotic cells, DNA is found in large linear portions, and is collectively known as 
the chromosome. The helical structure o f DNA, originating from the discoveries of
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Watson and Crick, is widely recognised. The helical DNA is held mostly within the 
nucleus, and is tightly packaged in higher order structures known as collectively as 
chromatin.
The term chromatin originates from the ease at which the material can be stained, and 
means quite literally, coloured material. Chromatin is varied in its packing configuration 
within the nucleus, at the very highest level o f compression is metaphase chromatin, it is 
physically robust and is responsible for the ‘X ’ shaped appearance of the chromosome. 
At the very lowest, the DNA is held in a form known as the nucleosome, and is the 
fundamental repeating unit o f chromatin.
The nucleosome is built around a core o f 8  histone proteins, H2A, H2B, H3 and H4, 2 o f 
each being present in the histone octamer. DNA is wrapped around the histone core in 
two superhelical turns, and contains 145 base pairs in total. The histones contain a 
terminal amino acid tail, rich in lysine residues, which is free o f the central histone 
octamer. An illustration o f the nucleosome can be seen in figures 3.1.1, and 3.1.2, 
showing the construction o f the nucleosome, the DNA, and the lysine rich tail portions 
free o f the histone core.
Fig. 3.1.1. A representation o f  a nucleosome showing a helical DNA sequence (orange) wrapping round a 
histone octamer core. Derived from the PDB database data 1KX5.
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Fig. 3.1.2. A side-on representation o f  a nucleosome showing a helical DNA sequence (orange) wrapping 
round a histone octamer core. Derived from the PDB database data 1KX5.
Repeating units o f nucleosomes on the DNA strand gives the so called “beads-on-a- 
string” appearance (figure 3.1.3).
Fig. 3.1.3. Sequential nucleosomes forming chromatin. The histone octamer is represented by grey 
rectangles, DNA is represented as a black cord.
The beads are condensed into 30 nm fibres with the addition o f histone HI, and 
compressed further by conversion into higher order chromatin such as euchromatin, and 
higher still to heterochromatin. As the DNA is compressed into the more densely packed 
forms o f chromatin, the accessibility o f  the DNA to proteins with which it can interact 
lessens, and therefore impacts on transcriptional activity. 134 The level o f chromatin 
compression is regulated through the modification of the lysine rich filaments which 
pass around and through DNA wrapped around the histone octamer. Modifications such 
as acetylation, methylation, and phosphorylation mediate the level o f chromatin 
compression, and is a prominent method within the cell by which it can regulate gene 
expression. This epigenetic process, one which influences the cell without altering the 
DNA, is heritable from one cell through to its decedents, is considered to provide a 
mechanism for the cell to respond to environmental changes through cell progression 
and differentiation. Recent evidence has shown that the perturbation of chromatin
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epigenetic processes causes silencing of genes, and is responsible for the underlying 
pathogenesis o f many types o f disease.
Chromatin remodelling is regulated by the activities of histone acetyltransferases 
(HATs) and histone deacetylases (HDACs). There is a constant flux between acetylation 
by HATs, expanding the chromatin and allowing the activation of genes, and 
deacetylation by HDACs, compressing chromatin to silence and deactivate gene 
sequences. Recently, associations between aberrant epigenetic states and tumours have 
revealed that chromatin remodelling is crucial to the onset and progression of cancer, 
particularly in initial stages o f tumourigenesis. 135,136 The prevention o f gene silencing by 
modulating epigenetic processes has therefore prompted considerable interest as a means 
to obtain therapeutic anti-cancer effects.
3.1.2 Histone Deacetylase
HDACs are members o f one o f the more ancient enzyme families, and they are 
expressed in a wide variety o f organisms from bacteria to humans, and are evolutionarily 
conserved. They are a group o f enzymes which facilitate the removal o f acetate groups
1 “xnfrom histone lysine rich tails, as well as the cytoskeletal protein tubulin and
1 1 C
transcription factors such as p53. HDACs have been considered to act mostly upon 
histones, however it is becoming apparent that acetylation and deacetylation may play a 
larger role, and may be as prominent as phosphorylation and dephosphorylation. 139’140
Four classes of HDAC have been identified in mammalian cells, and are classified 
according to their structural similarity to yeast HDAC enzymes, localization, and 
activities.
Class I is comprised o f HDAC 1, HDAC 2, HDAC 3, and HDAC 8 . They are 
homologous to yeast RPD3 protein, are Zn+ 2 ion dependent, and are found generally in 
the cell nucleus, and expressed in most human cell lines. Class II enzymes are also Zn+2  
dependent, share homology with yeast Hdal protein, and can move freely between the 
nucleus and cytoplasm. Enzymes contained within class II are HDAC 4, HDAC 5, 
HDAC 6 , HDAC 7, HDAC 9, and HDAC 10. Class III HDAC enzymes are homologues 
of the protein Sir2, and are NAD dependent. Class IV is occupied by HDAC 11, and
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resembles class I and class II HDACs in sharing sequence similarity within the catalytic 
core region, however, it is placed within a class of its own as it does not share any 
sufficient identity with the other HDAC classes.
3.1.3 Histone Deacetylase Active Site
Until very recently, the only source o f structural data on HDAC enzymes was the X-ray 
structure of Histone Deacetylase Like Protein (HDLP, PDB database ID: 1C3P), a 
HDAC analogue from Aquifex Aeolius. The function of HDLP is unknown, but the 
enzyme can deacetylate histones in vitro with a specific activity o f about 7.5% of FLAG 
tagged HDAC 1. HDLP has been used successfully in inhibition assays and 
computational studies, and has proved to be useful in determining the nature of the 
catalytic process underlying class I and class II HDAC deacetylation.
The ability of class I and II HDACs to deacetylate substrates stems from a central 
catalytic area, built around a Zn+2 ion contained within an angled cavity. The cavity 
consists o f a surface pocket, containing mostly hydrophobic residues, and descending 1 1  
A into the body o f the enzyme. The bottom of the pocket contains the central Zn+2 ion, 
and a series o f chelating residues important for the catalytic deacetylation process to 
occur. Deeper into the enzyme, the catalytic site extends a further 14 A and forms an 
internal cavity. A representation o f the catalytic are can be seen in figure 3.1.4.
1A angst om cavity
Fig. 3.1.4 A representation o f  the HDAC 1 11 A catalytic channel, and 14 A internal cavity.
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Surrounding the Zn+2 ion are three residues, Tyr 303 (HDLP: Tyr 297), His 141 (HDLP: 
His 132), and His 140 (HDLP: His 131), which constitute the main structural features of 
the catalytic deacetylation area. Mechanistic studies o f the catalytic site, conducted 
through mutagenesis studies o f mammalian HDACs and HDLP, indicated that His 140, 
and its associated His-Asp charge relay system was essential for catalytic function. 
Modification o f His 140 or the charge relay associated Asp 174 abolishes activity. 
Alteration of His 141 and its associated Asp 191 charge relay system reduces activity, 
but does not remove it completely. This indicated that His 141 is beneficial, but not 
essential to the catalytic functioning o f the enzyme. Furthermore, it was found Tyr 303 is 
essential to catalytic activity, and mutagenesis to phenylalanine indicated that removal 
would eliminate activity completely . 141
Ab initio studies o f the HDLP catalytic region142 have shown that the area is sufficiently 
basic around His 140 to deprotonate water. The presence of this ‘hydroxide’ ion in the 
catalytic area is believed to be essential for deacetylation to occur, and is associated with 
Tyr 303.143 An illustration o f the deacetylation mechanism in class I HDACs can be seen 
in figure 3.1.5.
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Fig. 3.1.5. Illustration of the HDAC catalytic deacetylation mechanism. X represents the lysine rich 
histone protein.143
The deacetylation process begins with the chelation of the acetylated residue to the Zn+2 
ion. The hydroxide ion, near to Tyr 303, attacks the carbonyl group o f acetate in a 
manner analogous to that observed in carbonic anhydrase. Proton transfer from His 140 
to His 141 occurs, and the tetrahedral transition state formed in B interacts with the 
newly transferred proton o f His 141, illustrated in C. Finally, the tetrahedral transition 
state collapses, resulting in cleavage o f the amide bond, and liberation of acetate and the 
free amine (D). The acetate is then passed into the 14 A cavity, 144 and a new water 
molecule binds to the site to restart the catalytic cycle.
3.1.4 Histone Deacetylase Inhibitors
HDAC inhibitors have the ability to selectively induce apoptosis in tumour cells at low 
toxicity levels, typically at levels 1 0  times less than the toxic dose for normal cells. 
Activity has been observed for a wide variety o f cancer cell lines, including leukaemia, 
lymphoma, breast, bladder, ovarian, prostate and lung. Activity of HDAC inhibitors has
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been postulated to be due to the interaction o f the inhibitor with the Zn+2 catalytic site, 
inhibiting deacetylation, and thus affecting chromatin remodelling and transcription. It 
has been shown, however, that HDAC inhibition can also affect other molecular 
processes including mitosis, DNA replication, and DNA repair. 145 It is becoming 
apparent that HDAC inhibitors may have a larger effect on cellular processes than was 
originally believed to be the case. Furthermore, the variation in HDAC activities, and the 
many HDAC variations in different tumour types, makes determination of the true 
inhibitory mechanism a challenging prospect.
One of the first HDAC inhibitors to be reported is trichostatin A (TSA, 144), isolated 
from Streptomyces platensis,146,141 and originally developed as an antifungal agent. It 
was found that at extremely low concentrations (nM), TSA could induce Friend 
leukaemia cell differentiation, and additionally inhibition of the cell cycle in G1 and G2 
phases. In vivo it was found to increase the accumulation of acetylated histones, and 
inhibit strongly the activity o f  partially purified histone deacetylase in vitro. It has not 
progressed into clinical trials, but has since been used as a useful tool in studying histone 
acetylation and mechanisms o f cell proliferation and differentiation.
O O
Fig. 3.1.6. HDAC inhibitors. 144. Trichostatin A (TSA); 145. Suberoylanilide hydroxamic acid (SAHA, 
Vorinostat); 146. MS-275.
TSA is a member o f a class o f HDAC inhibitors known as hydroxamic acids, which 
strongly chelate to Zn+ 2 within the HDAC catalytic site. The hydroxamic acids are the 
largest class o f HDAC inhibitors currently known, but other types exist, such as the 
benzamides (MS-275, 146), short-chain fatty acids (butyrate, valproic acid), and cyclic
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tetrapeptides (apicidin, depsipeptide). All HDAC inhibitors can be generally described to 
contain a chelating group, which binds to the Zn+2 ion in the core of the HDAC enzyme, 
a cap-group which interacts at the top o f the catalytic pocket, and a lipophilic linker
joining the two together and spanning the distance into the enzyme between the surface
+2and the Zn ion containing catalytic core.
TSA was first synthesised by Mori and Koseki, 148 and is considered to be an 
acetyl-lysine mimic. Modification o f TSA, alteration of stereochemistry, or addition of 
alternate groups and functionality, generally generate compounds that are less active 
then the original natural product; however, it does provide the basic structural template 
for the whole of the hydroxamic class o f inhibitors. One such inhibitor that can be seen 
to be adhering to the TSA pharmacophore is suberoylanilide hydroxamic acid (SAHA, 
145). SAHA is currently one o f the most important reverse amide hydroxamic acid 
HDAC inhibitors undergoing testing. SAHA has been shown to bind into the catalytic 
ion-containing region in the same manner as that o f TSA , 141 and has shown promising 
activity in T-cell lymphoma, myeloma, and breast cancer cells. SAHA is currently one of 
the most advanced HDAC inhibitors, and has entered phase III clinical trials for the 
treatment o f both solid and haematological tumours.
Clinical trials have shown that most HDAC inhibitors are well tolerated by normal cells 
and have good clinical activity. The inhibitors are a subject of great interest, and their 
potential to provide therapeutic effects not only in the treatment o f cancer, but for the use 
of antimalarial, antiviral, and antiprotozoan chemotherapy, has been the focus of many 
research groups in the effort to generate an ever more potent compound. There has been 
a multitude o f publications detailing analogue synthesis, in vivo and in vitro studies, and 
more recently studies o f HDAC inhibitors in silico.141’149'151
In silico analysis represents one o f the more modem methods of scientific analysis. The 
use of computers to correctly model and emulate a large biological system accurately, 
such as an enzyme, is only possible with the more powerful processing power of modem 
computers. Computational analysis has developed from a highly specialist, extremely 
expensive undertaking, to an efficient cost effective method of structural analysis and 
lead compound optimisation.
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3.2 Results and Discussion
The success o f molecular modelling depends greatly upon the preparation of the model 
used to describe the ligands, and the enzyme or macromolecule. The model itself can 
vary in a many ways, from the physical location of atoms within the model, to how the 
physical properties o f atoms are described. The choice of enzyme model and method of 
calculation are o f great importance in ensuring that information recovered from the 
analysis is viable and accurately predicts experimentally determined data.
Of the many examples o f computational software available, Autodock 3152 was chosen 
as the method to compute HDAC-ligand interactions, based upon its speed, accessibility, 
and demonstrably robust and superior docking o f ligands into metalloproteins. 153
The overall aim o f the project is to create a working computational model to aid in the 
analysis and synthesis o f novel HDAC inhibitors.
3.2.1 Preparation of the HDAC Enzyme
The first consideration was to determine the sequence and structure o f the HDAC 
enzyme to be used in the analysis. In previously reported analyses, the use of X-ray 
diffraction data are used extensively to aid development of the model. The use of 
experimental crystallographic data in computational studies can be highly desirable, as 
models can be validated by comparing computer calculated predictions with known 
interactions from experimentally derived data. In the case o f mammalian HDAC 
enzymes, only the structure o f HDAC 8  (PDB database id: 1W22) has been 
experimentally confirmed and reported. 154 ,155
A HDAC 1 homology model, originally constructed and reported by Wiest149 was 
chosen as the basis o f the enzyme model. The model was constructed by taking X-ray 
crystal structure data o f HDLP (PDB database ID: 1C3P), a HDAC homologue from 
Aquifex Aeolicus. A sequence alignment o f HDAC and HDLP shows a 35.2% sequence 
identity, in addition to conservation o f the residues around the important Zn+2 binding 
site and within the 11A channel. Substantial similarity between the two proteins allowed
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Wiest to use the positional data o f the HDLP protein to construct a HDAC 1 homology 
model, using the catalytic site and conserved features common to both as a template. 150
HDAC 1 MAQTQGTRRKV C Y Y YDGDVGN Y Y Y GQGHPMKPHRIRMTHNLLLNYGL YRK
HDLP -------MKKVKLIGTLDYGKYRYPKNHPLKIPRVSLLLRFKDAMNLI DE
*  .  .  . *
HDAC 1 ME IYRPHKANAEEMTKYHSDDYIKFLRSIRPDNMSEYSKQMQRFNVGEDC 
HDL P KELIKSRPATKEELLL FHTEDYINTLMEAERCQCVPKGAREKYNIGGYEN
: • •  *  •
HDAC 1 PVFDGLFEFCQLSTGGSVASAVKLNKQQTDIAVNWAGGLHHAKKSEASGF 
HDLP PVSYAMFTGSSLATGSTVQAIEEFLKG- -NVAFNPAGGMHHAFKSRANGF
*  *  . * *  . . * ! * * . ! *  I *  ! ! * . *  * * ^ * * *
HDAC 1 CYVNDIVLAILELLKY-HQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFH 
HDL P C YINNPAVGIE YLRKKGFKRIL YIDLDAHHCDGVQEAFYDTDQVFVLSLH
* * * ★ . *  *  *  * * * . ★ ★ * *  ★ * . * .  . * . *
HDAC 1 KYGEYFP - -GTGDLRDIGAGKGKYYAVNYPLRDGIDDESYEAIFKPVMSK 
HDLP QSPEYAFPFEKGFLEEIGEGKGKGYNLNIPLPKGLNDNEFLFALEKSLEI
• ★ *  # * * ^ . * * * * * * *  *  . . *  .  ^ . . .
HDAC 1 VMEMFQPSAWLQCGSDSLSGDRLGCFNLTIKGHAKCVEFVKSFNLPMLM 
HDLP VKEVFEPEVYLLQLGTDPLLEDYLSKFNLSNVAFLKAFNIVREVFGEGVY 
* ★.* * * *  ^ ^
HDAC 1 LGGGGYTIRNVARCWTYETAVALDTEIPNELPYNDYFEYFGPDFKLHISP 
HDLP LGGGGYHPYALARAWTLIWCELSGREVPEKLNN-----------------
HDAC 1 SNMTNQNTNEYLEKIKQRLFENLRMLPHAPGVQMQAIPEDAIPEESGDED
HDLP ------KAKELLKSIDFEEFD-------------------------------
. . . *  *  .  ^ >  ^ *  •
HDAC 1 EDDPDKRISICSSDKRIACEEEFSDSEEEGEGGRKNSSNFKKAKRVKTED 
HDLP -DEVDR------------------------------------------- SYML
HDAC 1 EKEKDPEEKKEVTEEEKTKEEKPEAKGVKEEVKLA
HDLP E T L BCD PWRGGEVRKEVKDT L E KAKAS S--------
*  * ★ *
Scheme 3.2.1. Sequence alignment of HDAC 1 and HDLP produced by ClustalX.
-indicates positions which have a single, fully conserved residue 
‘: ’ -indicates that one of the following 'strong' groups is fully conserved 
V -indicates that one of the following 'weaker' groups is fully conserved
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Fig. 3.2.2. Image of the homology model of HDAC 1 (left) and HDLP (right) proteins. Generated from 
PBD database entry 13CP and a HDAC 1 homology model reported by Weist.149
In order to generate a functioning computational model, the structural data for the 
HDAC 1 homology model provided by Weist, was extracted and imported into 
Autodock Tools. 156 This eliminated the need to generate new homology models and 
enabled an already validated HDAC 1 homology model to be used as a basis of our own 
studies.
All bonds in the model were reconstructed by distance, and all hydrogen atoms were 
added. The model was checked for missing atoms, and repaired where appropriate. The 
construction o f the catalytic Zn+2 domain was examined visually to ensure the correct 
conformation. All non-polar hydrogens were removed, and Kollman charges157 were 
added to the model, followed by solvation parameters.
With the basis o f the model prepared, attention was focused upon the catalytic core and 
the protonation states o f the residues localised within the area. Through previous ab 
initio studies o f HDLP, it was shown that His 131, analogous to His 140 in HDAC 1, 
deprotonated water when minimized within the active site. 142 This is in accordance with 
the proposed catalytic mechanism reported by Finnin et al.m  and indicates that the 
presence of any ligand in the catalytic area would also have the potential to be 
deprotonated. 151
The histidine residues in the model were protonated, and edited to reflect the 
configuration adopted when binding to a ligand. His 140 was defined as being 
protonated at both nitrogens (HE2 and HD1), and was intended to simulate the action of
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deprotonation in the catalytic area. His 178 was protonated only on HE2, and all other 
histidine residues were protonated on HD1.
Fig. 3.2.4. Image of the catalytic site in the HDAC 1 model, showing the protonation of the histidines 140 
and 141.
In accordance with the required Autodock 3 preparation procedure, it was essential to
computational studies have typically been problematic, coordination changes, problems 
accounting for charge, and radius are all variables that have to be accurately described in 
order to generate a working model. This is not restricted to zinc ions specifically, but to 
all metal ions in general.
The zinc parameters were derived from work reported by Stote and Karplus, 158 arid have 
been used successfully in other molecular dynamics studies concerning matrix 
metalloproteinases. 159 ,160 Wiest et al. 144>149 reports the successful use o f the non-bonded
OH
Fig. 3.2.3. Histidine image showing the HD1 and HE2 nitrogens.
have the Zn+2 ion in the centre o f the catalytic core accurately defined. Zn+2 ions in
Zinc parameters in the generation o f the HDAC 1 homology model, and successfully in 
HDLP docking studies where they have shown excellent agreement with calculated and 
experimental binding affinities.
The values used within the HDAC 1 homology model to define the zinc ion are; Gij =
1.95 A, £ij = 0.25 kcal/mol, with a charge o f +2 e.
With the HDAC 1 enzyme defined, it was possible to generate energy grid maps. These 
were generated by the Autodock package, within a 60 x 60 x 60 A cube centered around 
the top of the 1 1  A channel with a resolution o f 0.375 A. An illustration of the oxygen 
grid map can be seen in figure 3.2.5.
Fig. 3.2.5. An illustration showing the generated energy grid maps. This example shows the surface of the 
HDAC 1 enzyme in white, and the oxygen affinity areas cross-hatched.
3.2.2 Ligand Preparation
Ligands were initially prepared using ChemDraw, 161 and geometry minimized using 
modified version o f Allinger's MM2 force field. Geometry minimised ligands were 
saved in PDB format. Ligands were then converted to SYBYL MOL2 files, with the 
addition of Gasteiger charges162,163 using OpenBabel. 164
All hydroxamic acids were prepared in the deprotonated hydroxamate form. Ligand 
torsions were defined in the Autodock Tools software package, finally giving the fully 
prepared ligands. Prepared ligands can be seen in figure 3.2.6.
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Fig. 3.2.6. Ligands prepared for input into the computational model. 147. UCL159; 148. SAHA; 149. 
UCL171; 150. TSA; 151. UCL173; 152. UCL2200; 153. MGCD; 154. UCL158; 155. UCL169; 156. 
UCL174.
The computations were run using a Lamarckian Genetic Algorithm, 152 with a maximum 
of 100 runs and a population o f 50 per run. The maximum number of evaluations was 
defined as 2.5 x 106, and the maximum number o f generations to be 2.7 x 105.
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3.2.3 Analysis of the Computational Data
The integrity and ability o f the system to generate useful data was first established. It 
was necessary to determine if  the model could return data that was representative of the 
binding conformations o f each ligand. Concerns were focused upon the binding of the 
hydroxamate to the zinc metal atom in the core o f the catalytic site.
In order to determine if  the non-bonded zinc parameters were resulting in correct ligand 
binding predictions, a model was prepared from an existing HDLP crystal structure. The 
HDLP crystal structure was obtained from the PDB databank (PDB database ID: 1C3P) 
and contained a co-crystallized molecule o f TSA. The model was edited, and the bound 
TSA molecule was removed. The non-bonded Zinc parameters were added, and a new 
model was formed. A TSA ligand was prepared with Autodock Tools, and a docking 
against the new HDLP model was initiated.
B f l i  j  *
His 132
His 131
Fig. 3.2.7. Illustrations showing the HDLP model. TSA models shown in blue are derived from 
computational studies. TSA models shown in orange are derived from published experimental crystal 
structure data (PDB database entry 1C3R). Overlay of the computational and experimentally derived TSA 
structures indicates a good correlation between the model and the true binding mode of the ligand.
Results from the HDLP model indicated that the simulation was accurately defining the 
environment around the catalytic Zn+2 site, and would generate accurate data with 
respect to the hydroxamic acid and catalytic area. Figure 3.2.7 illustrates that the 
computed and experimentally determined positions o f the hydroxamic acid moiety are 
almost identical, and replicates the important H-bonds from Tyr 297, His 132, and His 
131 accurately.
Having demonstrated that the HDLP model around the catalytic site could be accurately 
defined and used in the docking model. The HDLP model parameters in the HDAC 1 
model could be used to generate HDAC 1-ligand docking information that would be 
accurate around the catalytic site with a high degree o f confidence. Ligands were 
processed using a Lamarckian Genetic Algorithm, sorted in the order o f decreasing 
energy conformation, and finally clustered according to a Root Mean Squared Deviation 
(RMSD) o f 1.25 A. Inspection of an energy histogram then gave the most favorable
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binding modes for each ligand, as low energy RMSD clusters. The lowest energy and 
correctly binding cluster was used in the study. The results from the computational study 
can be seen in table 3.2.8.
In vitro testing o f compounds were measured against deacetylation o f histone H4 by 
HeLa extract, 165' 168 and was used to derive IC50 values. Docking energy represents the 
calculated free energy o f the system; binding energy takes the energy o f the system and 
additional ligand torsional energy into consideration, and attempts to account for the loss 
of ligand mobility upon binding.
Structure ID
HDAC IC50 
(nM)
Binding
Energy
(kcal/mol)
Docking
Energy
(kcal/mol)
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UCL159
0.9
(± 0.3)
-10.05 -12.7
A
H
UCL171
3.6
(±1.8)
-9.71 -12.73
^ Y l X x - x ^ o
hn'oh
UCL173
50
(±21)
-10.61 -14.61
/-c rA y x i o
\=/ H
UCL169
12.8 
(± 5.2)
-10.36 -14.45
H
(jp£Tl
o
UCL174
22.4
(±8.9)
-10.46 -14.68
SAHA 13 -9.86 -13.02
0 o
A T T  "1
TSA 5 -10.18 -12.1
C l X % jO
H 1 H
1 H 
Y OH 
O
UCL2200 30 -13.21 -16.97
Table 3.2.8. Binding and docking energies of the prepared ligands. TSA and SAHA IC50 derived from PC- 
3 cell lines.169
One o f the most heavily studied HDAC inhibitors is TSA. It is widely used as a 
comparator for the assessment o f other HDAC inhibitors, and was chosen to serve the 
same purpose in this study. Calculations predicted that TSA would have a docking 
energy o f -12.1 kcal/mol and a binding energy o f -10.18 kcal/mol. This compares well 
with the data o f Wiest et al.149 with the reported calculated free energy of binding at -
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10.1 kcal/mol, and an experimental free energy of binding at -10.3 kcal/mol. 169 The 
binding conformation o f TSA also correlates with that of the established paradigm, and 
places the cap portion o f TSA towards Glu 98 and Pro 29. The hydroxamic acid moiety 
is also found to be binding correctly with an orientation indicating hydrogen bonding to 
Tyr 303, His 140, and His 141, mimicking the docking conformation found in the 
previous HDLP model. Computation results from SAHA indicate that the ligand is a 
weaker binder to HDAC 1 than TSA with a binding energy of -9.86 kcal/mol, consistent 
with reported experimental data. 170 Thus far, the model can be said to be predicting 
effectively, as it can correctly predict the binding mode, and approximate binding 
affinities o f well known HDAC inhibitors.
UCL173, UCL169, and UCL174 are analogues differing only in the length of their linker 
portions. It would be expected that these ligands would conform to the general 
conclusions derived from QSAR studies, 169’171 that is that there is an optimal length to 
the linker fragment, and deviation from that length will result in decreased efficacy. This 
can be rationalized by considering the two possible situations arising from suboptimal 
linker length. If the linker is too short, steric clashes within and around the catalytic site 
will make any Zn+ 2  binding conformation unfavorable. Should the linker be too long, 
then entropic considerations, in addition to steric clashes within the cap region and 
crowding within the catalytic channel, would be unfavorable to ligand-enzyme 
interaction.
The calculated binding energies for UCL173, UCL169 and UCL174 differ within a 
narrow range of only -0.25 kcal/mol. Experimentally, the activity o f the ligands is quite 
distinct, with UCL169 being the best binding molecule o f the three. The experimental 
values correlate with previous studies concerning linker length, and that is that the 
optimal length for the unsaturated linker is around 6  atoms in length. Disappointing as it 
is for the model to have failed to predict this, the inability of the model to mirror the 
experimental data can be rationalized by considering the size, and flexibility of the 
molecule. As the ligand under investigation is being processed, the bonds previously 
identified as being rotatable are randomly modified, and a series o f energy calculations 
are performed. As the molecule becomes larger, and the number of rotatable bonds 
increases, the number individual rotations required to manipulate the molecule into an 
acceptable conformation increases dramatically. Furthermore, it is necessary for the 
complete computation to be o f sufficient size to allow the exploration o f all possible
125
rotations and conformations. Should the computation be insufficient to allow complete 
exploration o f ligand conformations, the model will not be able to provide accurate 
information, and hence may be unable to differentiate between ligands bearing 
substantial similarity. It is this that appears to have befallen the UCL174, UCL169 and 
UCL173 ligands.
Observation o f the docking orientation (figure 3.2.9), shows the molecules all in a 
similar conformation. The hydroxamic acid and linker are all located in reasonable 
positions, and conform to the commonly accepted hydroxamate binding mode within the 
catalytic region.
The region the linker inhabits can be loosely described as a tube, and due to the 
multitude o f  steric clashes and strongly charged zinc atom, there are few minima the 
computation has to explore to obtain a reasonable conformation in this area. The 
molecules rapidly obtain a good binding conformation within the catalytic site, as many 
rotations are energetically unfavourable and discounted from the calculation. The model 
therefore predicts the binding conformation o f the ligands correctly within the Zn+2  
binding catalytic area.
In comparison to the catalytic site, the cap region o f the ligand is open, with an 
opportunity for ligand mobility across the surface. Coupled with the large number of 
rotatable bonds UCL169, UCL173 and UCL174 contain in the cap region, there is an 
increased computational overhead that was not satisfied by the constraints placed upon 
the model. Analysis o f the data produced by the calculations indicate significant 
movement around the cap region. Insufficient calculation time can be confirmed within 
RMSD clusters o f binding results, which show large numbers of widely spaced clusters, 
as opposed to highly populated singular clusters o f low energy binding modes. Analysis 
of the conformations contained within the clusters reveals that each cluster represents a 
conformation with typical Zn+2 binding, but with seemingly unresolved cap region 
binding (figure 3 .2 . 9  implies convergence o f the modelling result; however, as there is 
significant deviation within each cluster, it cannot be concluded that the conformations 
seen are accurate).
126
Fig. 3.2.9. Binding positions o f UCL169 (155, light blue), UCL173 (151, magenta) and UCL174 (156, 
yellow).
Analysis o f the binding energies also highlights further discrepancies in respect to these 
molecules. The calculated binding energies are seemingly comparable to that of TSA in 
magnitude, yet experimentally the compounds are far less potent. This indicates that in 
regard to these compounds, there is a failure of the model to correctly predict their 
inhibitory properties.
UCL158, UCL159 and UCL171 all correlate their binding energies to the experimentally 
determined IC5o. UCL159 and UCL171 both contain similarity to SAHA and TSA, and 
can be seen to occupy the same binding area in the computation. An illustration of the 
ligands with TSA can be seen in figure 3.2.10.
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Fig. 3.2.10. An illustration o f the binding modes o f TSA (150, blue), UCL159 (147, magenta) and 
UCL171 (149, yellow).
The planar rings can be seen to be occupying a flat hydrophobic area within the cap 
region, much like that observed with TSA and SAHA.
Figure 3.2.11. Illustration o f ligand binding in the catalytic region o f TSA (150, blue), UCL159 (147, 
magenta), and UCL171 (149, yellow).
Observation of the catalytic site, also shows a good comparison with the established 
TSA binding mode. UCL159 and UCL171 can both be seen to be in the correct 
conformation, with H-bonding to the important residues His 140, His 141 and Tyr 303.
UCL2200 is predicted to be a very potent binder to the HDAC 1 enzyme, with a binding 
energy o f -13.21 kcal/mol, greater than that o f TSA, one of the strongest binding ligands
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known. Although the calculated potency o f the compound is excellent, the model fails to 
predict the strength o f the compound accurately. Analysis o f the docking logs indicate 
that while there is a degree o f rotation in the cap region, there is a definite docking 
conformation, and it is unlikely that the loss in activity can be accounted for by 
incomplete computations. This may indicate that other factors may be influencing the 
inhibitory properties o f the HDAC inhibitors, factors that are external, and not accounted 
for within the model.
3.2.6 The Dimer Hypothesis
The computational model is unable to accurately predict the properties o f certain ligands. 
Small ligands such as TSA, and SAHA, appear to be correctly defined and tolerated by 
the model and correlate to previous studies. 144 ,149 Larger ligands, however, do not 
correlate experimental and predicted values. Other studies have found good agreement 
with in silico methods; however, many have found that for some compounds there is 
deviation from in vitro enzyme assay values. 144 ,149 '169,171 This appears to indicate a more 
wide-scale problem in predicting HDAC inhibition, namely that there is another 
important factor in HDAC inhibition that is not being considered in the model. As a 
hypothesis, we propose that species involving HDAC dimers (with and without ligand) 
may account for some o f the observed discrepancies.
It is known that mammalian HDACs associate not only with themselves to form
1 79homo-oligomers, but with other HDACs to form hetero-oligomers. Seiser et al. 
observed the ability o f HDAC 1 to self associate in vitro, and Hessig et a l.m  confirmed 
the ability o f HDAC 1 to form hetero-oligomers, through the immunoprecipitation of  
HeLa cells extract which coimmunoprecipitates HDAC 1 and HDAC 2. HDAC 1, in 
addition to association with other HDAC enzymes, can also be found associated with 
transcription related enzymes, such as CHD chromatin proteins, Sin3A/Sin3B, and 
RbAp48.166'172
Association o f enzymes to HDAC can be attributed to a particular domain, a series o f 60 
residues localized on the N-terminus o f the HDAC enzyme. Removal o f the residues 
results in reduction of deacetylation, presumably due to the inability to associate with 
enzymes such as RbAp48, and a reduction in the ability to dimerize. 172 A representation
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of HDLP bound to TSA in a dimeric form can be seen in figure 3.2.12, derived from X- 
ray crystallographic data; further dimeric examples can be found for HDAC 8  (PDB 
database ID. 1W22).
Fig. 3.2.12. Image o f the HDLP-TSA dimer, taken from the PDB database (ID: 13CR).
A vastly simplified representation o f the process that occurs as HDAC deacetylates 
histones can be seen in figure 3.2.13. For simplicity, only homodimeric HDAC species 
are considered; however, heterodimeric species are known have important biological 
roles.
Lys-Ac
HDAC-Lys-Ac - HDAC - Dimer(s)
HDAC(s) + Lys + Acetate
Fig. 3.2.13. A simplified representation o f HDAC deacetylation processes.
The HDAC enzyme exists as the monomeric form, as illustrated in the center o f figure 
3.2.13. An equilibrium exists between the self association with another HDAC enzyme 
to form a dimer, and association with other classes o f enzyme which will allow the 
HDAC enzyme to perform in deacetylation processes. Inhibition o f the HDAC enzyme
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with an inhibitor would therefore decrease deacetylation, but not necessarily inhibit the 
formation o f HDAC complexes through self association or otherwise.
Currently, the computational model only attempts correlation o f ligand interaction with 
ligand inhibitory activity. Should the ligand only inhibit deacetylation and the formation 
o f complexes required for deacetylation, one would expect a linear, and easily 
predictable model to result. This representation has been proven to be inaccurate, as the 
model fails in correctly predicting the potency o f certain compounds. The secondary 
process, alluded to earlier in the chapter and believed to be responsible for inaccuracies 
in the model, is represented on the right hand side o f figure 3.2.13 and is the formation 
o f HDAC dimers.
Should the use o f an HDAC inhibitor affect the ability o f HDAC enzymes to form 
dimers, the monomers-to-dimers equilibria will be shifted so that more monomeric 
enzyme is available, which would therefore be able to participate in deacetylation 
processes. If one extrapolates and considers how this would effect the relationship 
between the predicted inhibitory activity from the computational model, and the 
experimentally derived activity, a theorem as to the nature o f the discrepancy can be 
derived. If the inhibition o f dimer formation is high, then more HDAC enzyme monomer 
would be available, and inhibition would be less than predicted. Conversely, should the 
inhibitor not effect the formation o f the dimeric species, correlation between the 
calculated activity and the experimental activity will only rely on the effect o f the ligand 
on deacetylation directly, and should be relatively accurate. Modification of the 
deacetylation process in figure 3.2.13 to include HDAC-ligand interactions, can be seen 
in figure 3.2.14 which depicts for simplicity just one HDAC isoform.
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(HDAC)(HDAC-I)
HDAC-Lys-Ac ^
Lys-Ac Inhibitor I
HDAC-I
HDAC(s) + Lys + Acetate (HDAC)2 (HDAC-I)2
Fig. 3.2.14. Representation of processes occurring during HDAC inhibition, showing HDAC oligomers.
Analysis o f the processes to account for the various HDAC-ligand interactions and dimer 
generation leads to the following conclusions with respect to the model:
I. Destabilization of the HDAC dimer, either of the form of one 
HDAC enzyme and a HDAC-ligand complex (represented as 
(HDAC)(HDAC-I)), or two HDAC-ligand complexes (represented 
as (HDAC-I)2), will result in an increase of HDAC and more 
deacetylation. The single-molecule HDAC modelling will 
therefore predict the ligand to be better than experimentally 
determined.
II. Stabilization o f any HDAC dimer will result in a decrease o f 
HDAC, and hence an increase in effective inhibition through the 
reduction o f HDAC monomer, which is assumed to be the most 
potent/or most significant molecule in HDAC inhibition. Thus the 
effective inhibition produced by the molecule will be greater than 
predicted by single-molecule HDAC modelling.
III. Where dimers are not significant, or their concentrations are 
unaffected by the introduction o f an inhibitor, the single-molecule 
modelling will be accurate.
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Relating the observations to the compounds studied, UCL169, UCL171, UCL173, and 
UCL2200 are thought to be destabilizing to one or more dimeric species, and therefore 
are not as potent as predicted by the model. They are thus examples o f Type I. This 
could be attributed to the size o f the ligands, the inability of the dimer to accommodate 
them within the cavity, or the blocking o f favourable enzyme-enzyme interactions.
Examples o f Type II, involving the stabilization o f one or more HDAC dimers, could be 
found in the cyclic tetrapeptides, including Apicidin B (IC50 o f 0.7 nM vs.HDAC 1). 
Cyclic tetrapeptides are far more potent than predicted by computational models. The 
increased activity could be due to the stabilization o f the HDAC dimers arising from the 
extended plateau of the ligand, which could permit H-bonding and lipophilic interactions 
with the neighbouring HDAC enzyme in the dimer complex. It is also possible that 
cyclic depsipeptides, such as FK228, are very potent for similar reasons. In these cases, 
where a disulfide bridge is cleaved to reveal the HDAC inhibitor, the resulting thiol may 
subsequently form a new disulfide bridge with a cystine of the second enzyme within the 
HDAC dimer complex.
Examples o f type III appear to be TSA, SAHA, UCL158, UCL159, and correlate well 
with the model.
Correction o f the single-molecule model and accounting for the shift in potency due to 
additional favourable or unfavourable interactions could be achieved by creating an 
additional model based upon a (HDAC)(HDAC-I) dimer structure. The strength of 
interaction with the new HDAC dimer model could contribute to HDAC-I dimer stability 
information, and used in conjunction with the single-molecule binding energies to 
account for inhibitor-HDAC dimer effects.
3.2.7 A New HDAC Inhibitor
The construction of a new HDAC inhibitor was proposed, based upon the concept o f the 
cyclic tetrapeptide class o f inhibitors. Consisting of a Zinc Binding Group (ZBG), a 
large peptidic cap region moiety, coupled together with a linker, compounds such as 
these are known to form some o f the most potent HDAC inhibitors currently reported.
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Fig. 3.2.15. Structure of the new HDAC inhibitor.
Typically, the ZBG would be in the form of a hydroxamic acid; however, many other 
groups are known to chelate to the Zn+2 ion, including thiols, esters, and ketones. The 
choice o f an ester was considered to be sufficient to obtain a reasonable degree of  
chelation, while maintaining ease o f synthesis.
The cap region moiety consists o f a cyclic 11 membered system, and is formed using 
methodology reported by Hinterding et a l.llA The system is believed to occupy much of 
the space immediately above the catalytic cavity, forming H-bonds with exposed 
residues in close proximity, and hoped to be as effective as the cyclic peptide class of 
compounds.
The ZBG and cap region moiety are linked together with a short six-atom carbon chain, 
incorporating one unsaturated bond close to the cap region.
Fig. 3.2.16. Proposed binding conformation of the compound.
Modeling studies using an HDAC 1 model, indicate that the new HDAC inhibitor will 
bind in a similar orientation to that of UCL173, UCL174, and UCL169, rather than 
extending towards Pro 29 as in TSA and SAHA. Binding energies are predicted to 
be -9.79 kcal/mol, and a docking energy of -12.37 kcal/mol. If the prediction of the 
model is accurate, this would place the inhibitor within the same range o f activity as 
SAHA with an IC5o of 10-15 nM; however, as the calculated binding conformation 
parallels the position of UCL173, UCL174 and UCL169, one would expect the in vitro 
inhibition values to be less that those calculated in silico, which could be thought of 
being attributable to the dimer hypothesis.
3.2.8 Synthesis of an HDAC inhibitor
Construction of a HDAC inhibitor bearing similarities to the cyclopeptidic class of 
HDAC inhibitors was attempted.
Methodology to generate eleven-atom cyclic structures was previously reported by 
Hinterding174 as a by-product in an attempt to generate chiral polyketide units from an 
acetate enolate cleavage of an Evans oxazolidinone. It was found that the use of
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LiHMDS or NaHMDS in place o f KHMDS when generating the acetate enolate, 
increased the yield o f the eleven-membered cyclic structure. It was this approach 
combined with the construction o f a suitable fragment that was proposed.
The synthesis began with the preparation of the aldehyde 162, required for an Evans 
aldol addition to the Evans auxiliary fragment. The aldehyde fragment would contain the 
linker, and the important Zinc binding moiety.
Scheme 2.3.17. i. Dry methanol, NaOMe; ii. BH3.Me2S, THF, -10 °C; iii. PCC, DCM, Celite; iv. 
Ph3P=CHCHO, benzene, reflux.
Mono-methyl glutarate (159) was prepared from glutaric anhydride and sodium 
methoxide in dry methanol. 175 Reduction to methyl 5-hydroxypentanoate (160) was 
conducted according to the procedure reported by Heathcock176 with a yield of 95%. 
Oxidation to aldehyde 161 was achieved with a 56% yield using PCC in 
dichloromethane. The unsaturated aldehyde 162 was prepared with (£)-selectivity by
1 77using the procedure o f Gung, using the stabilised ylid 
(formylmethylene)triphenylphosphorane and generated the required conjugated aldehyde 
system.
The synthetic route used to couple the aldehyde fragment to the auxiliary, and 
continuation onto 167, can be seen in scheme 2.3.18.
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OH
165164163
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166
Scheme 2.3.18. Final stages in the synthesis of the HDAC inhibitor, i. Propionyl chloride, w-BuLi, THF; ii. 
(-)-sparteine, NMP, DCM, TiCl4, 162, -78 °C -  0 °C; iii. Ac20 , DMAP, CH2C12, Et3N; iv. LiHMDS, THF, 
-78 °C.
The Evans auxiliary was first coupled with propionyl chloride using «-BuLi in THF with 
84% yield. The auxiliary fragment then underwent Evans aldol addition with the 
previously prepared aldehyde 162. Coupling was not efficient, and only yielded 33% of 
the aldol product after purification. This was due to E/Z isomerization o f the terminal 
conjugated aldehyde moiety in 162, resulting in a reduced yield o f the required (£)- 
isomer, which could be isolated using column chromatography. Acetylation of 165 was 
conducted using acetic anhydride, DMAP, triethylamine in dichloromethane, and gave 
166 in 82% as a colourless oil. Preparation o f compound 167 was attempted by the 
dropwise addition of LiHMDS to 166 in THF at -78 °C. After quenching and extraction, 
the material was passed through a silica column to remove impurities. Further 
purification using flash column chromatography using an eluant o f 5 % 
methanol/dichloromethane, gave an intractable mixture o f compounds. NMR analysis o f  
the gave results that were consistent with product that contains 167, in addition to other 
complex material.
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Material obtained containing 167 was tested for HDAC inhibitory activity, and was 
found to have little, or no effect on the nM scale. While not consistent with the 
computational model predictions, this may be expected o f compounds that have been 
predicted to bind in the manner shown in figure 3.2.16. The large cap region portion o f  
the ligand may be inhibiting the formation of HDAC homo- and hetero-dimers. The 
unsaturated bond within the linker portion may also be introducing rigidity in the 
inhibitor too near the top o f the catalytic channel. This could be preventing the ligand 
from adopting a relaxed conformation onto the top o f the cap region, and instead could 
be being forced vertically outward. Destabilization of the HDAC dimers would thereby 
increase the level o f HDAC within the assay, and the molecule would therefore have an 
effective inhibition far less than that predicted by the computational model due to 
increased HDAC deacetylation.
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3.3 Conclusion
A computational model that can predict HDAC-ligand interactions has been described. 
The model is successful for small, TSA and SAHA like hydroxamate inhibitors; 
however, larger ligands are found to be problematic, as was discovered with the 
correlation between experimental and in silico analysis o f a new cyclic inhibitor.
Alleviation o f the large ligand discrepancy could be achieved through the construction of 
a model based upon the HDAC dimer hypothesis. A model consisting o f a HDAC 
dimers may be used to study ligand-HDAC dimer interactions, and used to adjust the 
single-molecule model and accounting for perturbation o f HDAC dimers. This should be 
explored both in silico, and through the construction o f appropriate analytical 
experiments to determine the nature of the HDAC dimers.
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3.4 Experimental
The general experimental section can be found in chapter 1.4.
5-Methoxy-5-oxopentanoic acid175 (159)
O O
Glutaric anhydride (6.0 g, 52.6 mmol), dry methanol (75 mL), and H 0  O
NaOMe (57 mg, 1.06 mmol) were stirred overnight at room temperature. Methanol was 
removed under reduced pressure, and the residue diluted with water (50 mL). Extraction 
with ethyl acetate (3 x 50 mL), drying (MgSCU), and concentration under reduced 
pressure gave the crude material. Column chromatography with an eluant of 1:1 
hexane:ethyl acetate gave the required product, 7.13 g, 93%. NMR data correlated to that 
found in the literature. 175 !H NMR (300MHz, CDC13), 8 H 3.61 (s, 3H, O-Ctb), 2.40-2.25 
(m, 2H, HOOC-CH2 -CH2 , CH2 -CH2-CHOOCH3), 1.85 (m, 2H, CH9-CH7-CHA
Methyl 5-hydroxypentanoate176 (160)
mmol), and dry THF (50 mL) cooled to -10°C, BH3 .Me2 S complex (37.6 mmol) was 
added dropwise. The mixture was then allowed to warm to room temperature, and left to 
stir overnight. Water was added (50 mL) at 0°C, and the reaction concentrated under 
reduced pressure. Material was then extracted using ethyl acetate (3 x 50 mL), and 
yielded material upon drying (MgS0 4 ) and concentration. Column chromatography 
yielded the required alcohol as a pale oil, 4.28 g, 95%. Spectral data correlated to that 
found in the literature.
Methyl 5-oxopentanoate177 (161)
g) in dry dichloromethane (50 mL), methyl 5-hydroxypentanoate (4 g, 30.3 mmol) was 
added dropwise at 0 °C. The mixture was stirred and allowed to warm to room 
temperature. TLC analysis indicated the progress o f the reaction. Upon completion, the 
reaction was diluted with ethyl acetate (100 mL) and filtered though a silica plug,
O
To a flask containing 5-methoxy-5-oxopentanoic acid (5 g, 34.2
O
To a stirring suspension o f PCC (9.8 g, 45.5 mmol) and Celite (9.8
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washing with ethyl acetate to remove any remaining material. Concentration of the 
filtrate gave 161 (2.22 g, 56%) as an oil that required no further purification. !H NMR 
(300MHz, CDC13), 8 h 9.74 (s, 1H, CHO-CHA 3.64 (s, 3H, CH3-O), 2.51 (t, .7=7.2 Hz, 
2H, OOC-CH2 -CH2), 2.35 (m, 2H, CHO-CH,-CH,l. 1.87 (m, 2H, CH2-CH2 -CH2). 13C 
NMR (75 MHz, CDCI3), 8 C 201.6, 173.4, 51.6,42.9, 32.9, 17.3.
(£)-M ethyl 7-oxohept-5-enoate (162)
O
(Formylmethylene)triphenylphosphorane (3.18 g, 10.45 O o  
mmol) was dissolved in benzene (15 mL), and methyl 5-oxopentanoate (1.13 g, 8.7 
mmol) was added in one portion. The reaction mixture was heated to reflux, and 
monitored by TLC. Upon completion, the reaction was concentrated under reduced 
pressure, and the residue filtered through a silica plug with an eluant o f 4:1 petroleum 
ether(40:60):ethyl acetate. The filtrate was concentrated under reduced pressure to give 
162 (1.15 g, 85%) as a yellow oil. NMR (300MHz, C D C 13) ,  8 H 9.53 (d, 7=13.0 Hz, 
1H, C H O - C H ) ,  6.80 (dt, 7=15.7, 6.7 Hz, 1H, C H = C H - C H 2) ,  6.11 (dd, 7=15.7, 13.0 Hz, 
1H, C H O - C H = C H ) ,  3.65 (s, 3H, O - C H 3 ) ,  2.41-2.33 (m, 2H, - C H r ) ,  1.94-1.64 (m, 4H, - 
C H 2 - ) .  13C NMR (75 MHz, C D C 13) ,  8 C 193.9, 173.4, 157.1, 133.5,51.7, 33.1,31.9,21.4.
(5)-4-Benzyl-3-propionyloxazolidin-2-one178 (164)
To a stirring solution o f (S)-4-benzyloxazolidin-2-one (5.8 g, 33 mmol) 
in THF (50 mL) at -78 °C, «-BuLi (1 eq, 33 mmol) was added. The 
reaction was stirred for 1 0  minutes, and propionyl chloride ( 1 . 2  eq,
3.66g, 39.6 mmol) was added slowly. The mixture was stirred for 1 
hour, then warmed to room temperature. The reaction was quenched with the addition of 
sat. ammonium chloride, and concentrated. The residue was washed with 
dichloromethane (3 x 50 mL), extracts dried (MgS0 4 ), and concentrated under reduced 
pressure to give 164 (6.46 g, 84%) as a colourless crystalline solid. Spectral data were 
identical to that found in the literature. 178 13C NMR (75 MHz, C D C I 3 ) ,  8 c 173.2, 153.5, 
135.3, 129.4, 129.0, 127.3, 66.2, 55.1, 37.9, 37.4, 17.7, 13.7
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(7S, 85VE)-MethyI 9-((5)-4-benzyl-2-oxooxazolidin-3-yl)-7-hydroxy-8-methyl-9-
oxonon-5-enoate (165)
To a stirring solution o f (S)-4-benzyl-3-propionyloxazolidin- 
2-one (0.2 g, 0.9 mmol) in dry dichloromethane (7 ml) at 0 
°C, TiCU ( 1  M in dichloromethane, 0.9 mmol) was added 
slowly and stirred for 5 min, generating a yellow solution.
(-)-Sparteine (0.2 g, 0.9 mmol) was added dropwise and 
stirred for 20 min, generating a deep red solution. Cooling to - 
78 °C, followed by the addition o f A-methylpyrrolidin-2-one (0.85 g, 0.9 mmol). After 
stirring for 10 min, (£)-methyl 7-oxohept-5-enoate (0.148 g, 0.95 mmol) was added 
dropwise, and stirred for 1 h, followed by warming to 0 °C and stirring for a further 30 
min. The reaction was quenched with half saturated ammonium chloride solution (3 
mL), and extracted using dichloromethane ( 3 x 5  mL). The combined organic fractions 
were dried (Na2S0 4 ), followed by concentration under reduced pressure gave the crude 
product as an oil. Purification using column chromatography with an eluant o f 2:1 
hexaneiethyl acetate gave 165 (0.13 g, 37%) as a colourless oil. IRvraax(KBr, cm'1) 3465 
(OH), 1782 (C=0), 1738 (C=0), 1690 (NC=0), 1639 (C=C). *H NMR (300MHz, 
CDC13), 5h 7.36-7.18 (m, 1H, Ar-H), 5.77 (dt, 7=16.2, 7.0 Hz, 1H, CH C H -C H A  5.29 
(dd, 7=6.1, 16.2 Hz, 1H, CH-CH=CH), 4.70-4.69 (m, 1H, CH2 -CH(CH2)-N), 4.45-4.42 
(m, 1H, CH-OH), 4.23-4.17 (m, 3H, OH, P-OH-CHT 3.87-3.83 (m, 1H, C(O)- 
CH(CH3)-CH), 3.65 (s, 3H, CH3-O), 3.24 (dd, 7=13.4, 3.2 Hz, 1H, Ph-CHH-CH), 2.78 
(dd, 7=13.4, 9.4 Hz, 1H, Ph-CHH-CH), 2.30 (t, 7=7.4 Hz, 2H, CH7-CH7-CHOOL 2.09 
(dt, 7=7.6, 7.0 Hz, 2H, CH-CH?-CHri. 1.72 (tt, 7=7.6, 7.4 Hz, 2H, CH^-OL-CHri. 1.24 
(d, 7=7.0 Hz, 3H, CH3 -CH). 13C NMR (75 MHz, CDC13), 6 C 176.6, 174.0, 153.2, 135.1, 
132.1, 130.1, 129.4, 129.0, 127.5, 72.6, 66.2, 55.2, 51.5, 42.8, 37.8, 33.3, 31.6, 24.3,
11.4. HRMS calcd. for C2 iH27N 0 6 389.1838, found 389.1845.
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(7S,85,£)-methyl 
oxonon-5-enoate (166)
7-acetoxy-9-((5)-4-benzyl-2-oxooxazolidin-3-yl)-8-methyl-9-
To a stirring solution o f (1S,SS,E)-methyl 9-((S)-4-benzyl-2- 
oxooxazolidin-3-yl)-7-hydroxy-8-methyl-9-oxonon-5-enoate 
(0.11 g, 0.29 mmol) in dichloromethane (2 mL) at 0 °C, acetic 
anhydride (44 mg, 0.44 mmol), DMAP (12 mg, 0.1 mmol), and 
triethylamine (0.46 mmol) was added sequentially. The 
mixture was stirred until completion by TLC. Water was added (5 ml), and the reaction 
mixture extracted with dichloromethane ( 3 x 5  ml). Combined organic fractions were 
dried (Na2 S0 4 ), and concentrated under reduced pressure to an oil. Column 
chromatography using an eluant o f 2 : 1  hexaneiethyl acetate gave 166 (0 . 1 0  g, 82%) as a 
colourless oil. *H NMR (300MHz, CDC13), SH 7.34-7.18 (m, 5H, Ar-H), 5.76 (dt, 
7= 16.9, 7.7 Hz, 1H, CH-CH=CH), 5.59-5.45 (m, 2H, CH=CH-CH2), 4.61-4.59 (m, 1H, 
CH2 -CH(CH2)-N), 4.24-4.04 (m, 3H, O-CHrCH, CH-CH(O)-CHCH), 3.65 (s, 3H, O- 
CH3), 3.25 (dd, .7=13.3, 3.2 Hz, 1H, PhCHH-CH), 2.76 (dd, .7=13.3, 9.8 Hz, 1H, Ph- 
CHH-CH), 2.28 (t, 7=7.4 Hz, 2H, OOC-CH^-CHA 2.11-2.05 (m, 2H, CH-CH^CH;,), 
2.04 (s, 3H, CH3-C(0 )), 1.70 (tt, 7=7.4, 7.3 Hz, 2H, CH2-CH2-CH2), 1.20 (d, 7=6.9 Hz, 
3H, CH3 -CH2). 13C NMR (75 MHz, CDC13), 6 C 173.9, 173.6, 170.2, 153.5, 135.3, 133.9, 
129.5, 128.9, 127.4, 126.8, 74.2, 66.3, 55.6, 51.5, 42.0, 37.9, 33.2,31.4,24.0,21.0, 11.5. 
HRMS calcd. for C2 3H29N 0 7 431.1944, found 431.1941.
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(2s)-Methyl-6-((3S',65,7S)-3-benzyl-6-methyl-5,9,ll-trioxo-l,8-dioxa-4- 
azacycloundecan-7-yl)hex-5-enoate (167)
To a stirring solution o f (7S,8.S,2s)-methyl 7- 
acetoxy-9-((S)-4-benzyl-2-oxooxazolidin-3-yl)-8- 
methyl-9-oxonon-5-enoate (100 mg, 0.23 mmol) in O 
THF (15 mL) at -78 °C, LiHMDS (1 M in THF, O'
0.69 mmol) was added dropwise. The reaction was 
stirred for 2 h. Addition o f 1:1:1 ammonium sulfate:water:methanol quenched the 
reaction. Products were extracted into dichloromethane (3 x 1 0  mL), dried (MgSC>4 ), and 
concentrated under reduced pressure. Column chromatography using an eluant o f 5% 
methanol/dichloromethane yielded 59.4 mg of a yellow oil. Analysis was inconclusive 
due to the purity o f the material obtained.
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Chapter 4 
Towards the synthesis of the (-)-Calyculin A Spiroketal 
Fragment
4.1 Introduction
In this chapter the novel marine phosphatase inhibitor, (-)-calyculin A, is examined. In 
particular, the chapter focuses upon the synthesis of the spiroketal core o f the molecule, 
and the application of a novel mercury mediated cyclisation strategy in the synthesis of 
the spiroketal fragment.
4.1.1 Calyculin
The calyculins represent a group o f natural marine compounds from the sponge 
Discodermia calx. First isolated from a sponge collected in the Gulf of Sagami, Japan,
1 70by Fusetani et al. The metabolites were found to exhibit strong activity in the starfish
180egg assay, and LI210 cells where the compounds were shown to possess strong 
cytotoxic effects. Isolation and structural elucidation o f one of the major active 
components successfully identified calyculin A (figure 4.1.1), a novel compound 
containing a spiroketal, phosphate, and oxazole functionalities.
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Figure 4.1.1. (-)-Calyculin A
Several other members o f the calyculin family, were isolated and characterised by 
Fusetani et a / . 181,182 and termed calyculins B through to H. Calyculins A, B, E, and F are 
all isomeric in the tetraene portion, and interconvert through exposure to light. 
Calyculins C, D, G, and H incorporate an extra methyl group at carbon 32, and are also 
interconverted around the tetraene portion through light exposure.
The calyculins have been shown to possess a wide range o f biological activity. They 
have been shown to inhibit protein phosphatases PP1 and PP2A in nanomolar
183 184concentrations, ’ possess a high level o f membrane permeability, exhibit strong 
tumour promoting effects, 185 and are cytotoxic with respect to leukaemia cell lines. 182
Calyculin, due to its impressive inhibitory properties, has found growing use in the 
exploration o f intracellular phosphorylation. Its cytotoxic effects have also prompted 
considerable interest in the synthesis o f the natural and unnatural forms.
4.1.2 The Synthesis of the Spiroketal Unit of Calyculin
1 fiACalyculin has been the focus o f synthetic attempts and studies for several years since 
the initial discovery and characterisation of the molecule. 179 Confirmation of the absolute
•I 0*7
configuration by Shioiri et al. was swiftly followed by the first total synthesis o f the 
unnatural (+)-calyculin A by Evans et al.m
149
In their strategy to synthesise (+)-calyculin A, Evans chose to separate the molecule into 
two fragments. A C26 to C37 fragment, and a Cl to C25 fragment, which could be 
easily combined to generate the entire scaffold of the molecule though a Wittig type 
process (figure 4.1.2).
O OR2
H t 2T
OR2 NMe«
26
Figure 4.1.2. Fragments C1-C25 and C26-C37 of the Evans (+)-calyculin A synthesis. R1 represents a 
phosphorous containing moiety suitable for Wittig type reactions. R2 represents protecting groups.
The Evans synthesis began with the preparation o f the spiroketal moiety o f calyculin, 
and utilised oxazolidinone auxiliaries in those very first stages to introduce the 
stereochemical centres o f the spiroketal core. The route used by Evans involved the 
synthesis o f two fragments which were combined to generate the spiroketal core. The 
synthesis o f the first fragment can be seen in scheme 4.1.3.
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Scheme 4.1.3. Preparation of the first fragment in the Evans preparation of the calyculin spiroketal core. i. 
(45)-4-benzyl-2-oxazolodinone, THF, pivaloyl chloride, Et3N, Et20 , -78 °C to 0 °C; ii. 2-(phenylsulfonyl)- 
3-phenyloxaziridine, THF, -78 °C, NaHMDS; iii. AlMe3, MeNH(OMe).HCl, dichloromethane, reflux; iv. 
NaH, p-methoxybenzyl bromide, THF/DMF, 0 °C; v. DIBA1-H, toluene, -78 °C; vi. MgBr2, 
dichloromethane, -40 °C, tributyl(3-methoxyallyl)stannane; vii. TES-OTf, 2,6-lutidine, dichloromethane, 0 
°C; viii. Rh(PPh3)3Cl, catecholborane, THF; H20 2; NaBH4, EtOH; ix. Pivaloyl chloride, DMAP, pyridine, 
dichloromethane; x. 0 s0 4, NMO, tert-butyl alcohol/THF/water, NaI04.
P = para-methoxybenzyl protecting group.
Preparation o f the compound 170 by auxiliary controlled hydroxylation generated the 
first stereochemical centre at C17 and proceeded with an 8 8 % yield with the production 
of one single diastereoisomer. Removal o f the auxiliary by trimethyl alumnimium- 
mediated conversion to the Weinreb amide gave 171. Protection of the free alcohol as a 
/ 7-methoxy benzyl grouping, allowed the unhindered reduction of the Weinreb to the 
aldehyde 172 using diisobutylaluminium hydride. Treatment of 172 with tributyl(3- 
methoxyallyl)stannane and magnesium bromide etherate gave 173 in 71% yield. 
Protection o f the alcohol 173 using a triethyl silane protecting group, and subsequent 
rhodium catalysed hydroboration gave 174. Formation o f the pivaloyl ester, osmylation 
and periodate cleavage generated the required fragment 175 in 8 8 % over the two steps.
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The preparation o f the second fragment can be seen in scheme 4.1.4.
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Scheme 4.1.4. Preparation of the second fragment in the Evans preparation of the calyculin spiroketal core,
i. «-Bu2BOTf, z'-Pr2NEt, acrolein, dichloromethane, -78 °C; ii. MeNH(OMe).HCl, AlMe3, THF; TES-C1, 
Et3N, dichloromethane. iii. DIBAL-H, THF, -90 °C.
The oxazolidinone 176 underwent aldol addition to give 177 in 83%. Conversion into the 
Weinreb amide using trimethylaluminium in tetrahydrofuran, silyl protection o f the 
alcohol, and reduction using diisobutylalumnium hydride gave the aldehyde 178.
The method used to couple the two fragments generating the spiroketal fragment can be 
seen in scheme 4.1.5.
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Scheme 4.1.5. Coupling of the two fragments in the Evans preparation of the calyculin core. i. TMS-OTf, 
Et3N, dichloromethane, 0 °C; ii. BF3.OEt2, dichloromethane, -78 °C; iii. 48% aq. HF, acetonitrile, water.
P = para-methoxybenzyl protecting group
Conversion o f 175 into the silyl enol ether 179, followed by aldol addition to 180 gave 
the carbon scaffold o f the spiroketal fragment 181 in 80% yield as a single 
diastereoisomer. Treatment with HF/acetonitrile/water at room temperature gave the 
diasteromeric spiroketals 182 and 183 in a 1:5 ratio. This completed spiroketal fragment 
was advanced by Evans and ultimately to the first total synthesis of (+)-calyculin A.
The Evans approach to the spiroketal core has since been used in other syntheses of the 
calyculin family, albeit modified to take advantage of new or alternative synthetic 
methodology. These can be seen in the work of Masamune et al.m  in their total 
synthesis o f the naturally occurring (-)-calyculin A, and in the work of Shioiri et al.190 in 
their synthesis o f the calyculin A C9 to C37 fragment. More recently the reports of 
Armstrong and Ogawa191 in their published synthesis of calyculin C, and in reports from 
Smith et al.192,193 in their total synthesis o f (+)-calyculin A and (-)-calyculin B. Also o f
153
note are the recently reported formal total synthesis of (+)-calyculin A by Anderson et 
al.,194 and the use of chiral pool and rhodium catalysed cyclisation approach by Trost 
and Flygare. 195
4.1.3 Synthesis of the (-)-Calyculin A Spiroketal Core
The spiroketal core o f (-)-calyculin A is a potential synthetic target which would 
demonstrate the synthetic utility o f the mercury mediated cyclisation strategy. Using a 
convergent approach requiring the synthesis o f two precursors, the synthesis o f the (-)- 
calyculin A spiroketal core was considered, with Hg+2 mediated cyclisation being an 
integral step.
The synthesis o f the first precursor in the synthesis can be seen in scheme 4.1.6.
Scheme 4.1.6. Preparation of the alkyne fragment.
The first precursor 187 would be prepared starting from inexpensive 2-methylbut-3-yn-
2-ol (184). Conversion to 185 using chemistry reported by Barbot and Miginiac, 196 was 
followed by acid catalysed conversion of the acetal to the aldehyde to give 186. Wittig 
chemistry could then be used to provide 187, the first fragment.
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Scheme 4.1.7. Preparation of the spiroketal scaffold of (-)-calyculin A. i. Wittig preparation of the olefin;
ii. MeNH(OMe).HCl, Me3Al, iii. 187, w-BuLi; iv. (7?)-alpine Borane reduction; v. Sharpless asymmetric 
epoxidation; vi. HgO, dil. H2S04; vii. Sharpless asymmetric dihydroxylation; viii. cat./?-TsOH.
The second fragment (190) is a Weinreb amide prepared from the allylic ester 189, 
which is in turn easily synthesised in a Wittig reaction from the aldehyde 188.
The two fragments, 190 and 187 would then be coupled to give the completed carbon 
scaffold 191. Asymmetric reduction, using (ft)-alpine borane, followed by Sharpless 
asymmetric epoxidation is expected to give 193. Mercury mediated cyclisation
1 07according to the procedures reported by Marson et al. would give the key 
dihydropyranone 194. Sharpless asymmetric dihydroxylation to give 195, followed by 
dilute acid to catalyse the formation o f the spiroketal, should furnish 196 cleanly from 
195.
This approach to the (-)-calyculin A core is flexible, and would allow other alkynes to be 
used in the synthesis; thus the generation o f quite different spiroketals using this route is 
possible. It is also a concise synthesis, incorporating stereocentres using well known and
155
established methodology and required only a few synthetic steps, making the route 
desirable in comparison to some o f the longer reported syntheses.
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4.2 Results and Discussion
4.2.1 Synthesis of the Weinreb Amide Fragment
Synthesis o f the Weinreb amide fragment began with the preparation of 189, the central 
scaffold o f the molecule. The synthetic route used to obtain 189 can be seen in scheme 
4.2.1. Reported syntheses o f  the alcohol 199, including benzylation of propane-1,3-diol 
with benzyl chloride, 198 benzyl alcohol with acrolein, 199 were discounted, and the 
synthesis focused upon a reductive ring opening o f the acetal 198 to furnish the required 
intermediate. Conventional synthetic methodology to effect the reductive ring opening, 
such as using DIBAL-H as reported by Martinelli200 and Takano et a l .201 or the use of 
borane-containing reagents as reported by Lewis et al. were disfavoured due to the 
large quantities o f material required from this particular stage. Instead, the use o f lithium
203aluminium hydride modified with aluminium chloride as reported by Eliel et al. was 
considered as an alternative. Oxidation, followed by Wittig homologation would then 
furnish 189.
Scheme 4.2.1. synthesis of 189. i. propane-1,3-diol, toluene, p-toluenesulfonic acid; ii. A1C13, LiAUL, 
Et20; iii. PCC, celite, dichloromethane; iv. 202, toluene.
The protection o f benzaldehyde with propane-1,3-diol was conducted by refluxing 
toluene using Dean-Stark apparatus with a small quantity of catalytic /?-toluenesulfonic 
acid.201 As the reaction progressed, water was removed as it was generated, and the 
volume o f water produced was used to monitor the progress of the reaction. Once 
complete, concentration o f the reaction mixture under reduced pressure gave the material
199 188
197 198 iv 87%
V
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198 as a colourless crystalline solid achieved in 74% yield. Lewis acid mediated 
reductive ring opening o f the crude acetal using a 4:1 ratio of aluminium trichloride and 
lithium aluminium hydride in dry diethyl ether at 0 °C gave the crude alcohol 199. 
Distillation at approximately 2 torr between 105 and 110 °C, gave 199 as a colourless oil 
in 76% yield.
Oxidation of the alcohol 199 to the aldehyde 188 was achieved by adding the alcohol to 
a suspension o f Celite and pyridinium chlorochromate (PCC) in dichloromethane, and 
stirring for 4 hours.2 0 4 ' 207 Filtration o f the reaction mixture through a small silica plug 
removed all Celite and chromium material. The aldehyde 188 was contained within the 
filtrate, and concentration under reduced pressure yielded the required material in high 
purity; however, short path flash chromatography was used to increase the purity o f the 
sample, and to ensure no chromium impurities were present prior to storage.
Br
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Scheme 4.2.2. Preparation of 202. i. PPh3, toluene; ii. 1 M NaOH.
The stabilised ylid 202 was prepared, which was required for the synthesis of 189. 
Triphenylphosphine was dissolved in toluene at 0 °C. Ethyl-2-bromopropionate was 
added, and the reaction allowed to warm up. After stirring for 12 hours at room 
temperature, a white precipitate could be easily removed from the reaction mixture, and 
after drying gave the phosphonium salt 201. Treatment with base gave the stabilised 
phosphonium ylide 202 as bright yellow crystals (mp. 161-163 °C) . 208
Synthesis o f 189 was prepared by a procedure similar to that described by Kodama et 
al.209 The Wittig coupling o f 188 and 202 furnished 189 in 87% yield as a pale yellow 
oil.2 1 0 ’211
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Scheme 4.2.3. Preparation of the Weinreb amide 190. i. LiOH, THF:water:methanol; ii. 'PrMgCl, 
MeNH(OMe).HCl, THF.
Saponification of the ester 189 proceeded with lithium hydroxide in a 1:1:1 mixture of 
THF:water:methanol at room temperature giving the acid in a surprisingly low yield.
212 213Conversion into the Weinreb amide was accomplished using the Merck protocol, ’ 
using isopropylmagnesium chloride and TV^V-dimethylhydroxylamine hydrochloride in 
dry THF. After quenching and workup, 190 was recovered in 50% yield from the acid 
203.
4.2.2 Synthesis of the Second Fragment
Preparation o f the acetylenic fragment was initially believed to be possible using the 
procedure illustrated in scheme 4.2.4.
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Scheme 4.2.4. Preparation of the acetylenic fragment, i. PBr3; ii. Mg, Et20; iii. (diethoxymethyl)benzene; 
iv. Acid catalysis; v. Phenol,/?-toluenesulfonic acid.
From the readily available and inexpensive starting material, 2-methyl-3-yn-2-ol, 
synthesis o f the bromide 184 was easily completed by the careful addition of phosphorus 
tribromide following a procedure described by Bruckner and Rank. 214 Distillation of the 
reaction mixture at 100 torr, at 40 °C gave the product as a colourless lachrymatory oil in 
37% yield.
Preparation o f 206 was conducted using a procedure reported by Miginiac et al. 
whereby triethyl orthoformate is heated in the presence of phenol, and a catalytic 
quantity o f p-toluenesulfonic acid. Ethanol, produced in the reaction, is distilled from the 
reaction mixture and gives the desired product 206 after a basic work up and distillation 
under high vacuum.
The bromide 184 was converted into a the Grignard reagent using magnesium and a 
small quantity of iodine. 206 was added to the reaction and the mixture stirred overnight. 
Quenching, and work up gave the desired material in 55% yield.
Attempts to generate the acetylenic aldehyde 186 through hydrolysis o f the acetal 185 
was unsuccessful. Several methods were conducted, oxalic acid, formic acid, and acetic 
acid catalysed hydrolysis all failed, generating inseparable mixtures. 196 ,216 Trapping of 
any aldehyde formed in solution was also attempted using Wittig chemistry, using 
(triphenyl-^5-phosphanylidene)-acetic acid ethyl ester. No products were found to be
160
formed in the reaction. Due to low yielding reactions, and failure o f the synthetic route 
to generate the aldehyde 186, alternative methods of synthesising the required fragment 
was explored.
4.2.3 An Alternative Acetylene Synthesis
An alternative to the synthesis to the acetylene fragment was sought in an analogous 
synthetic procedure to the one used in the construction of the Weinreb amide fragment.
Starting from benzaldehyde and using 2,2-dimethyl-1,3-propanediol as the basis for the 
core o f the acetylenic fragment, a synthetic procedure was devised to generate 215, as 
illustrated in scheme 4.2.5.
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Scheme 4.2.5. Preparation of the acetylene fragment, i. 2,2-dimethyl propane-1,3-diol, toluene, p- 
toluenesulfonic acid; ii. A1C13, LiAlFL*, Et20; iii. Py.S03, DMSO, dichloromethane, Et3N; iv. 
triphenylphosphanylidene acetic acid methyl ester, toluene, reflux; v. A1C13, dichloromethane; vi. PCC, 
Celite, dichloromethane; vii. bromomethyltriphenylphosphonium bromide, toluene; viii. CBr4, PPh3, 
dichloromethane, -15 °C; ix. «-BuLi, THF.
Benzaldehyde was converted into the acetal 207 using 2,2-dimethyl propane-1,3-diol in 
toluene and a catalytic quantity o f acid. A Dean-Stark apparatus was used to remove 
water from the reaction, thus driving it to completion. After approximately 4 hours, the 
reaction mixture was concentrated, and material recovered from the reaction used crude 
in the next synthetic step. Aluminium chloride and lithium aluminium hydride were used 
in diethyl ether to reductively ring open the acetal, to give the benzyloxy protected core 
of the acetylenic fragment 208 in 74% yield overall.203
Introduction o f the alkene moiety to the fragment was accomplished by first oxidising 
the alcohol 208 to the aldehyde using the mild, and highly successful Parikh-Doering 
procedure, 217 followed by Wittig coupling to generate an a,p-unsaturated ester. This
197 207
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furnished the material 210 containing a benzyl ether protected alcohol, intended for 
subsequent deprotection and modification to generate the acetylene, and an alkene which 
is to undergo future modification in the synthesis o f the spiroketal core.
In order to generate the acetylene moiety o f the molecule, it was necessary to remove the 
benzyloxy methyl protecting group. Most traditional methods of removal, the use of 
palladium, Raney nickel, or Birch reduction are not suitable as they would interfere with 
the ester or the alkene portions o f the molecule. An aluminium chloride mediated
^  1 Q 0 1 Q
deprotection, previously reported by Akita et a l  ’ and a similar method by Ozaki et 
al.220 were chosen due to the mild conditions, the rapidity, and the compatibility o f the 
reaction to olefin, and ester functionality. Deprotection o f 210 was conducted in 
dichloromethane with 5 equivalents o f aluminium chloride and a small quantity of 
m-xylene. The reaction progressed rapidly at 0 °C, and was quenched after 10 minutes 
by pouring the reaction mixture into a stirred mixture o f ice and concentrated 
hydrochloric acid. Extraction o f organic material gave the alcohol 211 in 75% yield. 
Successfully deprotected, the fragment could now be modified to incorporate the 
acetylene moiety.
Conversion into the acetylenic fragment was attempted through the aldehyde 212, 
conveniently prepared by PCC oxidation o f 211 in 77% yield. Initial synthetic attempts 
involved were based upon reports by Corey, involving the base mediated dehydro- 
halogenation o f a vinyl halide. 221 Preparation of a suitable vinyl alkene was 
accomplished using bromomethyltriphenylphosphonium bromide, 222 ' 224 in a Wittig 
reaction. Unfortunately, treatment of 213 with base failed to generate any o f the required 
acetylenic material.
Other methods o f acetylenic homologation were considered; o f particular note was the 
use o f Seyferth-Gilbert reagent2 2 5 ' 227 in an Ohira-Bestmann2 28 ,229 reaction. The Ohira- 
Bestmann reaction, however, was rejected in favour o f the two stage Corey-Fuchs 
reaction, 23 0 ' 233 due to concerns regarding the diazo Seyferth-Gilbert reagent. The Corey- 
Fuchs reaction was also advantageous in that over the two stages of acetylene 
generation, it would be convenient for the removal of the a,p-unsaturated ester which 
would be incompatible with later synthetic stages.
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Figure 4.2.6. Synthesis of the acetylene -  modification of the ester moiety, i. CBr4, PPh3, 
dichloromethane, -15 °C; ii. DIBAL-H, Et20 , -78 °C; iii. TBS-C1, imidazole, DMF; iv. w-BuLi, THF.
The first stage o f the Corey-Fuchs reaction was conducted in a solution o f dry 
dichloromethane at -15 °C, into which triphenylphosphine and carbon tetrabromide was 
added, followed shortly after by the aldehyde 212. The reaction was stirred for 1 hour, 
and yielded the dibromoolefin 214 in 75% yield. At this stage it was concluded that it 
would be convenient for the conversion o f the a,P-unsaturated ester into a less reactive 
moiety, and was rapidly reduced to the alcohol 216 in 83% with the use o f diisobutyl 
aluminium hydride. The resulting primary alcohol was transformed into the 
tert-butyldimethylsilyl ether, using ter/‘-butyldimethylsily 1 chloride, and imidazole in 
dimethyl formamide with a yield o f 95%. Finally, the acetylenic fragment was 
completed by treatment o f 217 with 2 equivalents o f «-butyllithium in tetrahydrofuran at 
-78 °C to give 218 in 82% yield.
4.2.4 Coupling of the Fragments
With the completion o f the two fragments, attention was focused upon combining them 
to generate the central scaffold o f the spiroketal fragment.
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Scheme 4.2.7. Coupling of the two fragments, i. w-BuLi, THF, -78 °C to 0 °C.
Examination o f the coupling o f the Weinreb amide 190 to the alkyne 218 and subsequent 
procedures thereafter, indicated that the route could be suboptimal, and that it may not be 
advantageous to couple the two fragments prematurely. As opposed to conducting 
Alpine borane reduction2 3 4  and Sharpless asymmetric epoxidation reactions upon the 
fully constructed carbon scaffold, it would be preferable to conduct the Sharpless 
epoxidation on the precursor 221 prior to coupling. Oxidation to the aldehyde would 
then enable the coupling to proceed, and would obviate the need for Alpine borane 
reduction.
Reduction of the ester 189 to the alcohol 221 was conducted using a suspension of 
lithium aluminium hydride in dry diethyl ether at 0  °C, with a yield of 87% after
235 238quenching with hydrochloric acid and work up. Sharpless asymmetric epoxidation 
of 2 2 1  using tert-butyl hydroperoxide and titanium isopropoxide according to a
91 nprocedure reported by Marshall et al. gave the material 222 in 90% yield. 
Derivitisation to the Mosher ester2 3 9 ,2 4 0  and analysis of the *H NMR spectrum quantified 
the e.e. to be 84%.
Oxidation using Parikh-Doering2 17 conditions gave the epoxy aldehyde 223 in 69% 
yield.
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Scheme 4.2.8. Preparation of the epoxy aldehyde 223. i. LiAlH4, Et20, 0 °C; ii. Sharpless asymmetric 
expoxidation; iii. Py.S03 , Et3N, DMSO, dichloromethane.
In preparation for the coupling o f the two fragments, concerns developed around the 
compatibility o f the unsaturated pyranone ring after cyclisation, and a future Sharpless 
asymmetric dihydroxylation required to generate the final spiroketal core. In order to 
address the potential conflict, a second modified acetylene fragment was prepared. The 
new acetylene fragment would undergo dihydroxylation prior to coupling, and would 
therefore negate any future incompatibilies. The modification of the acetylene can be 
seen in scheme 4.2.9.
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Scheme 4.2.9. Modification of the acetylene fragment, i. Sharpless asymmetric dihydroxylation; ii. 
2,2-dimethoxypropane, (+/-)-CSA, acetone.
The acetylene 218 was dihydroxylated using AD-mix p, in a 1:1 mixture of tert-butyl 
alcohol and water according to a general procedure reported by Sharpless et al.241 The 
diol was then protected as the acetal, giving 225 in a low yield of 40%. This is believed
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to be due to the cleavage o f the protecting group during purification, generating the diol 
which was recovered after collection o f 225.
Coupling of the acetylenes to the epoxy aldehyde 223 proceeded in THF, using 
«-butyllithium to generate the lithium acetylide. Addition o f the epoxy aldehyde then 
furnished the corresponding scaffold fragment 226 or 227.
23% 64%
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Scheme 4.1.10. Coupling of the aceylenes 225 and 218 to the epoxy aldehyde 223. i. w-BuLi, THF, 218; ii. 
«-BuLi, THF, 225.
Having assembled the carbon framework, the compounds were ready to be subjected to 
the mercury mediated cyclisation conditions to generate 2,3-dihydropyran-4-one 
systems. An illustration o f the reactions, and the expected products can be seen in 
schemes 4.2.11 and 4.2.12.
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Scheme 4.2.11. The mercury catalysed cyclisation of 226. i. HgO, dilute acid, acetone.
The material 226 (scheme 4.2.11) was taken and placed into a vessel containing 
analytical grade acetone. A solution o f mercury(II) in dilute acid was freshly prepared by 
dissolving yellow mercury(II) oxide into dilute sulphuric acid. After ensuring that the 
solution was clear and no precipitates had formed, a small quantity was added to the 
reaction mixture. TLC samples were taken and run at two minute intervals to assess the 
progress o f the reaction. As the reaction progressed, using cerium(IV) sulfate to visualise 
the epoxide, it was possible to clearly see the consumption of the starting material. 
Visualisation using anisaldehyde solution revealed the generation of products on the 
TLC plate. Once all starting epoxide had been consumed, sodium hydrogen carbonate 
was added to quench the reaction, and the mixture stirred for 1 hour. The reaction 
mixture, once quenched was filtered to remove solids, and was purified using column
1 13chromatography. Material that was recovered was analysed using H and C NMR 
spectroscopy.
Analysis o f the reaction products indicated that the required pyranone system had not 
been formed. ’H and 13C NMR spectra showed quite clearly that the protecting silyl 
group had been cleaved from the molecule. The acetylene moiety was not present, 
indicating that some form of cyclisation had occurred; however, the NMR spectra also 
indicated that the pyranone system was not present, and indicated the formation of 
aldehyde functionality. This is tentatively attributed to a 1,2-acetylenic rearrangement 
forming an aldehyde, followed by subsequent mercury mediated cyclisation forming a 
furanone system. Further studies will be required to confirm this conclusively.
The second constructed scaffold (227) was placed into the mercury mediated cyclisation 
conditions. TLC samples were taken at 2 minute intervals, and developed using eerie
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sulphate solution. Once all starting epoxide had been consumed, sodium hydrogen
carbonate was added, and the mixture stirred for 1 hour. Upon work-up, the material was
1 1 ^purified using column chromatography, and analysed by H and C NMR spectroscopy.
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Scheme 4.2.12. The mercury catalysed cyclisation of 227. i. HgO, dilute acid, acetone.
In this case, analysis revealed again that again the pyranone system had not been formed. 
It was hoped that the expected cyclisation, followed by acid catalysed deprotection of the 
acetal protected diol would lead to the required spiroketal product directly. NMR spectra 
show, in contrast to the previous olefinic adduct 226, that the silyl protecting group was 
present and intact, as was the acetal protected diol. Surprisingly, the benzyloxy 
protecting group was found to be absent, and it can be concluded that it was cleaved 
from the molecule during the course o f the reaction.
4.2.5 The Alternative Evans Auxiliary Route to the Spiroketal Core
The failure of the two scaffolds to cyclise in the manner that would have furnished the 
required intermediates to the spiroketal core prompted the investigation of simpler 
systems that could undergo a similar mercury mediated cyclisation. A method was 
devised to synthesise the (+)-calyculin A spiroketal fragment similar to that described by
1 0 9  1Smith et al., ’ to allow comparison o f published spectral data to that which would
hopefully be obtained from a correctly constructed fragment. An illustration of the 
synthetic route can be seen in scheme 4.2.13.
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Scheme 4.2.13. Preparation of the (+)-calyculin A core. i. Propionyl chloride, Et3N, dichloromethane; ii. 3- 
benzyloxypropionaldehyde, TiCLt, (-)-sparteine, dichloromethane -78 °C; iii. 3,4-dihydro-2//-pyran, THF, 
/?-toluenesulfonic acid, 0 °C; iv. MeNH(MeO).HCl, Et3N; v. 218, «-BuLi, THF, -78 °C; vi. cat. 
p-toluenesulfonic acid; vii. HgO, acetone.
Construction of the compound 232 by Evans aldol addition to 231 would prepare the two 
key stereocentres for the correct formation o f the pyranone ring. Protection o f the 
alcohol 232 as a tetrahydropyran moiety, followed by metal acetylide addition to the 
Weinreb amide 234 would form the scaffold 235. Deprotection, and Hg+2 catalysed 
cyclisation should yield 236. Through simplification of the cyclisation and removal of 
the epoxide, it was hoped that the precursor 235 would cyclise cleanly, and without 
further complications that have plagued the previous epoxide scaffolds.
Preparation o f the thiazolidinethione auxiliary was conducted according to a procedure 
reported by Delaunay et al.242 whereby (5)-phenylalaninol was heated to reflux in the 
presence of 1 M potassium hydroxide and carbon disulfide. 231 was prepared according 
to methodology reported by Crimmins et al. 243 ,244 yielding a bright yellow crystalline 
material that could be easily purified through recrystallization from hexane. Formation
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of the enolate at 0 °C using 1 equivalent of (-)-sparteine, and titanium tetrachloride in 
dry dichloromethane, gave the anti-Evans aldol addition product 232.244 Undesired 
material was easily separated from the required diasteroisomer using column 
chromatography, the compound being bright yellow in appearance, could be visually 
identified as it passed through the column and could be preferentially collected. THP 
protection o f the aldol adduct, yielded 233, and attempts were conducted to convert the 
fragment to the Weinreb amide 234. It has been reported that thiozolidinethione 
auxiliary can be easily displaced by nucleophiles, thus increasing the synthetic utility of 
the auxiliary in general. It was this property that underlied the selection of the auxiliary 
over the more traditional Evans auxiliaries, and it was expected that the conversion 
would be straightforward, with high yielding results. In practice, the generation of the 
Weinreb was not possible, and attempts to generate the Weinreb amide, using a variety 
of bases failed.
It is believed that this approach to the spiroketal fragment would be successful, perhaps 
through conversion to the aldehyde with DIBAL-H, addition of the acetylene portion, 
and oxidation to the ketone 235. It would also be possible to remove the 
thiozolidinethione auxiliary and utilise traditional Evans oxazolidinones in an effort to 
generate 234; however, time constraints limited the ability to explore the area fully and 
investigate this fragment.
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4.3 Conclusions
The construction of the (-)-calyculin A spiroketal fragment using the epoxy alkynols 226 
and 227 failed. Premature cleavage o f the protecting groups is one explanation for the 
failure o f the cyclisation; however, the cleavage is clearly not the only adverse process 
that occurs to the precursors. Future investigation into the effects o f mercury mediated 
cyclisation on large substituted systems would be beneficial, and may aid in the choice 
of protecting group to one which is unaffected by the Hg+2 cyclisation conditions.
Use o f the Evans aldol fragments is a promising alternative to the epoxy alkynols 
approach, and the simplified system would generate the required pyranone systems. 
Future work focused upon producing fragments such as 234, should be successful in 
achieving the synthesis o f the calyculin spiroketal fragments.
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4.4 Experimental
The general experimental section can be found in chapter 1.4.
2-Pheny 1-| 1,3] dioxane203 (198)
Benzaldehyde (27.9 g, 263 mmol), / 7-toluenesulfonic acid (0.08 g, 
catalyst), and propane-1,3-diol (20 g, 263 mmol), in toluene (80 mL), 
was heated to reflux in a Dean-Stark apparatus for 4 h. The mixture was 
then allowed to cool. The reaction mixture was then concentrated to a minimum under
reduced pressure. Upon standing, crystallisation occurred, yielding 198 (32.0 g, 74.1%)
1as a colourless crystalline solid. Analysis correlates to previously described material. C 
NMR (75 MHz, CDCh), 5C 138.8, 128.8, 128.3, 126.0, 101.7, 67.4, 25.8.
3-Benzyloxy-propan-l-ol203 245 246 (199)
Diethyl ether (100 mL) was placed in a dry round bottomed 
flask, and cooled to 0 °C. AICI3 (7.52 g, 131 mmol) was added
portionwise, cautiously. The mixture was stirred for 30 min at 0 °C as dissolution 
occurred. LiAH-L* (1.25 g, 32.9 mmol) was added to the reaction mixture portionwise, 
and the mixture kept at 0 °C after addition for a further 30 min. 2-Phenyl-[l,3]-dioxane 
(10.788 g, 65.7 mmol) was diluted into ether (100 mL) and added to the reaction vessel 
drop wise through an addition funnel. The reaction was allowed to warm to room 
temperature, and was stirred for 2 h. The mixture was quenched through the addition of 
10% sulfuric acid (100 mL, dropwise at first), and the resulting suspension filtered 
through celite. The organic fractions were separated, dried (Na2 S0 4 ), and concentrated to 
a pale yellow oil. Distillation o f the crude oil (approx 2 torr, 105-110 °C) gave 199 as a 
colourless oil (8.300 g, 76%). 'H NMR (300MHz, CDC13), 5H 7.48-7.36 (m, 5H, Ar-H), 
4.63 (s, 2H, Ph-CHj-O), 3.87 (t, 7 = 5 . 7  Hz, 2H, HO-CH2-CH2 ), 3.76 (t, 7=5.8 Hz, 2H, O- 
CH2-CH2 ), 2.63 (br, 1 H, OH), 2.01 - 1.93 (m, 2 H, CH2-CH2 -CH2). 13C NMR (75 MHz, 
C D C I 3 ) ,  8 c  138.6, 128.8, 128.1, 128.0, 73.6, 69.3, 61.6, 32.7. Analysis was consistent 
with that o f previously described material.
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Pyridinium Chlorochromate (PCC)
Chromium trioxide (10 g, 100 mmol) was dissolved in HC1 (6 M, 20 mL) and cooled to 0 
°C. Pyridine (8.06 mL, 100 mmol) was introduced to the reaction mixture dropwise over 
a 10 min. The mixture was re-cooled to 0 °C resulting in the generation o f a bright 
orange precipitate. The solid was obtained by vacuum filtration and was dried in a 
desiccator, to give 19.0 g, 8 8 %, o f the product as a bright orange solid.
3-Benzyloxy-propionaldehyde245'247 (188)
O
To a stirring suspension o f PCC (2.59 g, 12 mmol), celite (2.6 g), 
and dichloromethane (20 mL), the alcohol 3-benzyloxy-propan- 
l-ol (0.5 g, 3 mmol) was added in one portion. The mixture was stirred at room 
temperature for 4 h. The mixture was filtered through a silica plug, and the filtrate 
concentrated to an oil. Chromatography on silica gel (4:1 hexaneiethyl acetate) afforded 
188 (0.35 g, 71%) as a colourless oil. 'H NMR (300MHz, CDC13), 8H9.83 (s, 1H, CHO- 
CH2), 7.63 - 7.51 (m, 5H, Ar-H), 4.78 (s, 2H, Ph-CHj-O), 4.06 (t, .7=6.1 Hz, 2H, O-CH2 - 
CHj), 2.92 (t, 7=6.1 Hz, 2H, CH2 -CH2-CHO). 13C NMR (75 MHz, CDCI3), 8 C 201.3,
138.3, 128.8, 128.2, 128.1, 73.6, 64.3, 44.3, 35.6, 29.5. Analysis was consistent with that 
of previously described material.
(2is)-5-Benzyloxy-2-methylpent-2-enoic acid ethyl ester210 (189)
3-Benzyloxypropionaldehyde (2.38 g, 1.45 mmol), 2- 
(triphenyl-A.5-phosphanylidene)-propionic acid ethyl 
ester (0.525 g, 1.45 mmol), and dry dichloromethane (5 
mL) were combined in a vessel purged with an inert atmosphere. The reaction mixture 
was heated to reflux until all staring material had been consumed by TLC using an 
eluant o f 4:1 hexaneiethyl acetate. The reaction mixture was concentrated under reduced 
pressure to an oil. Ethyl acetate was added (10 mL) and the resulting solution passed 
through a short silica plug. The product containing solution was concentrated under 
reduced pressure to an oil, whereupon hexane was added. Filtration of the solution 
followed by concentration under reduced pressure gave 189 (0.318 g, 87%) as a pale 
yellow oil. ‘H NMR (300MHz, CDCI3), 8H7.55 - 7.46 (m, 5H, Ar-H), 6.99 (t, 7=7.1 Hz,
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1H, CH2-CH=C), 4.73 (s, 2H, Ph-CIfc-O), 4.36 (q, .7=7.1 Hz, 2H, O-CH2-CH3), 3.77 (t, 
7=6.7 Hz, 2H, 0 -CH2-CH2), 2.73 - 2.66 (m, 2H, CH2-CH2 -CH), 2.06 (s, 3H, CH3-C),
1.47 (t, 7=7.1 Hz, 3H, CH3 -CH2-O). 13C NMR (75 MHz, CDCI3), 8 C 168.0,138.3,129.5, 
128.4, 127.7, 73.0, 6 8 .6 , 60.5, 29.4, 14.3, 12.6. Analysis correlated with previously 
reported data. 211
5-Benzyloxy-pent-2-enoic acid (203)
5-Benzyloxy-2-methylpent-2-enoic acid ethyl ester (1.0 g,
4 mmol) and lithium hydroxide (0.192 g, 8  mmol) were 
dissolved in a 3:1:1 mixture of THF, methanol, and water.
The mixture was stirred for 2 h, followed by TLC using an eluant of 4:1 hexane:ethyl 
acetate. Upon completion, the mixture was diluted with ethyl acetate and was extracted 
with 2M hydrochloric acid and brine respectively. Organic fractions were dried 
(MgS0 4 ), and concentrated under reduced pressure to an oil. Chromatographic 
purification using an eluant o f 4:1 hexane:ethyl acetate gave 203 as a white solid (0.194 
g, 24%). ‘H NMR (300MHz, CDC13), 8H7.64 - 7.49 (m, 5H, Ar-H), 7.19 (t, 7=6.2 Hz, 
1H, CH2-CH=C), 4.77 (s, 2H, Ph-CH,-Q). 3.82 (t, 7=6.6 Hz, 2H, O-CH2-CH2), 2.79 -
2.72 (m, 2H, CH2 -CH2 -CH), 2.10 (s, 3H, CH3 -C). 13C NMR (75 MHz, CDC13), 8 C 173.6,
138.6, 132.5,129.2,128.8, 128.1, 73.6, 68.9, 30.1, 12.7.
5-Benzyloxy-pent-2-enoic acid methoxymethylamide (190)
To a slurry of 5-benzyloxy-2-methylpent-2-enoic O
acid ethyl ester (0.1 g, 0.4 mmol), N fl-  
dimethylhydroxylamine hydrochloride (0.059 g, 0.6
mmol), in dry THF (5 mL) was added isopropylmagnesium chloride (1.2 mmol) over 15 
min at -10 °C. After aging at -10 °C for 30 min, 25% w/w ammonium chloride solution 
(3 mL) was added to quench the reaction. Ethyl acetate was added (5 mL), and the 
mixture separated. Organic fractions were dried (MgS0 4 ), and concentrated under 
reduced pressure to an oil. Purification by flash column chromatography using an eluant 
of 2:1 hexane:ethyl acetate gave 190 as a colourless oil (49 mg, 50%). !H NMR 
(300MHz, CDCI3), 5h 7.34 - 7.22 (m, 5H, Ar-H), 5.87 (t, 7=7.1 Hz, 1H, CH2 -CH=C),
4.47 (s, 2H, Ph-CHz-O), 3.58 (s, 3H, CH3-O), 3.53 (t, 7=6.7 Hz, 2H, O-CH9-CHA 3.18
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(s, 3H, N-CHO. 2.46-2.39 (m, 2H, CH2 -CH2-CH2), 2.14 (s, 3H, CH3-C). HRMS calcd. 
for C15H21NO3 263.1521, found 263.1525.
(Diethoxymethyl)benzene215 (206)
Phenol (5 g, 53 mmol), triethyl orthoformate (7.86g, 53 mmol), and 
/ 7-toluene sulfonic acid (0.05 g) were placed into distillation apparatus 
and heated to 40 °C at approx. 150 torr, removing ethanol from the 
mixture. The crude product was washed with 5M sodium hydroxide and water 
respectively. Organic extracts were dried (NaCCL), filtered, and distilled at 75-80 °C 
under high vacuum to give 206 as a colourless oil (4.5 g, 44%). Analysis is consistent 
with data previously reported.
lU NMR (300MHz, CDC13), 6 H 7.31-7.03 (m, 5H, Ar-H), 5.72 (s, 1H, O-CH(O)-O), 
3.81 - 3.71 (m, 4H, CH3-CH2-O), 1.26 (t, 7=7.1 Hz, 6 H, CH3-CH2-O).
3-Bromo-3-methyl-but-l-yne214 (184)
A vessel was charged with 2-methyl-3-yn-2-ol (0.5 g, 5.9 mmol), to which 
was added PBr3 (0.22 mL, 2.36 mmol) dropwise. The mixture was stirred for ^
30 min at room temperature. The reaction mixture was distilled at approx. 100 torr, 40 
°C (lit. 30 °C, 80 torr). 184 was retrieved as a colourless oil (0.316 g, 37%). Analysis 
correlates to data previously reported. *H NMR (300MHz, CDCI3), 8 h 2.62 (s, 1H, 
UC=C), 1.93 (s, 6 H, C(CHVb). 13C NMR (75 MHz, CDC13), 8C36.5 ,47.3, 73.0, 88.0.
4,4-Diethoxy-3,3-dimethylbut-l-yne214 (185)
An argon purged vessel containing activated magnesium turnings (0.1 
g) was charged with dry THF (15 mL) and stirred. 3-Bromo-3- 
methyl-but-l-yne (0.5 g, 3.4 mmol) was added to the vessel, and the 
mixture stirred at room temperature for 1 h. (Diethoxymethyl)benzene (0.667 g, 3.4 
mmol) was added, and the mixture stirred overnight. The reaction was quenched with the 
addition of sat. ammonium chloride solution (5 mL) at 0 °C. Dichloromethane (15 mL) 
was added, and the reaction extracted. The organic fraction was then washed with 5M 
NaOH (10 mL), brine (5 mL), and dried (Na2 CC>3), and concentrated to an oil to give 
185 (0.318 g, 55%). Analysis correlated with previously reported data.
O'
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2,2-dimethylbut-3-ynal (186)
Method 1:
O
To a flask containing 4,4-diethoxy-3,3 -dimethylbut- 1 -yne (0.1 g, 0.6 mmol), and 1}
diethyl ether ( 2  mL), oxalic acid dihydrate (0.074 g, 0 . 6  mmol) was added. The A 
mixture was stirred and monitored using TLC. Upon the disappearance o f starting 
material, the reaction mixture was washed with water (1 mL). The extracted organic 
fractions were combined, and dried with MgSC>4 . Concentration gave crude material that 
did not contain 186.
Method 2:
To a flask containing 4,4-diethoxy-3,3-dimethylbut-1-yne (0.1 g, 0.6 mmol), and pentane 
(2 mL), formic acid (1 mL) was added. The mixture was stirred and monitored using 
TLC. Upon the disappearance of starting material, the reaction mixture was washed with 
water (1 mL). The extracted organic fractions were combined, and dried with MgSCT*. 
Concentration gave crude material that did not contain 186.
Method 3:
To a flask containing 4,4-diethoxy-3,3-dimethylbut-1-yne (0.1 g, 0.6 mmol), and pentane 
(2 mL), acetic acid (1 mL) was added. The mixture was stirred and monitored using 
TLC. Upon the disappearance of starting material, the reaction mixture was washed with 
water (1 mL). The extracted organic fractions were combined, and dried with MgSC>4 . 
Concentration gave crude material that did not contain 186.
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(ZT)-Ethyl 4,4-dimethylhex-2-en-5-ynoate
To a flask containing 4,4-diethoxy-3,3-dimethylbut-l-yne (0.1 g, O
0.6 mmol), and toluene (2 mL), (triphenyl-^5-phosphanylidene)- 
acetic acid ethyl ester (0.42 g, 1.2 mmol) was added and the 
mixture warmed to 50 °C and stirred. The reaction was left for 12 
h, and tested by TLC. (£)-Ethyl 4,4-dimethylhex-2-en-5-ynoate was not found to be 
formed.
3-Benzyloxy-2,2-dimethylpropan-l-ol (208)
A mixture of benzaldehyde (20.38 g, 192 mmol), 2,2- 
dimethylpropane-l,3-diol (20 g, 192 mmol), and 80 mg o f p- 
toluene sulfonic acid in 80 mL of toluene was heated in Dean- 
Stark apparatus to reflux. Azeotropic removal o f water was continued until no more 
water could be removed from the reaction. The reaction was then concentrated under 
reduced pressure reducing the volume to approx. one tenth. Aluminium chloride (25.6 g, 
192 mmol) was dissolved into 100 mL of dry diethyl ether at 0 °C under argon, and 
stirred for 30 min. Lithium aluminium hydride (3.64 g, 96 mmol) was then added, and 
stirred for a further 30 min at 0 °C. The crude reside was dissolved in 100 mL of dry 
diethyl ether, and added dropwise to the reaction mixture. Care was taken to maintain the 
temperature, and to prevent vigorous foaming during addition. The reaction was stirred 
at 0 °C for 3 h, and quenched with the addition o f 5% sulfuric acid solution. The silver 
solution was filtered through celite, the residue washed with diethyl ether (3 x 20 mL), 
organic fractions combined and concentrated under reduced pressure to an oil. 
Distillation afforded 208 (27.5 g, 74%) as a colourless oil. IR vmax (KBr, cm'1) 3345 
(OH). *H NMR (300MHz, CDC13), 6H7.34 - 7.26 (m, 5H, Ar-H), 4.49 (s, 2H, Ph-CH?- 
O), 3.44 (s, 2H, HO-CH2 -C), 3.22 (s, 2H, O-CH2 -C), 0.93 (s, 6 H, -(CHsh). 13C NMR (75 
MHz, CDCI3), 6 C 138.2, 128.5, 127.7, 127.5, 79.4, 73.5, 71.7, 36.3, 21.9. HRMS calcd. 
forCi2Hi80 2 194.1307, found 194.1308.
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3-Benzyloxy-2,2-dimethylpropionaldehyde (209)
A solution of 3-benzyloxy-2,2-dimethylpropan-l-ol (14.2 g, 73.3 
mmol), in dichloromethane (70 mL) and dimethylsulfoxide (14 
mL), was prepared and stirred at 0 °C. Triethylamine (4.65 mL, 293 
mmol) was added, followed by Py.SC>3 complex (23.3 g, 147 mmol). The reaction was 
stirred for 2 hours, and allowed to warm to room temperature. Ethyl acetate was added 
(100 mL), and the organic components washed with ice cold water (150 mL), saturated 
ammonium chloride (150 mL), and finally brine (20mL). Organic fractions were dried 
(MgS0 4 ), and concentrated under reduced pressure to an oil. Crude material was purified 
by column chromatography using an eluant o f 2:1 hexaneiethyl acetate giving 209 (13.2 
g, 83%) as a colourless oil. IR vmax (KBr, cm'1) 1729 (0=0). 'H NMR (300MHz, 
CDCI3), 8 h 9.57 (s, 1H, CHO-C), 7.37 - 7.05 (m, 5H, Ar-H), 4.47 (s, 2H, Ph-CIfc-O),
3.39 (s, 2H, O-CH2-C), 1.09 (s, 6 H-(CHj)2).
(22s)-5-Benzyloxy-4,4-dimethylpent-2-enoic acid methyl ester (210)
To 3-benzyloxy-2,2-dimethylpropionaldehyde (5 g, 26 mmol) 
in 100 mL of toluene was added triphenylphosphanylidene 
acetic acid methyl ester (8.7 g, 26 mmol) and heated to reflux 
for 5 h. After cooling, the majority o f toluene was removed 
under reduced pressure, 40 mL of 4:1 hexaneiethyl acetate was added resulting in the 
precipitation of a white solid. Filtration through a plug o f silica, followed by 
concentration of the filtrate afforded 210 (4.26g, 6 6 %) as a colourless oil. IR vmax(KBr, 
c m 1) 1704 (C=0), 1610 (C=C). ‘H NMR (300MHz, CDC13), 5H7.38 - 7.25 (m, 5H, Ar­
id), 7.03 (d, 7=16.1 Hz, 1H, C-CH=CH), 5.82 (d, 7=16.1 Hz, 1H, CH=CH-C(0)), 4.51 
(s, 2H, Ph-OLrO), 3.70 (s, 3H, CH3 -O), 3.26 (s, 2H, Q-CH,-C). 1.10 (s, 6 H, -(CH3)2). 
13C NMR (75 MHz, CDCI3), 8 C 167.4, 156.0, 138.4, 128.3, 127.5, 127.4, 118.4, 78.2,
73.3, 51.4, 38.3, 23.9. HRMS calcd. for C 15H2 0O3 248.1412, found 248.1410.
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(2is)-5-Hydroxy-4,4-dimethylpent-2-enoic acid methyl ester (211)
To aluminium chloride (0.267 g, 2 mmol) in 3 mL of dichloromethane
HO
at 0 °C, was added O.lg (0.4 mmol) o f 5-benzyloxy-4,4-dimethylpent-2- 
enoic acid methyl ester in xylene (0.63 mL). The mixture was stirred for 
10 min. The reaction was then poured into a stirred mixture o f ice (10 
g) and concentrated HC1 (1 mL). The aqueous mixture was then extracted with diethyl 
ether (3 x 10 mL), organic fractions were collected, washed with brine (10 mL), dried 
(MgSC>4 ), and then concentrated under reduced pressure to an oil. Purification by column 
chromatography (2:1 petroleum ether (40-60):ethyl acetate) gave 211 (0.047 g, 75%) as 
a colourless oil. Rf. 0.2 (2:1 petroleum ether (40-60):ethyl acetate). IR vmax(KBr, cm'1) 
3350 (OH), 1705 (C=0), 1614 (C=C). *H NMR (300MHz, CDC13), 6 H6 . 8 8  (d, 7=15.8 
Hz, 1H, C-CH=CH), 5.72 (d, 7=15.8 Hz, 1H, CH=CH-C(0)), 3.58 (s, 3H, CH3-O), 3.29 
(s, 2H, HO-CH2-C), 0.94 (s, 6 H, -(CHA). 13C NMR (75 MHz, CDC13), 6 C 167.3, 155.4,
119.3, 70.9, 51.5, 39.2, 23.1. HRMS calcd. for C8Hi40 3158.0943, found 158.0946.
(2£)-4,4-Dimethyl-5-oxo-pent-2-enoic acid methyl ester (212)
4,4-Dimethyl-5-oxo-pent-2-enoic acid methyl ester (1.75 g, 11.1 mmol) in 
2 mL of dichloromethane was added to a stirring suspension of 
dichloromethane (25 mL), celite (4.79 g), and PCC (4.79 g, 2.22 mmol).
The mixture was stirred at room temperature until complete by TLC. The 
reaction was filtered through silica, and the filtrate concentrated under reduced pressure, 
yielding 212 (1.34 g, 77%) as a colourless oil requiring no further purification. IR vmax 
(KBr, cm'1) 1731 (C=0), 1707 (C=0), 1610 (C=C). *H NMR (300MHz, CDC13), 6H9.55 
(s, 1H, CHO-C), 6.97 (d, 7=16.1 Hz, 1H, C-CH=CH), 5.88 (d, 7=16.1 Hz, 1H, CH=CH- 
C(O)), 3.75 (s, 3H, CHrO), 1.26 (s, 6 H, -(C H A ).
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(2£',5£')-6-Bromo-4,4-dimethylhexa-2,5-dienoic acid methyl ester (213)
(Bromomethyl)-triphenylphosphonium bromide (0.1 g, 0.23 mmol) in 
3 mL of dry THF was cooled to -78 °C. w-Butyllithium (0.21 mmol) 
was added to the dropwise, resulting in the formation o f a yellow .
O O
solution. The mixture was allowed to stir for 15 min. 0.034 g (0.21 
mmol) o f 4,4-dimethyl-5-oxo-pent-2-enoic acid methyl ester in 0.5 mL of dry THF was 
then added to the reaction mixture, while maintaining the temperature at -78 °C. An off- 
white precipitate was seen to be formed during the progress of the reaction. The reaction 
mixture was warmed to room temperature, and concentrated under reduced pressure. 2 : 1  
petroleum ether:ethyl acetate was added, and the resulting suspension filtered through a 
short silica plug, the residue was washed, and the filtrate concentrated under reduced 
pressure to give 213 (31 mg, 63%) a light yellow oil.
'H NMR (300MHz, C D C I 3 ) ,  SH 6.99 (d, 7=15.5, 1H, CH=CH-COO), 5.82 (d, 7=9.7, 1H, 
Br-CH=CH), 5.75 (d, 7=15.5, 1H, CH=CH-COO), 4.97 (d, 7=9.7, 1H, Br-CH=CH).
3.73 (s, 3H, CH3-O), 1.16 (s, 6 H, -fCHVb). 13C NMR (75 MHz, CDCI3), Sc 167.5, 156.5,
144.7, 117.7, 112.4,51.5,39.7, 29.2.
(2£)-6,6-Dibromo-4,4-dimethyIhexa-2,5-dienoic acid methyl ester (214)
To a cold (-15 °C) stirred solution o f triphenyl phosphine (12.6 mmol,
3.29 g) in 10 mL of dry dichloromethane, carbon tetrabromide (2.08 | f -
Br ^
g, 6.28 mmol) in 6  mL of dry dichloromethane was added, and |
continuously stirred for 30 min. 4,4-dimethyl-5-oxo-pent-2-enoic acid O
methyl ester (0.419 g, 3.14 mmol) in 5 mL of dichloromethane was added slowly, and 
the reaction stirred for 1 h. The mixture then filtered through a short slug o f silica using 
an eluant of initially hexane, then 5% ethyl acetate/hexane gave 214 (0.73 g, 75%) as a 
colourless oil. ‘H NMR (300MHz, C D C I 3 ) ,  8 H 6.99 (d, 7=16.0 Hz, 1H, C H = C H - C O O ) ,  
6.70 (s, 1H, B r ? - C = C H ) .  5.87 (d, 7=16.0 Hz, 1H, C H = C H - C O O ) ,  3.73 (s, 3H, C H 3 - C ) ,
1.30 (s, 6 H, -(CHjh). 13C NMR (75 MHz, CDCI3), 8 C 167.2, 153.2, 143.3, 118.8, 89.3, 
51.6,41.2, 27.0. HRMS calcd. for C9H 12Br2 0 2  309.9204, found 309.9207.
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(2£}-6,6-Dibromo-4,4-dimethylhexa-2,5-dien-l-ol (216)
To a stirred solution o f 6,6-dibromo-4,4-dimethyl-hexa-2,5-dienoic ^  
acid methyl ester (2.5 g, 8.0 mmol) in dichloromethane (36 mL) at - 
78 °C, DEBAL-H (2.5 eq, 20% wt.% in toluene, 20.0 mmol) was 
added dropwise and the reaction stirred for 30 minutes. The reaction 
mixture was quenched with the addition of saturated NH4 CI solution at -78 °C. The 
quenched reaction was then warmed to 0 °C and 20 mL of 1 M HC1 was added, and 
stirred for 15 minutes. The mixture was filtered through a small celite plug, which was 
then washed with 2 x 1 0  mL portions of diethyl ether. The combined mixture was dried 
(MgSC>4 ) and concentrated under reduced pressure to a colourless oil. Purification by 
column chromatography using an eluant o f 5% ethyl acetate/petroleum spirit (40-60 °C), 
gave 216 (1.871 g, 83%) as a colourless oil. 'H NMR (300MHz, CDCI3), SH 6.31 (s, 1H, 
Br2-C=CH), 5.76 (d, .7=13.1 Hz, 1H, C-CH=CH). 5.65 (dt, 7=13.1, 5.4 Hz, 1H, CH=CH- 
CH2), 4.14 (d, 7=5.4 Hz, 2H, CH-CH2 -OH), 1.75-1.63 (br, OH), 1.26 (s, 6 H, -(CH3)2 ). 
13C NMR (75 MHz, CDCI3), 8 C 145.0, 137.8, 126.7, 87.6,63.7,40.6,27.5.
(2ii)-terf-Butyl-(6,6-dibromo-4,4-dimethylhexa-2,5-dienyloxy)-dimethylsilane (217)
To 59 mg, 0.21 mmol, o f 6,6-dibromo-4,4-dimethylhexa-2,5-dien- Br 
l-ol in 1 mL of dimethyl formamide at 0 °C, imidazole (19 mg, gr 
0.27 mmol), and tert-butyldimethylsilyl chloride (35 mg, 0.23
'O
mmol) were added. The mixture was stirred at ambient temperature 
for 12 h. The reaction mixture was extracted between diethyl ether and water, the 
product containing organic fractions were combined, dried (MgS0 4 ), and concentrated 
under reduced pressure to an oil. Column chromatography using an eluant o f 10% ethyl 
acetate/petroleum ether (40-60 °C) gave 217 (80 mg, 95%). NMR (300MHz, CDCI3 ), 
5h 6.58 (s, 1 H, Br2-C=CH), 5.73 (d, 7=15.4 Hz, 1 H, C-CH=CH), 5.53 (dt, 7=15.4, 4.9 
Hz, 1 H, CH=CH-CH2), 4.18 (d, 7=4.9 Hz, 2H, CH-CH2 -O), 1.26 (s, 6 H, -(CH3)2), 0.90 
(s, 9H, O-TBS). 0.06 (s, 6 H, O-TBSl. I3C NMR (75 MHz, CDC13), 8 C 145.2, 135.7,
127.0, 87.2, 63.8, 40.5, 27.5, 26.0, 18.5, 1.0. HRMS calcd. for Ci4H2 6Br2SiO 396.0120, 
found 369.0122.
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(2£)-ter^Butyl-(4,4-dimethylhex-2-en-5-ynyIoxy)-dimethylsilane (218)
To a stirred,-78 °C solution of fert-butyl-(6,6-dibromo-4,4-
dimethylhexa-2,5-dienyloxy)-dimethylsilane (0.576 g, 1.8 mmol) in
tetrahydrofuran (3 mL), «-butyllithium (3.6 mmol, 2.5 M in hexanes)
was added dropwise. The mixture was stirred for 1 h, and then warmed ,
TBS
to 0 °C. Saturated ammonium chloride was then added to quench the 
reaction, and subsequently extracted with dichloromethane. Organic fractions were 
combined, and dried (M gS04). Concentration under reduced pressure yielded the crude 
product as a colourless oil. Purification by column chromatography using an eluant o f  
10% diethyl ether/petroleum ether (40-60 °C) gave 218 (224 mg, 82%) as a colourless 
oil. *H NMR (300MHz, CDC13), 6H5.76 (dt, .7=15.3, 4.8 Hz, 1H, C-CH=CH), 5.54 (dt, 
7=15.3, 1.6 Hz, 1H, CH2-CH=CH), 4.19 - 4.14 (m, 2H, CH-OL-O). 2.28 (s, 1H, HC=C- 
C), 1.24 (s, 6 H, -(CH3)2), 0.84 (s, 9H, O-TBS), 0.06 (s, 6 H, O-JBS). 13C NMR (75 MHz, 
CDC13), 6 c 136.2, 127.4, 90.3, 69.8, 63.9, 33.4, 30.0, 26.3, 18.8, -4.7. HRMS calcd. for 
Ci4H26SiO 238.1753, found 238.1760.
(2£}-5-Benzyloxypent-2-en-l-ol210 (221)
5-Benzyloxy-2-methyl-pent-2-enoic acid ethyl ester 
(3.5 g, 14.1 mmol) was added dropwise to a rapidly
stirring suspension of lithium aluminum hydride (0.40 g, 10.6 mmol), in dry diethyl 
ether (35 mL) at 0 °C and stirred for 1 h. A solution of 2 M hydrochloric acid (40 mL, 
careful dropwise addition initially) was added and the mixture stirred for 30 min. 
Extraction with ethyl acetate (3 x 30 mL), combination o f product containing fractions, 
drying (M gS04), and concentration under reduced pressure gave the crude product. 
Purification by column chromatography 4:1 hexaneiethyl acetate to 3:1 hexane:ethyl 
acetate gave 221 (2.53 g, 87%) as a colourless oil. Analysis correlates with previously 
reported examples. ‘H NMR (300MHz, C D C I 3 ) ,  §H 7.37 - 7.26 (m, 5H, Ar-H), 5.45 ( t ,  
J= 5.8 Hz, 1H, C H 2 - C H = C ) ,  4.52 (s, 2H, P h - C H , - Q ) .  3.99 (s, 2H, H O - O f c - C ) ,  3.49 ( t ,  
.7=6.9 Hz, 2H, O - C H 2 - C H 2 ) ,  2.41-2.36 (m, 2H, C H 2 - C H 2 - C H ) ,  1.68 (s, 3H, C H 3 - C ) .  13C 
NMR (75 MHz, C D C I 3 ) ,  8 C 138.4, 136.8, 128.4, 127.7, 127.6, 122.0, 72.9, 69.7, 68.7, 
28.3, 13.8.
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((25,3<S)-3-(2-(Benzyloxy)ethyl)-2-methyloxiran-2-yl)methanoI210 (222)
(+)-Diisopropyl tartrate (0.108 g, 0.46 mmol), Ti('PrO) 4  (S) .^O
(0.108 g. 0.38 mmol), ^ -b u ty l hydroperoxide (5.2 mL,
2.5 M, 16.6 mmol) and 4A molecular sieves (300 mg) 
were cooled in dichloromethane (80 mL) to -20 °C in an inert atmosphere. The mixture 
was aged for 30 min. The mixture was cooled to -28 °C and benzyloxypent-2-en-l-ol 
(1.5 g, 7.3 mmol) was added slowly. The reaction stirred at -28 °C for 12 h. The reaction 
was monitored by TLC 2:1 hexane:ethyl acetate. Upon completion, water (12 mL) was 
added and vigorously stirred for 60 min. 30% NaOH/sat. brine (3 mL) was added and the 
mixture stirred for 60 min. The reaction mixture was then filtered, and the filtrate 
extracted with dichloromethane (2 x 30 mL). Drying (anhydrous Na2 SC>4 ) and 
concentration yielded the crude product as an oil. Purification by column 
chromatography using an eluant o f 2:1 hexane:ethyl acetate gave 222 (1.47 g, 90%) as a 
colourless oil. *H NMR (300MHz, CDC13), 5H7.38 - 7.25 (m, 5H, Ar-H), 4.53 (s, 2H, 
Ph-CH2-0 ), 3.69 - 3.52 (m, 2H, HO-CH2-C), 3.64 (t, 7=5.7 Hz, 2H, O-CH9-CHA 3.18 
(t, 7=6.3 Hz, 1H, CH2 -CH(0)-CH), 2.04 - 1.79 (m, 2H, CH2 -CH2-CH), 1.28 (s, 3H, 
CH3-C). 13C NMR (75 MHz, CDC13), 5C 138.2, 128.4, 127.6, 73.1, 67.4, 65.4, 60.9, 57.9,
29.0, 14.4. Analysis correlates with previously reported material. !H analysis of the 
Mosher ester239 ,240 indicated an e.e. o f 84%.
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3-(2-Benzyloxyethyl)-2-methyl-oxirane-2-carboxaldehyde (223)
To a 0 °C stirred mixture o f dimethyl sulfoxide (1.85 _ (S).^Q
mL), triethyl amine (1.46 mL, 9.2 mmol), [3-(2- 
benzyloxyethyl)-oxiranyl]-methanol (300 mg, 1.3 mmol), 
and dichloromethane (3.2 mL), pyridine SO3 complex dissolved in dimethyl sulfoxide (1 
mL) was added dropwise. The mixture was stirred for 2 h at 0 °C, after which TLC 
analysis (eluant o f 3:1 hexaneiethyl acetate) indicated that the reaction was complete. 
Addition of 10 mL o f 1:1 hexane:diethyl ether to the solution, was followed by 
extraction with ice cold water (15 mL). The aqueous washings were extracted with 2 x 
15 mL of diethyl ether. The organic fractions were combined, then washed once again 
with ice-cold water(10 mL). The organic fractions were then dried (Na2 SC>4 ) and 
concentrated under reduced pressure to an oil. Purification by column chromatography 
(3:1 hexane:ethyl acetate), gave 223 (0.191 g, 69%) as a colourless oil. *H NMR 
(300MHz, CDCI3), 8 h 8 . 8 6  ( s , 1H, CHO-C), 7.47 - 7.26 (m, 5H, Ar-H), 4.54 (s, 2H, Ph- 
CH2-O), 3.66 (t, J=  6.3 Hz, 2H, O-CH2-CH2 ), 3.33 (t, J=5.7 Hz, 1H, CH2-CH(0)-C), 
2.04 - 1.86 (m, 2H, CH2 -CH2-CH), 1.41 (s, 3H, CH3 -C). 13C NMR (75 MHz, CDC13), 8 C
200.0, 138.0, 128.5, 127.8, 127.6, 73.2, 66.9, 62.1, 57.9, 28.8, 10.2. HRMS (positive ion 
FAB) calcd. for Ci3H 160 3 (M+Na) 243.0997, found 243.0981.
(£)-l-((25',35)-3-(2-(Benzyloxy)ethyl)-2-methyloxiran-2-yl)-7-(/^r/- 
butyldimethylsilyloxy)-4,4-dimethylhept-5-en-2-yn-l-ol (226)
To a stirring solution of dry 
tetrahydrofuran (3 mL) and tert-butyl- 
(4,4-dimethylhex-2-en-5-ynyloxy)- 
dimethylsilane (100 mg, 0.7 mmol) at - 
78 °C, H-butyllithium (2 M in hexanes,
0.8 mmol) was added dropwise. The mixture was stirred for 30 min, and the reaction 
mixture transferred via cannula to a vessel charged with dry tetrahydrofuran (3 mL), and
3-(2-benzyloxyethyl)-2-methyl-oxirane-2-carboxaldehyde (185 mg, 0.84 mmol) at -78 
°C. The reaction was stirred for 2 h, and allowed to warm to 0 °C. The reaction was 
quenched with the addition of saturated ammonium chloride solution, and extracted with 
dichloromethane ( 3 x 5  mL). The organic fractions were combined, dried (MgS0 4 ), and
TBS
185
concentrated under reduced pressure to give the crude material. Purification by column 
chromatography using an eluant of 4:1 hexane:ethyl acetate gave 226 (75 mg, 23%) as a 
pale oil. ‘H NMR (300MHz, CDC13), 8 H 7.37-7.26 (m, 5H, Ar-H), 5.81-5.75 (m, 1H, 
CHCH-CHA. 5.60 (d, 7=15.3 Hz, 1H, C-CH=CH), 4.69 (br, 3H, C-CH(OH)-C, Ph- 
CH2 -O), 4.17-4.15 (m, 2H, CH-CH,-Q). 3.65 (t, 7=7.7 Hz, 2H, O-CH2 -CH2), 3.24-3.22 
(m, 1H, C-CH(0)-CH2), 2.04-1.83 (m, 2H, CH2-CH2-CH), 1.40 (s, 3H, CH3-C), 1.29 (s, 
6 H, C-(CH3)2), 0.90 (s, 9H, O-TBSl. 0.07 (s, 6 H, O-TBSl. 13C NMR (75 MHz, CDCI3), 
5C 138.2, 136.0, 128.4, 127.6, 126.9, 82.7, 79.8, 73.2, 67.4, 66.2, 63.4, 62.7, 58.3, 33.2,
29.7, 29.0, 26.0, 18.4, 13.0. HRMS calcd. for C27H4204Si (M+H) 459.2931, found 
459.2933.
Catalytic Mercury Solution
To a rapidly stirred mixture o f water (1.2 mL) and concentrated sulfuric acid (0.125 
mL), mercury (II) oxide yellow (0.11 g, 0.5 mmol) was added. Upon dissolution, 3.7 mL 
of water was added, forming the catalytic mercury solution.
(25,3/?,2i)-2-(2-(Benzyloxy)ethyI)-6-(5-(terr-butyldimethylsilyloxy)-2-methylpent-3- 
en-2-yl)-3-methyl-2,3-dihydropyran-4-one (228)
To a stirring solution o f l-[3-(2- ^
benzyloxyethyl)-2 -methyl-oxiranyl] -7-{tert-
butyldimethylsilyloxy)-4,4-dimethylhept-5- JL /TBS
(| O (S) O jC v  O
en-2-yn-l-ol (50 mg, 0.1 mmol) in acetone '
(5 mL), 0.05 mL of a Hg2+ stock solution 
was added. The reaction was continued until 
complete by TLC. Sodium hydrogen
carbonate (100 mg) was added and the reaction stirred for 1 h. The reaction was filtered 
and concentrated under reduced pressure to give crude material. Purification and analysis 
indicated that 228 had not been formed.
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l-(terf-Butyl-dimethylsilyloxy)-4,4-dimethylhex-5-yne-2,3-diol (224)
To a stirring mixture o f tert-butyl alcohol (5 mL) and water (5 mL) TBS
/
AD-mix p (1.4 g) was added at room temperature. Methane sulfonamide O 
(95 mg, 1 mmol) was added, and the mixture cooled to 0 °C. The alkene, HO^ .UR) 
ter/-butyl-(4,4-dimethylhex-2-en-5-ynyloxy)-dimethylsilane (1 mmol,
0.238 g) was added and the mixture stirred until all starting material was 
consumed, as indicated by TLC. Sodium sulfite was added to quench the reaction, and 
was stirred while allowing to warm to room temperature for 30 min. The reaction 
mixture was extracted with dichloromethane ( 3 x 1 0  mL) and organic fractions washed 
with 2M KOH solution. Organic material was combined, dried (MgSCU) and 
concentrated under reduced pressure to an oil. Purification by column chromatography 
using an eluant of 4:1 hexane:ethyl acetate gave 224 (237 mg, 87%) as a colourless oil. 
‘H NMR (300MHz, CDCI3), SH 4.35-4.04 (m, 2H, 0-Ofc-CH ), 3.68-3.64 (m, 1H, CH2- 
CH(OH)-CH), 3.32 (m, 1H, CH-CH(OH)-C), 2.03-2.02 (m, 1H, H O C ). 1.27 (s, 6 H, - 
(CHOA 0.89 (s, 9H, O-TBSl. 0.08 (s, 6 H, O-TBSl. 13C NMR (75 MHz, CDCI3), 8 C
90.0,75.8, 70.2,69.6, 66.2,29.0, 26.1,24.4,18.7.
tert- Butyl- [5-(l ,l-dimethylprop-2-ynyl)-2,2-dimethyl- [ 1,3] dioxolan-4-ylmethoxy] - 
dimethylsilane (225)
A stirring solution of acetone (3.5 mL), 2,2-dimethoxypropane (1.5 n
(fvT \ y
mL), and camphor sulfonic acid (12 mg, 0.05 mmol) was prepared ' ' O '
and stirred for 5 min. The diol, l-(ter/-butyldimethylsilyloxy)-4,4- | ^
dimethylhex-5-yne-2,3-diol (1 mmol, 272 mg) was added in one 
portion, and the mixture stirred at room temperature. Upon completion by TLC, a small 
quantity o f sodium hydrogen carbonate was added, and the reaction concentrated under 
reduced pressure. Purification by column chromatography using an eluant of 9:1 
hexane:ethyl acetate, and concentration o f product containing fractions gave 225 (128 
mg, 41%). ‘HNMR (300MHz, CDC13), 8H4 .10-4.04 (m, 1H, CH2-CH(0)-CH), 3.88 (dd, 
.7=11.2, 3.1 Hz, 1H, TBS-O-CHH-CH), 3.81 (d, 7=7.2 Hz, 1H, C-CH(Q1-CH1. 3.73 (dd, 
7=11.2, 4.5 Hz, 1H, TBS-O-CHH-CH), 2.13 (s, 1H, HC=C), 1.43 (s, 3H, CHj-acetal),
1.39 (s, 3H, CHj-acetal), 1.28 (s, 3H, C-CH3), 1.23 (s, 3H, C-CH3), 0.90 (s, 9H, O-TBS). 
0.08 (s, 6 H, O-TBSl. 13C NMR (75 MHz, CDCI3), 8 C 109.1, 88.9, 82.5, 79.7, 69.7, 65.0,
187
33.8, 27.5, 27.4, 26.7, 26.0, 24.9, 18.5. HRMS calcd. for CnHszOsSi 312.2121, found 
312.2126.
l-((25,3<S)-3-(2-(Benzyloxy)ethyl)-2-methyloxiran-2-yl)-4-((4K,5l?)-5-((ter*- 
butyldimethylsilyloxy)methyl)-2,2-dimethyl-l,3-dioxolan-4-yl)-4-methylpent-2-yn-
l-o l (227)
To a stirring solution o f ter/-butyl-[5-(l,l- 
dimethylprop-2-ynyl)-2,2-dimethyl-[ 1,3]dioxolan-
4-ylmethoxy]-dimethylsilane (128 mg, 0.4 mmol) 
in dry tetrahydrofuran (1 mL) at -78 °C, n- 
butyllithium (2.5 M in hexanes, 0.44 mmol) was 
added dropwise and the reaction stirred for 30 min. The solution was then added 
dropwise to a separate flask, charged with tetrahydrofuran (1 mL) and 3-(2- 
benzyloxyethyl)-2-methyl-oxirane-2-carboxaldehyde ( 8 6  mg, 0.39 mmol) at -78 °C. The 
reaction was stirred for 2 h, and warmed to 0 °C. Saturated ammonium chloride solution 
was added, and the reaction mixture extracted with ethyl acetate ( 3 x 5  mL). Organic 
fractions were combined, dried (MgSO^, and concentrated under reduced pressure to 
give the crude product. Column chromatography using an eluant of 4:1 hexane:ethyl 
acetate gave the 227 as an oil (133 mg, 64%). ‘H NMR (300MHz, CDC13), 6 H 7.47-7.24 
(m, 5H, Ar-H), 4.53 (s, 2H, Ph-CH7-Q). 4.15-4.04 (m, 2H, O-CH2 -CH2), 3.84-3.59 (m, 
5H, TBS-O-Ofc-CH, CH(epoxide)-CH(OH)-C), 3.22-3.20 (m, 1H, CH2-CH(epoxide)), 
2.03-1.91 (m, 2H, CH2 -CH2-CH), 1.42 (s, 3H, CH,-C('Oi). 1.39 (s, 3H, CHj-acetal), 1.38 
(s, 3H, CHj-acetal), 1.27 (s, 3H, C-CH3), 1.20 (s, 3H, C-CH3 ), 0.90 (s, 9H, O-TBSl. 0.07 
(s, 6 H, O-TBSl. 13C NMR (75 MHz, CDCI3), 8 C 138.2, 128.4, 127.6, 109.2, 82.7, 79.8,
73.1, 67.3, 66.1, 65.4, 64.9, 62.5, 60.4, 58.1, 28.9, 27.5, 26.6, 26.0, 25.3, 18.4, 14.2. 
HRMS calcd. for C30H48O6Si (M+H) 533.3298, found 533.3304.
OH
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(25,3/?)-2-(2-(benzyloxy)ethyl)-6-(2-((45,,55)-5-((ter/-butyldimethylsilyloxy)methyl)- 
2,2-dimethyl-l,3-dioxolan-4-yl)propan-2-yl)-3-methyl-2,3-dihydropyran-4-one (229)
To a stirred solution of l-[3-(2- 
benzyloxyethyl)-2-methyl-oxiranyl] -4-[5 - 
(tert-butyldimethylsilyloxymethyl)-2 ,2 - 
dimethyl-[ 1,3]dioxolan-4-yl]-4-methyl-pent-
i ^
2-yn-l-ol (50 mg, 0.1 mmol), in acetone (5 mL), 0.05 mL o f a Hg solution was added. 
The mixture was stirred until all epoxide material was consumed by TLC (visualisation 
using cerium(IV) sulphate stain). Column chromatography using an eluant o f 4:1 
hexaneiethyl acetate recovered 36 mg o f material as an oil. Analysis indicated that 229 
had not been formed.
(*S)-4-Benzylthiazolidine-2-thione242 (230)
To a stirring solution of (.S)-phenylalaninol (5 g, 38 mmol) in 150 mL of 1 
M potassium hydroxide, CS2 (12.6 g, 9.92 mL, 165 mmol) was added and 
the reaction heated to reflux for 12 h. After cooling, the reaction was 
extracted with dichloromethane (3 x 100 mL), organic fractions combined, 
dried (Na2 SC>4), and concentrated under reduced pressure to give the crude product. 
Purification by column chromatography using an eluant o f 4:1 hexane:ethyl acetate 
(0.5% acetic acid) gave 230 (5.06 g, 74%) as a bright yellow solid. Analysis o f a 
recrystallised sample (ethanol) correlates spectral data with that o f previously reported 
material. HRMS (Cl) calcd. for C10H 11NS2 (M+H) 210.0411, found 210.0397.
(S)-l -(4-Benzyl-2-thioxothiazolidin-3-yI)propan-l -one243 244 (231)
_ O
To a stirring solution o f (S)-4-benzylthiazolidine-2-thione (4 g, 19.1 S 3 ^ /
/  Nmmol), triethylamine (6 . 6 6  mL, 47.75 mmol), in dichloromethane (120 s. 
mL) at 0 °C, propionyl chloride (2.49 mL, 28.65 mmol) was added 
slowly. The mixture was allowed to warm to room temperature, and 
stirred for 12 h. The reaction mixture was washed with water (2 x 40 mL),
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dried (MgS0 4 ), and concentrated under reduced pressure to give the crude material. 
Recrystallisation from hexane afforded 231 as bright yellow crystals (3.43 g, 6 8 %). 
Analysis was consistent with that o f previously reported data.
(2/?,35}-l-((5r)-4-Benzyl-2-thioxothiazolidin-3-yl)-6-(benzyloxy)-3-hydroxy-2- 
methylhexan-l-one (232)
S O OH
To a 0 °C solution of (S)-l-(4-benzyl-2-thioxothiazolidin-3- 11 J1 !
N
yl)propan-l-one (1.5 g, 5.6 mmol), in dry dichloromethane v _ i  I 
(30 mL), TiCL (1 M in dichloromethane, 5.6 mmol) was 1
added dropwise. The mixture was stirred for 5 min, and (-)- ( f  j  
sparteine (1.29 mL, 5.6 mmol) was added and stirred for a
further 20 min. The reaction was cooled to -78 °C and 3-benzyloxypropionaldehyde 
(1.01 g, 6.16 mmol) was added dropwise. The reaction was stirred at -78 °C for 1 h, and 
allowed to warm to 0 °C. The reaction was quenched with 1:1 saturated ammonium 
chloride:water. Organic material was extracted, dried (Na2 S0 4 ), and concentrated under 
reduced pressure. Column chromatography using an eluant o f 4:1 hexane:ethyl acetate 
gave 232 (0.78 g, 32%) as a yellow oil. 0.86 g of unreacted auxiliary was recovered. *H 
NMR (300MHz, CDC13), 8 H 7.59-7.26 (m, 10H, Ar-H), 5.40-5.36 (m, 1H, N-CH(CH2)- 
CH2), 4.53 (s, 2H, Ph-CLh-O), 4.29-4.15 (m, 1H, CH-CH(OH)-CH2), 3.71-3.65 (m, 2H, 
0 -CH2 -CH2), 3.38-2.85 (m, 4H, S-CKh-CH, Ph-CHrCH), 2.03-1.73 (m, 3H, CH3-CH, 
CH(OH)-CH2 -CH2), 1.23 (d, 7=7.3 Hz, 3H, CILs-CH). 13C NMR (75 MHz, CDC13), 8 C
201.4, 177.6, 138.1, 137.9, 129.5, 128.9, 128.4, 127.7, 127.5, 127.3, 73.4, 71.6, 64.9,
43.8, 43.2,38.3,36.8,21.1, 11.3.
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(2/?,3S)-l-((S)-4-Beiizyl-2-thioxothiazolidin-3-yl)-6-(benzyloxy)-2-iiiethyl-3- 
(tetrahydro-2//-pyran-2-yloxy)hexan-l-one (233)
To a solution o f  (2^,35)-l-((*S)-4-benzyl-2-thioxothiaLZolidin- s  O OTHP
mmol) were added at 0 °C. The mixture was stirred and
allowed to warm to room temperature. The reaction was concentrated under reduced 
pressure, and purified by column chromatography using an eluant o f 9:1 hexane:ethyl 
acetate to give the desired material as an oil, 415 mg, 87%. The material was 
immediately transferred into the next synthetic stage. HRMS calcd. for C2 8H3 5N 0 4 Si 
(M+H) 514.2086, found 514.2064.
(2/?,3*S)-6-(Benzyloxy)-Ar-methoxy-Ar,2-dimethyl-3-(tetrahydro-2//-pyran-2- 
yloxy)hexanamide (234)
To a stirring solution o f (2/£,3»S)-l-((iS)-4-benzyl-2- O OTHP 
thioxothiazolidin-3-yl)-6-(benzyloxy)-2-methyl-3-(tetrahydro- 
2//-pyran-2-yloxy)hexan-l-one (200 mg, 0.39 mmol) in / 0  
dichloromethane (10 mL), a solution consisting of dichloromethane (5 mL), 
triethylamine (0.47 mmol, 47 mg), and A^O-dimethyl hydroxylamine hydrochloride 
(0.43 mmol, 42 mg), was added slowly. The reaction was stirred for 12 h. Upon work up, 
no products were found to have been formed.
3-yl)-6-(benzyloxy)-3-hydroxy-2-methylhexan-1 -one (500 
mg, 1.1 mmol) in dry tetrahydrofuran (5 mL), / 7-toluene 
sulfonic acid (5 mg), and 3,4-dihydro-2//-pyran (91 mg, 1.08
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Appendix A
Table 1. Crystal data and structure refinement.
Identification code 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume
Z
Density (calculated) 
Absorption coefficient 
F(000)
Crystal 
Crystal size
Grange for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to 6= 27.50° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [F2 > 2o(F2)] 
R indices (all data)
Absolute structure parameter 
Extinction coefficient 
Largest diff. peak and hole
04srcll24 (139JM)
c 18h 23n o 6
349.37 
120(2) K 
0.71073 A 
Monoclinic
P2 i
a = 8.713(4) A a=  90°
b = 6.582(4) A J3= 101.70(5)°
c = 15.739(7) A y=  90°
883.9(8) A3 
2
1.313 Mg /m 3 
0.099 mm-1 
372
Blade; colourless 
0.60 x 0.06 x 0.01 mm3 
3.37-27.50°
-11 <h<  11,-8 < k<  8 ,-2 0  < /<  20 
3834
3834 [Rinl = 0.0000]
98.6 %
Semi-empirical from equivalents 
0.9990 and 0.9432 
Full-matrix least-squares on F2 
3834/ 1 /233 
1.380
R1 = 0.0570, wR2 = 0.0983 
R1 = 0.0811, wR2 = 0.1043 
0.1(13)
0.059(5)
0.239 and -0.210 e A“3
D iffrac tom eter: Nonius KappaCCD area detector (<p scans and (O scans to fill asymmetric unit sphere). C ell determ ination: DirAx 
(Duisenberg, A.J.M.(1992). J. Appl. Cryst. 25, 92-96.) D ata  collection: Collect (Collect: Data collection software, R. Hoofi, Nonius 
B.V., 1998). D ata  reduction and cell refinem ent: Denzo (Z. Otwinowski & W. Minor, Methods in Enzymologv (1997) Vol. 276: 
Macromolecular Crystallography, part A, pp. 307-326; C. W. Carter, Jr. & R. M. Sweet, Eds., Academic Press). Absorption  
correction: SORTAV(R . H. Blessing, Acta Cryst. A 51 (1995) 33-37; R. H. Blessing, J. Appl. Cryst. 30 (1997) 421-426). Structure  
solution: SHELXS97 (G. M. Sheldrick, Acta Cryst. (1990) A 46  467-473). S tructu re  refinem ent: SHELXL97 (G. M. Sheldrick 
(1997), University o f  Gottingen, Germany). G raphics: Cameron - A Molecular Graphics Package. (D. M. Watkin, L. Pearce and C. 
K. Prout, Chemical Crystallography Laboratory, University o f  Oxford, 1993).
Special details:
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